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ABSTRACT OF DISSERTATION

INHIBITION OF CALPAINS BY CALPASTATIN:
IMPLICATIONS FOR CELLULAR AND FUNCTIONAL DAMAGE
FOLLOWING TRAUMATIC BRAIN INJURY
Traumatic brain injury (TBI) is a devastating health problem based on its
high incidence, economic burden, and lack of effective pharmacological
treatment. Individuals who suffer an injury often experience lifelong disability. TBI
results in abrupt, initial cell damage leading to delayed neuronal death. The
calcium-activated proteases, calpains, are known to contribute to this secondary
neurodegenerative cascade. Prolonged activation of calpains results in
proteolysis of numerous cellular substrates including cytoskeletal components,
membrane receptors, and cytosolic proteins, contributing to cell demise despite
coincident expression of calpastatin, the specific inhibitor of calpains.
A comprehensive analysis using two separate calpastatin transgenic
mouse lines was performed to test the hypothesis that calpastatin
overexpression will reduce posttraumatic calpain activity affording
neuroprotection and behavioral efficacy. Increased calpastatin expression was
achieved using transgenic mice that overexpress the human calpastatin (hCAST)
construct under control of a neuron-specific calcium-calmodulin dependent
kinase II  or a ubiquitous prion protein promoter. Both transgenic lines exhibited
enhanced calpastatin expression within the brain, extending into peripheral
tissues under the prion protein promoter. hCAST overexpression significantly
reduced protease activity confirmed by reductions in acute calpain-mediated
substrate proteolysis in the cortex and hippocampus following controlled cortical
impact brain injury. Aspects of posttraumatic motor and cognitive behavioral
deficits were also lessened in hCAST transgenic mice compared to their wildtype
littermates. However, volumetric analyses of neocortical contusion revealed no
histological neuroprotection at either acute or long-term time points in either
transgenic line. Partial hippocampal neuroprotection observed at a moderate
injury severity in neuron-specific calpastatin overexpressing transgenic mice was
lost after severe TBI. Greater levels of calpastatin under the prion protein
promoter line failed to protect against hippocampal cell loss after severe brain
injury.

This study underscores the effectiveness of calpastatin overexpression in
reducing calpain-mediated proteolysis and behavioral impairment after TBI,
supporting the therapeutic potential for calpain inhibition. However, the reduction
in proteolysis without accompanied neocortical neuroprotection suggests the
involvement of other factors that are critical for neuronal survival after contusion
brain injury. Augmenting calpastatin levels may be an effective method for
calpain inhibition and may have efficacy in reducing behavioral morbidity after
TBI and neurodegenerative disorders.

KEYWORDS: Calpain, Calpastatin, Neuroprotection, Transgenic, Traumatic
Brain Injury
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CHAPTER 1

Introduction

TRAUMATIC BRAIN INJURY
Prevalence and Etiology
Traumatic brain injury (TBI) is a devastating health problem that afflicts
approximately 1.7 million individuals each year in the United States, resulting in
52,000 deaths, 275,000 hospitalizations, and 1.3 million emergency room visits
(Faul et al., 2010). Despite these already staggering statistics, the prevalence of
TBIs may be underestimated, as many individuals may be unaware of the
underlying severity of the injury or unwilling to seek treatment, causing many
milder injuries to go undiagnosed and untreated. TBIs most often result from falls
and motor vehicle accidents (Faul et al., 2010); however, more recent attention
has been given to head injuries that arise from sports-related incidents and
military conflicts. The mild, repeated head trauma sustained by some athletes
and individuals of the armed forces is often non-lethal but can result in
progressive damage to the brain, causing persistent deficits well past the initial
injuries (Stern et al., 2011, Goldstein et al., 2012).
Although brain trauma can affect any individual regardless of age, gender,
or race, TBI predominates in young children and adolescents and has led to
approximately 3.2-5.3 million brain injury survivors with long-term disabilities
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(Coronado et al., 2011). The price of injury not only includes an estimated $11.5
billion in annual medical expenses incurred by the victims, but also indirect costs
associated with lost productivity that account for an additional $64.8 billion
(Coronado et al., 2012). Those patients in need of continued care may also incur
extra expenses related to rehabilitation and health insurance. Due to the early
age and enduring costs of injury, TBI remains a significant health problem in the
United States, creating a large medical and monetary burden.

Clinical manifestations
TBIs are commonly categorized as a mild, moderate, or severe injury
using the Glasgow Coma Scale (GCS), a globally recognized clinical standard
developed to provide a consistent, objective assessment of the severity of initial
injury (Teasdale and Jennett, 1974) and patient outcomes (Levin et al., 1990,
Marmarou et al., 2007). The GCS separately evaluates eye opening, verbal
response, and motor response and the cumulative score is used to classify injury
severity upon presentation. A GCS score of 13-15 identifies a mild injury, a GCS
9-12 a moderate injury, and a GCS 8 or less a severe injury. Despite the clinical
utility of the GCS in classifying the initial severity of TBI and predicting patient
outcome, the heterogeneity of injury makes it difficult to accurately diagnose the
underlying nature and extent of the injury, particularly following severe TBI. For
instance, in a comparison of six different TBI victims receiving a GCS score of
less than 8, or severe TBI, each individual’s CT scan identified different
pathologies including contusion, subarachnoid hemorrhage, and diffuse axonal
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injury (Saatman et al., 2008), indicating that separate or mixed
pathophysiological mechanisms can be grouped under the same clinical
classification. The use of additional assessments in combination with the GCS
and CT scan may help to verify diagnosis and enhance predictive value (Narayan
et al., 1981, Choi et al., 1994). Varied clinical presentations not only complicate
the categorization of injury but also confound successful implementation of
therapies for the treatment of TBI. As a result, limited intervention strategies are
available for TBI patients during the early medical management of a TBI.
Standard emergency care for TBI includes computed tomography (CT) scan to
diagnose any brain abnormalities, intracranial pressure monitoring, and attempts
to control ischemia and inflammation events that can accompany a brain injury
(Rosenfeld et al., 2012). In severe cases or with worsening condition, surgical
intervention may be required.
Both motor and cognitive dysfunctions are evident after human TBI with
approximately 80-90% of patients reporting persistent physical, emotional, or
cognitive disability years after the injury (Lew et al., 2006). The severity and
persistence of these behavioral consequences can depend on both on the cause,
location, and severity of injury as well as factors associated with the health of the
individual and posttraumatic rehabilitation efforts. Common physical symptoms of
a TBI include headache, dizziness, nausea, and possible loss of consciousness
(Silver et al., 2009, Faul et al., 2010). Changes in memory, attention, speech and
language, and personality have also been reported after TBI, with clear
implications toward a person’s overall health, social relationships, and job
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performance. Not only can TBI disturb an individual’s physical and cognitive
function closely following the injury, but may also predispose patients to longterm psychological problems, depression, epilepsy, and dementia (McAllister,
2011).
Existing strategies targeting prevention, clinical care, and management
techniques have been successful in standardizing treatment for TBI, yet these
approaches primarily focus on reducing intracranial pressure, controlling
hematoma, and monitoring cerebral perfusion (Rosenfeld et al., 2012). To date,
there is no successful pharmacological agent that can mitigate the pathology and
long-term consequences of TBI. The absence of an effective treatment increases
the likelihood that TBI victims will suffer acute and long-term repercussions of
injury, including memory loss, emotional issues, and risk for other brain disorders
such as epilepsy or Alzheimer’s disease (Thurman et al., 1999, Corrigan et al.,
2004). Difficulty in mitigating pathological consequences necessitates continued
research in order to understand and treat the overwhelming problem of TBI.

Experimental models
In an effort to understand the injury mechanisms associated with TBIs and
to develop effective treatment strategies, various experimental models have been
developed to recreate aspects of human TBI. Isolated, neuronal events can be
closely replicated using in vitro, or cellular, models of injury. In these types of
preparations, the pathological events associated with neuronal injury are
produced by the application of chemicals or by physical stretching or tearing of
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the neurons. In vitro models are effective in monitoring discrete events
associated with neuronal and axonal damage, yet are limited in defining the
injury within the context of the whole brain (Kumaria and Tolias, 2008).
In vivo, or whole animal, models help to more accurately recreate head
injuries in an environment that includes cerebral pressure changes, vascular
alterations and ischemia, inflammation, and glial interactions. In an attempt to
narrow the heterogeneity of TBI, several in vivo injury models have been
developed to reproduce the focal and diffuse aspects of clinical TBI.
Characteristics of traumatic axonal injury, diffuse swelling or diffuse vascular
injury are typically produced by impact or inertial acceleration models that mimic
the head rotation and deformation of human TBI (Marmarou et al., 1994, Ross et
al., 1994, Cernak et al., 2004). Focal injuries with localized damage can be
recreated in the rodent using the weight drop model (Feeney et al., 1981, Chen
et al., 1996); however, modifications to the severity of impact and head
stabilization can produce more diffuse patterns of injury (Albert-Weissenberger
and Siren, 2010). As one of the most common types of TBI, focal contusion injury
is reliably reproduced using the controlled cortical impact (CCI) device, tested
both in rodents and larger mammals (Morales et al., 2005) (Figure 1.1). Contact
of a metal impactor tip to the animal’s brain is both rapid and transient, creating a
focal injury site that can range in severity depending on the depth and velocity of
impact as well as the size and shape of the impactor (Lighthall, 1988, Saatman et
al., 2006, Pleasant et al., 2011). Aspects of both focal contusion and diffuse brain
injury can be evaluated in the fluid percussion injury (FPI) model (Dixon et al.,
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1987, McIntosh et al., 1987, McIntosh et al., 1989). FPI has been extensively
characterized in the rat with much less utilization in mice. By contrast, the CCI
model is widely used in mice making it a highly appropriate model for studies that
rely on transgenic or knockout mice.
In vivo models in combination with in vitro paradigms have advanced
understanding on the progression of pathology in human TBI, identifying cellular
and molecular mechanisms that collectively result in neuronal damage and
death.
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Figure 1.1. Controlled cortical impact (CCI) injury model for experimental
contusion brain injury. The controlled cortical impact (CCI) device is a welldocumented model for the replication of contusion brain injury in small mammals.
Programmed depth and velocity values determine the movement of a metal
impactor tip delivered to the exposed cortical surface, producing varying degrees
of cortical and hippocampal cell damage and behavioral abnormalities (Goodman
et al., 1994, Smith et al., 1995). For contusion injury, the cortical surface of the
brain is exposed by surgical craniotomy prior to impact and positioned below the
impactor tip.
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Primary and secondary injury mechanisms
TBI is characterized by an initial mechanical insult to the head that can
result in varying amounts of damage to brain tissue, termed the primary phase of
injury, characterized by direct rupture of membranes or increased plasma
membrane permeability (LaPlaca et al., 2007). Primary damage, given its
immediate and mechanical nature, is difficult to target therapeutically. Efforts to
reduce primary injury have focused on injury prevention or mitigation of the
magnitudes of force and acceleration associated with impact. However, the
primary phase triggers a myriad of secondary pathogenic events including
ischemia, alterations in ionic homeostasis, oxidative damage, mitochondrial
dysfunction, inflammation, and the excessive release of excitatory
neurotransmitters (Ray et al., 2002, Dash et al., 2010) (Figure 1.2). Events
associated with the secondary phase can be targeted for intervention and,
therefore, are important avenues of TBI research in selecting cell and molecular
targets for the treatment of TBI.
The brain communicates within itself and throughout distant areas of the
body via neurotransmitter signaling between neurons. The excitatory
neurotransmitter, glutamate, is especially important in action potential
propagation and synaptic plasticity. When released from the presynaptic neuron,
glutamate binds to ligand-gated N-methyl-D-aspartate (NMDA) and AMPA
receptors, resulting in the influx of sodium and calcium ions necessary to
propagate signals along the postsynaptic neuron and to its target. However,
under conditions of membrane damage that result from TBI, the excessive
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release of excitatory neurotransmitters can create an excitotoxic environment
characterized by the overactivation of glutamate receptors and overwhelming
influx of sodium and calcium, potassium efflux, and prolonged membrane
depolarization.
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Calcium concentrations are highly regulated by the neuron in order to
participate in the important functions of neurotransmitter release and other
intracellular signaling events. Under baseline conditions, the intracellular freecalcium concentration is approximately 100 nM, compared to the much greater 2
mM concentration in the extracellular environment. Within the cell, calcium is
sequestered in the endoplasmic reticulum and mitochondria and buffered by
various calcium handling proteins and extrusion mechanisms. The concentration
gradient of calcium can prime the cell for damage if any of these regulatory
mechanisms is altered. Studies using experimental models of contusion brain
injury have established multiple pathways through which calcium homeostasis
becomes dysregulated, including excitotoxicity, widespread depolarization,
voltage-gated calcium channel opening, or membrane disruption (Faden et al.,
1989, Palmer et al., 1993, Arundine and Tymianski, 2004, Weber, 2004). As a
consequence, increases in intracellular free calcium can trigger mitochondrial
dysfunction and energy depletion, stimulation of proteases and enzymes, free
radical production, and altered gene expression (Arundine and Tymianski, 2004,
Weber, 2004). Notably, the calcium-dependent proteases, calpains, are activated
by calcium dysregulation. The family of calpain proteases can function in necrotic
and apoptotic cell death cascades by cleaving a variety of cellular substrates.
Among these substrates are receptors or proteins involved in maintaining
calcium homeostasis; thus, substrate cleavage by calpains may exacerbate
calcium-induced neurotoxicity. If the neuron is unable to circumvent or recover
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from the proteolysis of cellular substrates, normal cellular structure and function
are at risk and cell death is imminent.
Marginal success has been achieved in clinical trials targeting NMDA
receptor activation with a receptor antagonist after TBI (Bullock et al., 1999,
Yurkewicz et al., 2005); however, because of the vital role these receptors play in
normal synaptic function, prolonged antagonism of glutamate receptors can lead
to undesirable side effects (Ikonomidou and Turski, 2002). In addition, excitotoxic
events trigged by glutamate receptor overactivation may happen too quickly after
neuronal damage for effective post-injury treatment. Therefore, downstream
effectors, like calpains, that mediate pathological damage within the cell have
become attractive targets for therapeutic intervention.

CALPAINS
Biochemical structure and regulation
Calpains are commonly defined as neutral cysteine proteases distributed
within the cytosol that require calcium binding to elicit full activity (Goll et al.,
2003, Croall and Ersfeld, 2007). Fifteen isoforms of calpain have been identified
to date with either ubiquitous or tissue-specific localization (Sorimachi et al.,
2011). The two most commonly studied isoforms are the ubiquitous -calpain
and m-calpain, which share a similar heterodimeric structure but are activated by
differential concentrations of ionic calcium. Under in vitro conditions, micromolar
concentrations of calcium are needed to activate -calpains, while m-calpains
require millimolar amounts (Goll et al., 2003).
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The heterodimeric structure of vertebrate - and m-calpains is composed
of an 80 kDa catalytic subunit and a common 28 kDa regulatory subunit (Goll et
al., 2003). The catalytic subunits of - and m-calpain, termed calpain-1 and
calpain-2, respectively, are distinct, but closely homologous. They are generally
divided into four regions, or domains, along the protein (Figure 1.3A) with the Nterminal region of the catalytic subunit designated as Domain I. Domain II, often
referred to as the catalytic domain, contains the cysteine, histidine, and
asparagine amino acid residues necessary for the proteolytic function of
calpains. In addition to linking the catalytic domain with the C-terminal region,
domain III consists of residues that function in associating with plasma
membranes and calcium binding. Finally, domain IV contains four EF hand
sequences responsible for calcium binding. The small regulatory subunit
(calpain-4) is common to both - and m-calpain isoforms and composed of
Domains V and VI containing hydrophobic residues that help to achieve
membrane interaction (Domain V) and additional calcium-binding EF hand
sequences (Domain VI). The catalytic and regulatory subunits remain associated
under inactive conditions and likely continue to interact when activated (Goll et
al., 2003).
Upon calcium binding, - and m-calpain autolyze, or self-cleave, an Nterminal portion of the large and small subunits to achieve full proteolytic activity.
The 80 kDa subunit is reduced to a molecular mass of 76 kDa or 78 kDa for
calpain-1 or -2, respectively, and the common small subunit reduces to 18 kDa
(Goll et al., 2003). Although it has been contested whether this self-cleavage is
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required for activation, autolysis reduces the calcium concentration requirement
for calpains’ proteolytic activity (Edmunds et al., 1991, Goll et al., 1992) thereby
increasing the plausibility that calpains can become activated following
physiological calcium changes. In addition, calcium binding elicits a
conformational change in calpain structure, bringing the catalytic amino acid
residues together for proteolytic activity (Moldoveanu et al., 2002) (Figure 1.3B).
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Figure 1.3. Basic structure and activation of the ubiquitous - and mcalpains. A) The ‘typical’ calpains, -calpain and m-calpain, share a similar
heterodimeric structure composed of a large catalytic subunit and small
regulatory subunit. Domain II of the large subunit includes the amino acid
residues responsible for proteolysis. Calcium binding primarily occurs at EF hand
sequences located on domains IV and VI. B) Binding of calcium to calpain elicits
autolysis and conformational change in the protease’s structure, positioning
specific amino acid residues within domain II in an arrangement facilitating
proteolytic activity.
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Calpains are most notably regulated by calcium concentrations within the
cell to achieve proteolytic activity. As indicated previously, micromolar range
concentrations of ionic calcium are necessary to activate -calpains in vitro while
millimolar calcium concentrations activate m-calpains. This calcium requirement
for activation of either isoform is notably higher than the nanomolar
concentrations within the cell under physiological conditions. Various
mechanisms including autolysis and phospholipid interaction reduce the calcium
requirement for activation and, therefore, regulate calpains’ proteolytic function
(Goll et al., 2003, Campbell and Davies, 2012). In addition, calpain activity is
regulated by binding of a common endogenous inhibitor, calpastatin. The calcium
requirement for calpastatin binding to calpain is lower than the concentration
needed for calpain activation (Goll et al., 2003), suggesting that an additional
mechanism such as localization or protein modification can alter the interaction of
calpain with its inhibitor to regulate proteolytic function. Once activated, calpains
must have access to cellular substrates, which are shared across isoforms and
identified based on the protein substrate’s conformation instead of amino acid
sequence and are cleaved into large fragments (Goll et al., 2003). The proteolytic
fragments are often stable and can exert physiological functions independent of
their parent or full-length protein, suggesting calpains can act as a modulatory
protease. This property of calpains is evident in the cleavage of substrates p35
(Hashiguchi et al., 2002), protein kinase C (Kishimoto et al., 1989), or NMDA
receptor subunit (Simpkins et al., 2003) that remain constitutively active with
proteolysis. Calpains can also be influenced by their chemical environment as
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decreased pH or increased ionic strength or oxidation lead to a loss of proteolytic
activity (Guttmann and Johnson, 1998, Geesink and Koohmaraie, 2000,
Maddock et al., 2005).

Physiological expression and function
That the calcium requirements for - and m-calpain activation far exceed
the normal intracellular free calcium concentration creates speculation regarding
the function or necessity of each isoform under physiological conditions.
Traditionally, -calpain was theorized to act under physiological calcium
changes, while m-calpain, requiring a much greater calcium concentration for
activation, mediated proteolysis under pathological calcium changes. This dogma
was challenged, however, by the finding that genetic disruption of the catalytic
subunit of m-calpain (calpain-2, capn2) results in embryonic lethality (Dutt et al.,
2006). By contrast, mice with genetic deletion of the large subunit of -calpain
(calpin-1, capn1) are viable, despite dysfunctional platelet aggregation (Azam et
al., 2001). Disruption of the small regulatory subunit gene (calpain-4, capn4) that
abolishes both - and m-calpain activity resulted in embryonic lethality (Arthur et
al., 2000, Zimmerman et al., 2000), again indicative of calpains’ importance to
normal cell function. Loss of -calpain alone may be compensated for by mcalpain or another of the fifteen calpain isoforms; however, due to the lethality of
m-calpain knockout, the latter isoform appears to exert physiological functions
independent to those of -calpain. Recently, a study determined the necessity of
calpain-2 is due to placental cell survival and demonstrated that conditional
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calpain-2 and conditional dual calpain (calpain-1 and calpain-2) knockouts
survive to adulthood (Takano et al., 2011). These knockout models not only offer
valuable insight into the isoform-specific functions of - and m-calpain but also
underscore their essential role in normal cell function.
The developmental expression of both calpain-1 and calpain-2 in the
rodent central nervous system (CNS) has been documented with varied results.
Although one study documented early downregulation of calpain-2 protein
expression but stable calpain-1 levels in the brain throughout postnatal mouse
development (Zhu et al., 2005), another identified steady message and protein
levels of calpain-2 with increasing calpain-1 expression in the developing rat (Li
et al., 2009). In addition to these developmental discrepancies, relative levels of
adult calpain-1 versus -2 have varied between studies with reports of
considerably greater calpain-2 mRNA expression above calpain-1 in mouse CNS
tissues (Li et al., 1996) or the opposite (Li et al., 2009). Unfortunately, differences
in the probes, antibodies, or species used in these studies prevent definitive
conclusions on the developmental and adult calpain expression. Regional mRNA
analysis by in situ hybridization determined that calpain-1 was homogenously
distributed throughout the brain while calpain-2 appeared to predominate in
neuronal versus non-neuronal cell types (Li et al., 1996). Studies identifying the
calpain-mediated cleavage products support a neuronal localization of calpain
activity (Saatman et al., 1996a, Newcomb et al., 1997). While calpains have
historically been deemed cytosolic proteases, they also have associations with
specific structures within the cell including the nucleus (Mellgren and Lu, 1994),
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phospholipids of the endoplasmic reticulum and Golgi apparatus (Hood et al.,
2003), and the mitochondria (Garcia et al., 2005, Cao et al., 2007), perhaps
indicating substrate specificities and additional regulation through subcellular
interactions.
Regardless of their subcellular localization, calpains are multi-faceted
regulators of physiological functions such as cytoskeletal remodeling for cell
growth and motility, fibroblast migration for wound healing, cell cycle and
differentiation processes, apoptosis, and long-term potentiation (Goll et al., 2003,
Sorimachi et al., 2011). Calpains are known to cleave cytoskeletal proteins
(spectrin, neurofilaments, tubulin, and microtubule associated proteins like MAP2 and tau), cytosolic proteins involved in signal transduction and cell cycle
(calcium-calmodulin dependent kinase, protein kinase C, calcineurin, and cyclindependent kinase 5), transcription factors for gene expression (c-Jun, c-Fos,
p53), apoptotic proteins (caspases, Bcl-2 family proteins), and membrane
channels and receptors (NMDA receptor, voltage-gated sodium channel, sodiumcalcium exchanger) (Goll et al., 2003, Saatman et al., 2010). Although proteolysis
of many of these substrates has been determined from in vitro or in vivo studies,
the consequences of calpain activation and substrate proteolysis under different
physiological stimuli may vary. It is also unclear whether the limited proteolysis of
some substrates by calpains results in protein turnover or induces an alternative
function in the cell.

Pathological activation
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Identifying either physiological or pathological calpain activation can be
technically difficult, requiring arduous purification steps or large amounts of
protein. Gel electrophoresis can aid in visualization of calpain activation into its
autolytic fragments but with relatively poor resolution. Alternative methods take
advantage of the proteolytic function of calpains, by identifying cleavage of a
casein substrate within a zymogram gel or the appearance of breakdown
products associated with calpain-specific substrate cleavage. Under pathological
conditions such as TBI, calpains can cleave cytoskeletal elements, membrane
receptors, mitochondrial proteins, and gene regulatory elements leading to
necrosis and apoptosis (Saatman et al., 2010). Events such as global ischemia,
stroke, and spinal cord injury and neurodegenerative diseases including
Alzheimer’s disease, Huntington’s disease, and Parkinson’s disease share
several pathological secondary mechanisms with TBI, and therefore couple
calpain activation and substrate proteolysis, in part, to neurodegeneration (Nixon,
2003, Ray and Banik, 2003, Bevers and Neumar, 2008).
Neurofilaments, microtubule-associated proteins, and spectrins are
proteins involved in the composition or stabilization of the neuronal cytoskeleton.
The cytoskeleton is necessary for axonal transport, serving as the route for the
movement of proteins, mitochondria, and neurotransmitters to and from the
soma. In addition, structural cytoarchitecture is responsible for protein
scaffolding, anchoring of channels and receptors within the membrane, and
synaptic integrity. Cytoskeleton proteins are also commonly recognized calpain
substrates, especially following TBI. One of the most extensively studied calpain
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substrates is -spectrin, a submembrane cytoskeleton protein involved in
structural support and protein anchoring. Spectrin is cleaved by calpain from its
intact 280 kDa form into characteristic 150 and 145 kDa breakdown products,
while cleavage by caspase-3 results in 150 and 120 kDa fragments. These
characteristic, stable breakdown products allow definitive identification of calpain
activation, especially with disease or pathological insult. Numerous studies have
documented the temporal pattern of calpain-mediated spectrin breakdown into
150 kDa and 145 kDa products after TBI via immunoblot, demonstrating an early
rise in spectrin proteolysis that peaks in rodents at approximately 24 h after CCI
injury in the cortex and hippocampus (Kampfl et al., 1996, Pike et al., 1998, Hall
et al., 2005, Thompson et al., 2006, Deng et al., 2007). Calpain-mediated
spectrin breakdown products were also observed to be concomitant with
compacted neurofilament protein (Buki et al., 1999) that preceded axonal
transport disruption (Saatman et al., 2003), suggesting a mechanistic link
between calpain proteolysis of the cytoskeleton and structural and functional
demise of the axon. In addition to spectrin, significant calpain-specific cleavage
of the microtubule associated protein tau was detected in the rat cortex as early
as 2 h post-CCI (Liu et al., 2011). Given the integral role of the cytoskeleton in
cells, posttraumatic cytoskeleton cleavage has clear implications for neuronal
structure, axonal transport, and synaptic integrity.
Calpains are also known to cleave membrane proteins, which provide a
multitude of functions to neurons, including binding neurotransmitters, mediating
action potential propagation, ion permeability, and calcium regulation. Proteolysis
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of the sodium-calcium exchanger and voltage-gated sodium channel after
calcium perturbation could be limited with calpain inhibition (von Reyn et al.,
2009, Brustovetsky et al., 2010). Glutamate stimulation in cell culture triggered
degradation and down-regulation of the NMDA receptor that was prevented by
the presence of calpastatin or pharmacological calpain inhibitors (Guttmann et
al., 2002, Wu et al., 2005). Subsequent reports demonstrated that cleaved
NMDA receptors remained active at the cell surface (Simpkins et al., 2003),
suggesting continued contribution to excitotoxic damage. Therefore,
fragmentation of membrane proteins and ion channels that control ion flux may
exacerbate calcium dysregulation and lead to the loss of normal cell function,
prompting cell death. Alternatively, protein breakdown products may mediate
modified functions within the cell that are different from the parent protein. Under
conditions of TBI, however, knowledge of the implications for certain cytoskeletal
and membrane protein breakdown is relatively incomplete, yet this substrate
proteolysis may ultimately contribute to neuronal dysfunction and cell death.
Strong evidence exists for calpain activation after TBI, pointing to these
proteases as key mediators in cell death and dysfunction. Both lateral FPI
(Saatman et al., 1996a) and CCI injury (Newcomb et al., 1997) triggered early
posttraumatic calpain activity recognized by an antibody specific for calpainmediated spectrin proteolytic fragments in association with regions of subsequent
cell death. These results were supported by immunoblot data demonstrating calpain activation within 6 h of CCI injury, preceding a rise in spectrin breakdown
products and neuronal degeneration (Kampfl et al., 1996). These studies and
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others provide compelling evidence for a relationship between calpain activation
and the neurodegenerative pathology of TBI.
Calpain inhibition by exogenous synthetic agents has helped to directly
identify calpains as major mediators of pathology, making calpain inhibition a
plausible strategy for therapeutic intervention. Pharmacological calpain inhibitors
include several classes of peptide compounds targeted at the catalytic site of
calpains as well as non-peptide inhibitors, which affect the catalytic properties of
calpains by indirectly binding to target sites responsible for conformational
changes of the protein (Carragher, 2006). The effectiveness of each inhibitor
varies based on its cell permeability, solubility, and pharmacokinetics, requiring
careful consideration in choosing the most appropriate inhibitor. Above all, the
primary limitation to these inhibitors has been their lack of specificity for calpains
compared to other cysteine or enzymatic proteases like cathepsins, so their
results must be interpreted carefully. By contrast, calpastatin, the endogenous
inhibitor of calpains, is specific for calpains.

CALPASTATIN
Biochemical structure
Calpastatin is an intracellular 110 kDa protein consisting of an N-terminal
leader domain followed by four identical inhibitory domains, each able to
specifically inhibit one molecule of calpain (Maki et al., 1987, Goll et al., 2003,
Hanna et al., 2008) (Figure 1.4A). This basic inhibitory structure is consistent
across the several known calpastatin isoforms that result from different
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promoters or alternative splicing of the N-terminal region (Takano et al., 1999,
Takano et al., 2000, Parr et al., 2004). Type III, or prototypical, calpastatin is
ubiquitously expressed within the cytosol of mouse tissue (Goll et al., 2003).
Calpastatin reversibly binds at both sides of calpain’s active site to block
its enzymatic activity (Crawford et al., 1993, Goll et al., 2003, Hanna et al., 2008,
Moldoveanu et al., 2008). When free calcium levels rise and activate calpains, a
conformational change in the protease allows for inhibitor binding across the
active site of calpain, blocking the active site and its access to substrates (Hanna
et al., 2008, Moldoveanu et al., 2008) (Figure 1.4B). Studies performed with
purified calpastatin have documented its degradation into smaller-sized
fragments when co-incubated with calpains (Pontremoli et al., 1991, Doumit and
Koohmaraie, 1999), suggesting calpastatin may mediate inhibition of calpains by
acting as a suicide substrate. However, calpastatin degradation could be
competitively inhibited by the addition of another calpain substrate (Pontremoli et
al., 1991) such that calpastatin may not be a preferential substrate for calpain in
the presence of additional protein substrates. In addition, calpastatin actually
appears to evade proteolysis by calpains through a unique interaction with the mcalpain active site domain (Hanna et al., 2008, Moldoveanu et al., 2008).
Calpastatin has also been recognized as a substrate for caspase-3 and caspase1 during apoptosis (Wang et al., 1998) pointing to a mechanism for increased
calpain activity and crosstalk between the two proteolytic families. Limited
proteolysis of calpastatin, however, may not completely destroy its inhibitory
activity and instead may cause the release of its repetitive inhibitory domains (De
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Tullio et al., 2000). Despite these reports citing calpastatin degradation, changes
in the molecular weight of calpastatin can be the product of its random coil
conformation causing anomalous migration patterns during gel electrophoresis or
alternative splicing (Goll et al., 2003) and, therefore, must be interpreted
carefully.
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Figure 1.4. Basic structure and function of calpastatin, the specific
inhibitor of calpains. A) The structure of prototypical calpastatin consists of an
N-terminal leader (L) domain, followed by four identical inhibitory domains (1-4).
Each inhibitory domain contains subdomains A, B, and C, specific sequences
that bind across the calpain molecule. B) Calpastatin’s inhibitory regions
reversibly bind to calcium-bound calpain blocking its enzymatic activity and
access to substrates. Calpain domain IV of the large subunit and domain VI of
the small subunit are essential in mediating this close contact with calpastatin.
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Physiological function and regulation
As the specific inhibitor of calpains, calpastatin is co-expressed with
calpains in the cytosol of vertebrate cells (Goll et al., 2003) and is found uniformly
throughout the brain (Li et al., 1996). Throughout development, protein and
message levels of calpastatin were shown to parallel a progressive increase in
calpain-1 between embryonic day 18 and postnatal day 90 in the rat brain (Li et
al., 2009). The physiological or pathological significance of calpastatin
expression data alone is difficult to interpret since various regulatory mechanisms
are available to influence calpastatin’s interaction with calpain and thus its
inhibitory activity. Calpastatin does not contain any predicted calcium-binding
sites, yet calcium binding to calpains and accompanying autolysis reduces the
calcium concentration required for calpastatin binding to calpains (Kapprell and
Goll, 1989, Goll et al., 2003). Therefore, alternative mechanisms that change the
location or protein interaction of calpains and calpastatin are necessary for
calpain proteolysis to occur under physiological conditions. Both protein kinase A
(PKA) and protein kinase C (PKC) are intracellular kinases shown to
phosphorylate calpastatin, affecting its localization and function, respectively.
Phosphorylation of calpastatin by PKA promotes calpastatin aggregation while
phosphorylation by PKC reduces its inhibitory function (Salamino et al., 1997,
Averna et al., 2001). These modifications restrict or reduce calpastatin’s
interaction with calpain resulting in calpain’s proteolytic activation and substrate
degradation. Several reports cite the presence of additional endogenous calpain
inhibitors, Gas2 and serpins, that act to regulate apoptotic and necrotic
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mechanisms, respectively (Brancolini et al., 1995, Benetti et al., 2001, Luke et
al., 2007); however, limited information regarding their specificity, tissue
expression, or pathological function prevents direct comparison to the unique
inhibitory properties of calpastatin.

Calpastatin in pathology
Few studies have assessed the inhibitory or expression changes of
calpastatin that could lead to increased calpain activity following
neurodegeneration disease or traumatic insult. Under conditions of ischemia, a
decrease in calpastatin expression concomitant with its degradation was noted in
vulnerable cell populations and brain regions, suggesting dysregulated calpain
activation after insult and support for endogenous calpastatin as a substrate of
calpains (Saido et al., 1997, Blomgren et al., 1999). Reductions in calpastatin
were also identified in the cortex and hippocampus of a transgenic mouse model
of Alzheimer’s disease (Vaisid et al., 2007), later confirmed in diseased human
brains coincident with increased calpain activity and tau hyperphosphorylation
(Rao et al., 2008). With age, it appears that calpains become abnormally
activated both by dysregulated calcium homeostasis and a decline in regulation
by calpastatin that can ultimately lead to neuronal death and synaptic loss. This
age-related decline in calpastatin expression was also identified in older rats, and
was associated with greater pathological damage after spinal cord injury
(Wingrave et al., 2004). In turn, reduced calpastatin levels due to proteolysis or
transcriptional regulation may provide a trigger for increased calpain activation
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and partially explain the increased susceptibility for neurodegenerative disease
or damage with age.
Despite the rapid activation of calpains after TBI, only delayed increases
in calpastatin protein (Newcomb et al., 1999) and mRNA (Ringger et al., 2004)
were identified in the cortex and hippocampus after CCI injury. The reciprocal
relationship between calpain and calpastatin appears to be a combination of
abnormal calpain activity and loss of calpastatin through proteolysis; however,
the transcriptional regulation or possible feedback mechanisms within the
calpain-calpastatin system is relatively unknown, especially with trauma. In a
transgenic model of retinal degeneration, reductions in mRNA and protein
expression of calpastatin and its supposed transcriptional activator, CREB, were
coincident with increased calpain activity without transcriptional changes in
calpain isoforms (Paquet-Durand et al., 2006), but it is unclear whether increased
calpain activity led to decreased calpastatin or vice versa.
Despite limited understanding of pathological calpain-calpastatin
regulation, the apparent decline in expression or activity of calpastatin after
disease or traumatic insult in addition to the unregulated increase in calpain
activity supports the participation of calpains in mediating excitotoxic and
neurodegenerative pathology. Therefore, strategies targeting calpains or
augmenting calpastatin may ameliorate neuronal damage and dysfunction
associated with ischemia, age-related disease, and trauma.

MANIPULATING CALPAINS AND CALPASTATIN
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Clear evidence is available to link increases in calpain activity or loss of
endogenous inhibition by calpastatin to calcium-induced physiological and
pathological events. Pharmacological and genetic strategies that target calpains
or calpastatin have been developed to identify the distinct role calpains play in
neurodegenerative diseases and trauma and investigate the therapeutic potential
of calpain inhibition in these processes.

Strategies targeted at calpains
Support for pharmacological calpain inhibitors in the treatment of
excitotoxic injury was propelled by studies in models of ischemia. Administration
of calpain inhibitors such as E-64-d, AK275, AK295, MDL-28170, and SNJ-1945
were effective in reducing infarct volume after focal ischemia in the rodent
(Bartus et al., 1994a, Bartus et al., 1994b, Markgraf et al., 1998, Tsubokawa et
al., 2006, Koumura et al., 2008). This neuroprotective outcome was maintained
even when treatment with MDL-28170 or SNJ-1945 was delayed up to 6 h postischemia (Markgraf et al., 1998, Koumura et al., 2008). In models of transient
global ischemia, continuous pre-treatment with the calpain inhibitor leupeptin
afforded protection of CA1 hippocampal cell viability and electrophysiological
function (Lee et al., 1991). When treatment was initiated after ischemia,
continuous intravenous administration of MDL-28170 or CEP-3453 also reduced
ischemia-induced CA1 cell death (Rami et al., 2000, Frederick et al., 2008). The
duration and route of administration may be important factors in achieving
neuroprotection as only modest, non-significant reductions in CA1 cell death
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were identified with repeated intraperitoneal doses of MDL-28170 following
reperfusion (Li et al., 1998).
Early studies in spinal cord injury demonstrated that treatment with the
calpain inhibitor E-64-d could reduce calpain activity and apoptosis (Ray et al.,
2000, Ray et al., 2001), while treatment with CEP-4143 could further preserve
axonal structure and motor function (Schumacher et al., 2000). Direct intraspinal
administration or daily intraperitoneal injections over 7 d of MDL-28170 was
required for improved long-term tissue sparing and locomotor function after
spinal cord injury (Yu and Geddes, 2007, Yu et al., 2008), which may be
mechanistically linked to reductions in calpain substrate proteolysis (Zhang et al.,
2003, Hung et al., 2005). Spinal cord injured rats receiving single injections, both
early and delayed, of AK295 exhibited a decrease in numbers of apoptotic cells
and reduction in long-term motor deficits (Colak et al., 2009), indicating next
generation inhibitors may not require continued post-injury dosing.
Despite their promise in ischemia and spinal cord injury, use of
pharmacological calpain inhibitors in TBI has generated mixed results.
Reductions in calpain-mediated spectrin or neurofilament breakdown were
identified in studies using calpain inhibitor 2, MDL-28170, and SNJ-1945
following CCI injury (Posmantur et al., 1997, Thompson et al., 2010, Bains et al.,
2012), showing promise for posttraumatic calpain inhibition in protecting against
neurochemical proteolytic events. However, the histological neuroprotective
effect of calpain inhibition is less clear. Treatment with calpain inhibitor 2
decreased contusion volume by qualitative analysis at 24 h post-CCI (Posmantur
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et al., 1997), an outcome that was not evident after administration of the more
selective inhibitors MDL-28170 or AK295 quantified at 48 h or one week after
injury, respectively (Saatman et al., 2000, Thompson et al., 2010). Single dose,
pre- or post-injury administration of MDL-28170 reduced axonal damage
following diffuse brain injury (Buki et al., 2003, Ai et al., 2007); however, preinjury dosing alone was ineffective after in vivo optic nerve stretch (Ma et al.,
2012a) suggesting that prolonged or post-injury treatment may be necessary for
sufficient calpain inhibition in the context of axonal injury. Despite this
discrepancy in neuronal protection or axonal preservation with calpain inhibition,
treatment with AK295 or SJA-6017 afforded behavioral improvement after lateral
FPI or weight drop injury, respectively, which did not require reductions in
calpain-mediated proteolysis of spectrin (Saatman et al., 1996b, Saatman et al.,
2000, Kupina et al., 2001).
These studies indicate the effectiveness of pharmacological calpain
inhibitors at reducing calpain activation or behavioral dysfunction after injury.
Depending on the inhibitor used, timing of administration and dosing paradigm,
calpain inhibition afforded structural and functional benefits in several models of
excitotoxic or traumatic injury. However, properties associated with their
selectivity, bioavailability, tissue penetration, and administration parameters have
obvious implications for data interpretation. Strategies that achieve a more
specific inhibition of calpain may have greater utility towards clearly implicating
calpains in the pathogenic cascade of neurodegeneration and injury.
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Due to the embryonic lethality of dual isoform and calpain-2 knockout
mice, genetic models for calpain inhibition that target calpains have been
restricted to calpain-1 knockout mice or viral-mediated gene knockdown. The few
studies that have employed these strategies following excitotoxic pathology show
compelling results. Knockdown of the catalytic subunit of m-calpain increased
hippocampal neuronal survival after NMDA-mediated excitotoxicity (Bevers et al.,
2009) while -calpain but not m-calpain knockdown suppressed ischemiainduced CA1 hippocampal cell death and protected neuronal function (Bevers et
al., 2010). Following spinal cord injury, knockdown of calpain-1 reduced both
histopathological and locomotor deficits (Yu et al., 2012). Additionally, calpain-1
deletion reduced cortical cell death, neurodegeneration and apoptosis following
contusion TBI (Yamada et al., 2012). These studies continue to support a
neuroprotective outcome through reduction in calpains, now with more direct
targeting of these proteases by genetic manipulation. Additionally, novel mouse
models with conditional calpain-2 or dual isoform knockout (Takano et al., 2011)
offer innovative tools to study the role of calpains in neurodegeneration and
traumatic injury, especially ideal for understanding the isoform-specific roles of and m-calpains in pathology.

Strategies targeted at calpastatin
Manipulation of calpastatin to enhance endogenous inhibitory
mechanisms enables suppression of both - and m-calpain, providing a powerful
research tool for understanding the role of pathological calpain proteolysis. In
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addition, the specific nature of calpastatin’s inhibition of calpains is a unique and
important element. Therefore, potential problems associated with the delivery
and selectivity of pharmacological calpain inhibitors can be minimized or avoided.
The efficacy of transgenic calpastatin manipulation in reducing calpain
activation is documented in several studies. Transgenic mice expressing
calpastatin under a neuron-specific calcium-calmodulin dependent protein kinase
II  (CaMKII) promoter exhibited potent reduction in in vitro m-calpain activity,
resulting in significantly fewer apoptotic events and less hippocampal cell death
in response to excitotoxic insult (Higuchi et al., 2005, Takano et al., 2005). An
alternative calpastatin overexpressing mouse (Thy1.1 promoter) confirmed the
therapeutic potential for calpastatin overexpression following excitotoxicity by
demonstrating reductions in calpain-mediated substrate proteolysis and CA1
hippocampal cell death (Rao et al., 2008). Genetic overexpression of calpastatin
in these models conferred similar neuroprotective outcomes seen in excitotoxicity
studies using pharmacological calpain inhibitors (Rami et al., 1997, Volbracht et
al., 2001), confirming a direct link between calpain activation and hippocampal
cell death. In a model of Alzheimer’s disease, mice with calpastatin
overexpression exhibited reduced -amyloid and tau pathology and longer
lifespan compared to control diseased mice (Higuchi et al., 2012), such that
restoring calpastatin levels could hinder calpain-mediated formation of hallmark
Alzheimer’s pathology. Constitutive calpastatin overexpression in transgenic
models undoubtedly has implicated calpains in disease or traumatic pathology,
but restricts manipulation of the timing and location of calpain inhibition that may
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be necessary to optimize the effectiveness of treatment. Therefore, strategies
that are more adaptable can increase understanding on the actions of calpains
after injury and may more readily lead to translatable therapeutics.
Viral-mediated delivery of calpastatin once again takes advantage of the
specificity of calpastatin and may circumvent some of the limitations associated
with genetic alterations. Calpastatin overexpression through adenoviral infusion
afforded neuroprotection of dopamine neurons and behavioral improvements in a
model of toxin-induced Parkinson’s disease in rodents (Crocker et al., 2003,
Grant et al., 2009). Only one study has investigated use of viral-mediated
calpastatin expression and in vivo traumatic injury, reporting partial preservation
of axons with calpastatin overexpression after optic nerve stretch injury (Ma et
al., 2012b). Genetic or viral-mediated alterations of calpastatin are ideal for
preclinical studies since full-length calpastatin is unable to cross the blood-brain
barrier for exogenous delivery. Yet, these strategies may be difficult or
impractical to translate into treatments for human patients. Thus, novel peptide
inhibitors or calpastatin mimetics that exploit the specific nature of calpastatin’s
inhibitory interaction with calpains provide an alternate approach. Membranepermeable peptides derived from the essential subdomains of calpastatin
inhibitory sequences were shown to inhibit calpain activity in vitro (Gil-Parrado et
al., 2003a, Fiorino et al., 2007) and in models of cell death and ischemia
(McCollum et al., 2006, Anagli et al., 2009).
Overall, strategies aimed at reducing the activation of calpain proteases
after neurodegeneration or trauma generally have been effective in reducing
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calpain activity or calpain-mediated substrate proteolysis. Pharmacological,
genetic and gene-knockdown strategies targeted at calpains have helped
elucidate a role for calpain activity after trauma but have also generated
considerable uncertainty given the apparent isoform-specific functions of - and
m-calpains and drugs’ lack of specificity for calpains. Genetic models that
overexpress calpastatin or calpastatin-like mimetics seem to be the most optimal
approaches to specifically implicate calpains in posttraumatic pathology and
guide further advancements in drug design for TBI patients. Given the highly
specific inhibition of calpain by calpastatin, genetic overexpression of calpastatin
was chosen to determine the efficacy of posttraumatic calpain inhibition.
Calpastatin transgenic mice are evaluated using a comprehensive set of
substrate proteolysis, neuronal degeneration and death, and behavioral
outcomes in subsequent chapters.

CELLULAR AND FUNCTIONAL OUTCOMES USED TO EVALUATE THE
EFFICACY OF POSTTRAUMATIC CALPAIN INHIBITION
Substrate proteolysis
An essential method of examining effective calpain inhibition is through
immunohistochemical or immunoblot analysis of various calpain substrates after
injury. Calpain-mediated fragmentation of substrates is validated when cleavage
patterns are reproduced in vitro or in situ by incubation with purified calpains. The
development of antibodies that bind to these calpain-specific breakdown
products has further enhanced identification of calpain activity in vivo, as it may
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be difficult to assess acute changes in the enzyme itself. In turn, prevention of
substrate loss or its characteristic fragmentation in vivo by specific inhibition of
calpains using knockout or calpastatin overexpression strategies confirms
calpain-specific cleavage. Because each substrate serves an important purpose
in neuronal structure or function, analysis of substrate proteolysis may indicate a
mechanism by which calpains cause damage, cell death, and functional
abnormalities after traumatic injury.
Substrate proteolysis is a telltale sign of calpain activation, especially if
cleavage can be directly linked to calpains via production of unique fragments
after incubation with the protease or detection by calpain cleavage-specific
antibodies. However, it may be difficult to contextualize calpain-mediated protein
cleavage within the posttraumatic environment considering the simultaneous
involvement of other secondary mechanisms. Thus, a reduction in substrate
proteolysis achieved by calpain inhibition is not a complete or direct measure of
neuroprotection and behavioral efficacy. Additional cellular and functional
measurements are necessary to draw conclusions about the protective or
beneficial effects of calpain inhibition.

Neurodegeneration and cell death
Cell death is a principal outcome following traumatic injuries as a result of
secondary neurodegenerative mechanisms that alter ion homeostasis, induce
oxidative damage and drive protease activation. Common methods for analyzing
cell death include terminal deoxynucleotidyl transferase dUTP nick end labeling
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(TUNEL) to identify DNA damage coupled with the assessment of necrotic and
apoptotic morphology or staining with the fluorochrome, Fluoro-jade, to discern
degenerating cells. These markers provide a discrete snapshot of regional and
temporal posttraumatic cell death within the injured brain. Silver staining for
neurodegeneration can provide a more cumulative assessment of evolving
cellular and axonal pathology occurring many hours to days after injury.
Alternatively, neuronal staining using hematoxylin and eosin, cresyl violet, or
NeuN will identify viable neurons and thus can be used as a marker to determine
the extent of neuronal survival after injury. While each marker offers its own
separate advantages in identifying pathology, neuronal degeneration and death
is an important outcome in evaluating brain injury-induced damage and the
efficacy of calpain inhibition.
In contusion CCI injuries, neuronal death begins within hours of impact,
with significant cortical cavitation and regional hippocampal cell degeneration
observed up to 24 h after severe TBI in mice (Pleasant et al., 2011). Progressive
neurodegeneration in the injured hemisphere was observed to peak 48-72 h after
CCI (Hall et al., 2005, Hall et al., 2008), which is subsequent to the peak in
spectrin breakdown (Kampfl et al., 1996, Hall et al., 2005, Deng et al., 2007).
Manipulation of calpains via pharmacological inhibition post-CCI was ineffective
at attenuating neuronal loss (Saatman et al., 2000, Thompson et al., 2010).
However, injured calpain-1 knockout mice exhibited a significant reduction in
cortical contusion size following CCI brain injury (Yamada et al., 2012). Due to
limited selectivity of pharmacological calpain inhibitors in the former two studies,
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more specific calpain inhibition with genetic knockout may be required to
conclusively determine a role for calpains in injury-induced neurodegeneration. In
addition, systemic administration of exogenous inhibitors may delay the time to
reach therapeutic concentrations in vulnerable brain regions after injury, leading
to incomplete conclusions on the efficacy of calpain inhibition. Difficulties in drug
administration can be avoided with genetic manipulation and may provide clearer
support for the neuroprotective potential of calpain inhibition.
Functional deficits may arise as a result of cell death after TBI, or
alternatively from sublethal cellular changes such as axonal or synaptic injury.
Pathogenic events occurring at the level of the axon or synapse are not easily
accounted for by overt neuronal labeling, yet may be modulated by calpain
inhibition. Behavioral assessments can further validate the extent of injury or
repair and are key indicators of the therapeutic relevance of a particular
intervention.

Behavioral assessments
Experimental injury to particular brain regions, especially the cortex and
hippocampus, can reproduce many of these behavioral outcomes and help
identify pathological targets or areas involved in mediating the dysfunction. In
rodents, motor behavior deficits are often characterized by reflex and balance
impairment, hemiparesis with unilateral injuries, and limb weakness (Fujimoto et
al., 2004, Saatman et al., 2006) and are often assessed experimentally by tasks
that evaluate and score limb movement and balance. Although rodents exhibit
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spontaneous recovery of function over time, the initial deficits are often large
enough to allow beneficial effects of treatments targeting early secondary
mechanisms of damage, including calpains, to be detected (Zhao et al., 2012). In
rodent models of TBI, cognitive and emotional abnormalities manifest as spatial
and recognition memory impairment, increased anxiety, and depressive behavior
(Smith et al., 1995, Fujimoto et al., 2004, Saatman et al., 2006, Washington et
al., 2012). Cognitive evaluations have typically relied on the Morris water maze
task to assess encoding, consolidation, and retrieval aspects of learning and
memory. Additional cognitive measures including the novel object recognition
paradigm evaluating recognition memory also show TBI-induced deficits (Prins et
al., 2010, Scafidi et al., 2010, Wakade et al., 2010). In addition to markers of
neuronal damage, behavioral measurements are valuable tools for evaluating
treatment strategies, like calpain inhibition, that can improve outcome after TBI.
Brain injury-induced motor and cognitive behavioral impairments in
rodents are lessened with calpain inhibition. Persistent motor and memory
deficits evaluated at 48 h following lateral FPI in rats were alleviated with
continuous intraarterial infusion of AK295 initiated 15 min post-injury (Saatman et
al., 1996b). Consistent with this improved outcome, calpain activation
suppressed by compound SJA6017 administered up to 4 h after weight-drop
injury was associated with improvements in forepaw gripping ability in mice
(Kupina et al., 2001). Behavioral improvements identified above in diffuse or
mixed focal and diffuse models show promise for calpain inhibition as a treatment
strategy following injury. However, no studies prior to our work have assessed
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the therapeutic potential of calpain inhibition on behavioral parameters following
CCI injury, which produces a contusive, focal pathology.

SUMMARY
Given the scope of TBI, it is imperative to find an effective therapeutic
agent or pharmacological treatment that can successfully mitigate the
pathological responses to injury. Among these responses, the calciumdependent proteases, calpains, are chief mediators of cellular damage, acting
downstream of rapid and prolonged injury-induced calcium dysregulation.
Apparent unregulated cleavage of vital cytoskeletal, membranous, and cytosolic
proteins by calpains occurs despite coincident expression of calpains’
endogenous inhibitor, calpastatin. Genetic and pharmacological methods of
calpain inhibition have been evaluated in a variety of neurodegenerative disease
and trauma models; however, embryonic lethality with constitutive genetic
deletion of calpains prevents disruption of both calpain isoforms, and problems
associated with drug selectivity and delivery complicate attempts to specifically
implicate calpains as central mediators of damage.
The dissertation herein describes the comprehensive studies undertaken
to investigate the therapeutic potential of calpastatin following contusion injury
(Figure 1.5). Inhibition of calpains by calpastatin takes advantage of the specific
nature of the calpain-calpastatin interaction in order to clearly implicate calpains
in cell death and behavioral dysfunction after TBI. To this end, two separate
models of transgenic mice were used to test the hypothesis that calpastatin
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overexpression will reduce posttraumatic calpain activity affording
neuroprotection and behavioral efficacy. Neuronal-specific calpastatin expression
was achieved using transgenic mice that overexpress the human calpastatin
(hCAST) construct under control of a calcium-calmodulin dependent kinase II 
promoter (Chapter 2). While hCAST expression in this model previously afforded
hippocampal neuroprotection after excitotoxic stimulus (Higuchi et al., 2005), our
studies are the first to evaluate transgenic calpastatin overexpression after
experimental TBI. Subsequently, we characterized a novel calpastatin
overexpressing transgenic mouse model with ubiquitous hCAST expression
driven by the prion protein promoter (Chapter 3). This model exhibits robust
calpastatin expression within nervous system and peripheral tissue, at levels that
surpassed the previously tested neuron-specific mouse model. Significant
attenuation of calpain activation observed with ubiquitous hCAST expression
propelled additional investigations of posttraumatic behavior and
neurodegeneration in the CCI model (Chapter 4). Collectively, our analysis of
protein, histological, and behavioral data from two separate transgenic mouse
lines has generated considerable speculation on calpastatin as a therapeutic
approach to TBI, requiring thorough discussion of our major findings and
considerations for future research directions (Chapter 5).
Although genetic alterations are not feasible for rapid translation to clinical
TBI, strategies like calpastatin overexpression that are able to specifically inhibit
calpains can provide valuable information on the role of calpains in the sequelae
of injury and invariably link calpain activation to a multitude of traumatic and
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neurodegenerative pathologies. If protective, calpastatin can be used as a model
for the design of novel pharmacological inhibitors to specifically target regions of
calpain activation in TBI and neurodegenerative disorders.
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Figure 1.5. Calpastatin overexpression as a therapeutic approach to
traumatic brain injury. A) Brain injury results in rapid, overwhelming calcium
influx into the neuron leading to the activation of calcium-dependent proteases,
calpains. Subsequent proteolysis of numerous cellular substrates contributes to
neuronal damage and death and motor and cognitive functional impairments. B)
Although the specific inhibitor of calpains, calpastatin, is present within neurons,
normal levels of calpastatin are unable to fully prevent the damaging proteolytic
activity of calpains after injury. Therefore, we hypothesize that overexpression of
calpastatin will effectively inhibit calpain activation, sparing substrates and
neurons from damage and ultimately mitigate behavioral deficits following severe
brain injury.

Copyright © Kathleen Marie Schoch 2013
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Preface

Chapter 2 is reprinted, with alterations described herein, from
Experimental Neurology, Vol. 236(2), K.M. Schoch, H.N. Evans, J.M. Brelsfoard,
S.K. Madathil, J. Takano, T.C. Saido, and K.E. Saatman, “Neuronal-specific
calpastatin overexpression limits calpain-mediated proteolysis and behavioral
deficits following traumatic brain injury,” pp. 371-382. Copyright 2012, with
permission from Elsevier. Alterations to the published manuscript were made to
the “Introduction” to reduce redundancies with Chapter 1. Figure legends were
expanded from the original manuscript to provide greater detail. Minor additions
to other sections were included for coherency.
Work in this chapter represents a collaboration among the coauthors.
Specific contributions are as follows: Immunohistochemical and immunoblot
characterization of calpastatin transgenic mice (Figure 2.1) was performed by
K.M. Schoch with the exception of protease activity data (Figure 2.2) by S.K.
Madathil. Homogenates for spectrin proteolysis were generated by S.N.
Thompson (Figure 2.3A) and K.M. Schoch (Figure 2.3B, C) and analyzed by
K.M. Schoch. All behavioral testing and histological analyses were performed by
either H.N. Evans or J.M. Brelsfoard. Breeder pairs of mice were contributed by
J. Takano and T.C. Saido. Preparation of the manuscript for publication was
performed by K.M. Schoch and K.E. Saatman.
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CHAPTER 2

Neuronal-specific calpastatin overexpression limits calpain-mediated
proteolysis and behavioral deficits following traumatic brain injury

INTRODUCTION

Efforts to reduce the high incidence of traumatic brain injuries (TBIs) are
primarily preventative, and currently no pharmacological treatment has been
proven to lessen the secondary neurodegenerative pathology, indicating a critical
need for an effective treatment that could mitigate these early cellular events and
prevent the long-lasting deficits of injury. Various targets for treatment have been
identified through extensive study of the secondary injury mechanisms that
mediate cellular and functional damage after TBI and other neurodegenerative
conditions. Many of these mechanisms involve calcium dysregulation associated
with excitotoxicity and calcium influx following mechanical damage to the cell
membrane, overactivation of membrane receptors and channels, or excessive
depolarization (Faden et al., 1989, Palmer et al., 1993, Arundine and Tymianski,
2004, Weber, 2004).
Increases in intracellular free calcium or altered calcium handling
mechanisms result in the activation of calcium-dependent proteases, or calpains,
that contribute to the secondary injury cascade (Palmer et al., 1993, Arundine
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and Tymianski, 2004, Sun et al., 2008). Calpain activation contributes to the
evolution of neurodegeneration in Alzheimer’s disease, Parkinson’s disease, and
amyotrophic lateral sclerosis as well as damage associated with stroke, TBI, and
spinal cord injury (Camins et al., 2006). The pathological activation of calpains
that occurs after TBI and other traumatic insults results in the cleavage of cellular
proteins. Without appropriate regulation, calpains can mediate proteolytic
damage within the cell and lead to cell demise.
Although no neuron-specific calpains have been identified, the highly
studied ubiquitous calpains, - and m-calpain, have been implicated in neuronal
degeneration in TBI. In rodents, posttraumatic -calpain autolysis precedes the
accumulation of calpain-mediated -spectrin breakdown products in the injured
cortex (Kampfl et al., 1996, Pike et al., 1998). Calpain-mediated spectrin
proteolysis appears early in soma and dendrites and, in the hours following
injury, in regions closely correlating with subsequent neurodegeneration
(Saatman et al., 1996a, Newcomb et al., 1997). Pharmacological inhibition of
calpains results in improved motor and cognitive behavior and decreased axonal
injury with little alteration in contusion size and inconsistent or incomplete
attenuation of calpain-mediated spectrin breakdown (Saatman et al., 1996b,
Posmantur et al., 1997, Saatman et al., 2000, Kupina et al., 2001, Buki et al.,
2003, Ai et al., 2007, Thompson et al., 2010). However, limitations in the
specificity, solubility, tissue penetration, and stability of these calpain inhibitors
can complicate interpretation of pathological outcomes. Investigations into the
endogenous, specific inhibitor of calpains, calpastatin, may be advantageous in
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limiting calpain-mediated protein degradation and critical in designing future,
more effective calpain inhibitor therapies.
Despite its co-expression with calpains in the cytosol, few studies have
assessed the action of calpastatin in response to injury. After trauma, prolonged
calpain activity suggests that the endogenous action or levels of calpastatin may
be insufficient to fully inhibit the proteolytic activity of calpain. Employing a
transgenic model of calpastatin overexpression allows researchers to specifically
target calpains without the technical hurdles associated with proper timing and
dosing regimens of a pharmacological inhibitor. Transgenic calpastatin
expression previously was shown to be neuroprotective following excitotoxic
insult, with reductions in both dendritic degeneration and axonal damage
(Higuchi et al., 2005). Alternatively, genetic deletion of calpastatin resulted in
increased calpain-mediated substrate cleavage and hippocampal
neurodegeneration (Takano et al., 2005). Based on these results, calpains are
clear mediators of excitotoxic injury and inhibition by calpastatin is effective in
reducing cellular damage. The characteristic excitotoxicity and calpain activation
that occur with TBIs may similarly be mitigated by calpastatin overexpression.
We hypothesized that calpastatin overexpression in a transgenic mouse
model would reduce proteolysis after TBI, thereby attenuating cell death and
behavioral dysfunction. To this end, we comprehensively assessed acute
calpain-mediated spectrin breakdown, cortical and hippocampal neuroprotection,
and motor and cognitive function after contusion brain injury in mice expressing
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human calpastatin under control of a neuron-specific calcium-calmodulin
dependent kinase II  subunit promoter (CaMKII-hCAST).
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METHODS

Experimental animals
Transgenic mice expressing human calpastatin (hCAST) under control of
the neuron-specific CaMKII promoter were created on a C57Bl/6 background
and characterized as previously described (Higuchi et al., 2005, Takano et al.,
2005). These mice exhibit a 3-fold increase in calpastatin activity and display no
adverse phenotype (Higuchi et al., 2005). A colony was established at the
University of Kentucky from which CaMKII-hCAST transgenic (Tg) and wildtype
(WT) littermates were bred for experimental studies. All mice were housed in
controlled conditions under a 14:10 light:dark photoperiod and allowed food and
water ad libitum. Animal husbandry and surgical procedures were performed
according to standards set by the University of Kentucky Institutional Animal
Care and Use Committee and federal guidelines (National Research Council
(U.S.). Committee for the Update of the Guide for the Care and Use of
Laboratory Animals. et al., 2011).

Tissue processing
For calpastatin inhibitory activity or immunoblot analyses of brain tissue,
mice were asphyxiated with carbon dioxide gas and decapitated. Brain tissue
was promptly removed and the contralateral and ipsilateral cortices and
hippocampi were dissected apart. Tissue chunks were flash frozen in cold
methanol and stored at -80C until homogenization.
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For histological preparation of brain tissue, mice were anesthetized (65
mg/kg sodium pentobarbital, intraperitoneally), transcardially perfused with 0.9%
heparinized saline followed by 10% neutral buffered formalin, and decapitated.
After overnight fixation of the head, the brain was removed from the skull and
fixed an additional 24 h before being placed in 30% sucrose. Brains were frozen
in cold (-30°C) isopentanes and cut in coronal sections (40 m) on a sliding
microtome (Dolbey-Jamison, Pottstown, PA). Free-floating tissue sections were
stored in cryoprotectant (30% ethylene glycol, 30% glycerol) at -20C until use.

Immunohistochemistry
Free-floating tissue sections were rinsed in Tris-buffered saline (TBS) and
pretreated with 3% hydrogen peroxide solution for 30 min to quench endogenous
peroxidases. Nonspecific antibody binding was blocked via incubation in 5%
NHS/0.1% Triton X-100/TBS solution for 30 minutes. Sections were incubated at
4°C overnight in anti-calpastatin primary antibody (mouse, 1:1000, Millipore Co.)
diluted in 5% NHS/0.1% Triton X-100/TBS. Incubation in secondary antibody
diluted in 5% NHS/0.1% Triton X-100/TBS solution (donkey anti-mouse IgG
1:5000, Jackson ImmunoResearch Laboratories, Inc., West Grove, PA) was
performed for 1 h at room temperature. Signal from the secondary antibody was
amplified using an avidin-biotin complex solution (1:50, Vectastain Elite ABC kit,
Vector Laboratories, Inc., Burlingame, CA) and developed using
diaminobenzidine (DAB) (Vector Laboratories, Inc.). Negative controls were
treated identically but were incubated overnight in diluent without primary
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antibody. Cortical and hippocampal areas were imaged under a light microscope
(Eclipse 50i, Nikon Corporation, Tokyo, Japan) to compare the presence or
absence of immunoreactivity between genotypes.

Calpastatin inhibitory activity
Cortical and hippocampal tissues were homogenized via sonication in a
calcium-free buffer solution (20mM Tris, 1mM EDTA, 100mM KCl, 0.1% 2mercaptoethanol), and centrifuged at 21,500 g or 20 min at 4°C. Supernatant
fractions were collected for protein concentration determination (Pierce BCA
protein assay kit, Thermo Scientific, Rockford, IL). To determine calpastatin’s
inhibitory activity, samples were incubated in the presence of calcium-free buffer
solution and BODIPY-FL casein substrate (EnzChek® Protease Assay Kit,
Invitrogen, Carlsbad, CA) with or without exogenous calpain-II (15.51 g/ml,
porcine kidney calpain-II, Calbiochem, Gibbstown, NJ) for 30 min. Proteases,
including calpains, present in the sample cleave the casein substrate into
fluorescent cleavage products. Sample fluorescence was measured using a
spectrafluorometer (Synergy HT Multi-Mode Microplate Reader, Biotek
Instruments, Winooski, VT) at 485 nm excitation and 528 nm emission
wavelengths. Fluorescence readings were corrected by both EDTA- and calciumcontaining blanks, normalized to soluble protein concentration (Pierce BCA
protein assay kit, Thermo Scientific), and recorded in units of fluorescence/mg of
protein. All samples were run in duplicate or triplicate and the average
fluorescence reading was used for analysis.
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Controlled cortical impact brain injury
Contusion brain injury and its secondary pathology are reproducibly
modeled in mice by a controlled cortical impact (CCI) device (Smith et al., 1995,
Hannay et al., 1999, Hall et al., 2005), which uses a pneumatically driven piston
to deliver a rapid, focal impact injury to the exposed cortex. Operation of the CCI
device is controlled by a computer program allowing for the adjustment of impact
depth and velocity. At a 1.0 mm depth, CCI injury results in regionally selective
hippocampal neurodegeneration and early cortical cell damage that progresses
to cortical cavitation within hours to days after injury (Saatman et al., 2006,
Pleasant et al., 2011). In preparation for CCI injury, adult mice were initially
anesthetized with 3.0% isoflurane (3.0 L/min oxygen) and subsequently
maintained on 2.5% isoflurane (3.0 L/min oxygen) throughout the surgical
procedure. Anesthetized mice were placed within a stereotaxic frame (Kopf,
Tujunga, CA) and a midline scalp incision was made to expose the underlying
skull. A circular, 5 mm diameter craniotomy was made over the left hemisphere,
centered between the bregma and lambdoidal sutures and lateral to the sagittal
suture. Contusion injury was created using a CCI device (TBI-0310 Impactor,
Precision Systems and Instrumentation, Fairfax Station, VA) with a 3.0 mm
diameter, rounded, steel impactor tip. Impact velocity and dwell time were set at
3.5 m/s and 500 ms, respectively, while depth was varied to produce a moderate
(0.5 mm) or severe (1.0-1.2 mm) injury (Saatman et al., 2006). Following impact,
a small cranioplast made of dental cement was secured over the injury site and
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the incision was sutured. Sham mice received identical surgical procedures
without induction of CCI injury. Mice were placed on a heating pad (37°C) for
maintenance of body temperature until fully recovered from anesthesia and freely
ambulating.

Immunoblot for calpastatin and -spectrin
Brain tissue was homogenized via sonication in a lysis buffer solution
(20mM Tris, 150mM NaCl, 5mM EGTA, 10mM EDTA, 10mM HEPES, 1% TritonX, 10% glycerol) containing protease inhibitors (Complete MiniTM Protease
Inhibitor Cocktail tablet, Roche Applied Science, Indianapolis, IN). Samples were
centrifuged at 19,000 g for 20 min at 4C and supernatant fractions were
collected for protein concentration determination (Pierce BCA protein assay kit).
Cortical and hippocampal samples (5 g) were run on 3-8% Tris-Acetate gels
(Criterion XT Precast Gels, Bio-Rad Laboratories, Hercules, CA) and
subsequently transferred to nitrocellulose membrane using a semi-dry
electrophoretic transfer cell. Membranes were blocked in a 5% milk solution in
TBS prior to overnight incubation at 4°C in primary antibody (-spectrin 1:5000,
human calpastatin 1:1000; Millipore Co., Billerica, MA), diluted in 5% milk
solution in 0.05% Tween 20/TBS. Secondary antibodies were prepared in a 5%
milk solution in 0.05% Tween 20/TBS (goat anti-mouse IgG IRDye800 1:5,00010,000; Rockland Immunochemicals, Gilbertsville, PA). Membranes were
visualized using an Odyssey infrared imaging system (LI-COR Biosciences,
Lincoln, NE) and band intensities quantified using Odyssey imaging software.
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Neocortical tissue damage
Tissue sections at 400 m intervals from bregma 0 to -3.5 mm (Paxinos
and Franklin, 2001) were mounted on gelatin-coated slides and dried overnight.
Slides were rehydrated through graded alcohols before staining with 0.5% cresyl
violet (Acros Organics, Morris Plains, NJ). Stained tissue was viewed on a light
microscope (BH2, Olympus America Inc.) equipped with a CCD camera. Using
Bioquant software (version 8.40.20, Bioquant Life Science), the area of intact or
‘spared’ neocortex was analyzed on a live image, alternating between 2X and
10X magnifications as previously described, to separately outline the boundaries
of the ipsilateral and contralateral neocortices at 2X that contained surviving
neurons as verified by Nissl staining and morphological assessment at 10X
magnification (Pleasant et al., 2011). The area of neocortical tissue damage was
calculated as the difference between the contralateral and ipsilateral neocortical
areas, and then integrated over the inter-section distance to obtain the volume of
tissue damage. Data are expressed as a percentage of contralateral neocortical
volume to control for any potential variation in brain size due to age, sex, or
tissue processing.

Fluoro-jade B staining
Degenerating neurons can reliably be detected in injured tissue using the
fluorochrome Fluoro-jade B (Schmued et al., 1997). Prior to mounting on gelatincoated slides, free-floating tissue sections (40 m) were initially exposed to DAB
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for 5 min to react with endogenous peroxidases, eliminating nonspecific
fluorescence due to hemorrhage. Slides were warmed at 40-45°C for 30 min and
dried overnight at room temperature. Following rehydration in 1% NaOH and
alcohol gradient and 0.06% potassium permanganate treatment for 10 min,
tissue was stained with 0.01% Fluoro-jade B (Millipore Co.) in 0.1% acetic acid
and heat-dried at 50°C for 30 min. Slides were immersed in xylenes and
coverslipped with Cytoseal XYL (Richard-Allan Scientific, Kalamazoo, MI). Tissue
sections were imaged on a fluorescence microscope equipped with
epifluorescence (AX80, Olympus America Inc., Melville, NY). The number of
Fluoro-jade B positive cells was counted separately within the dentate gyrus,
CA3/CA3c, and CA1 of the hippocampus and averaged across three sections
selected at 400 m intervals within the injury epicenter (approximately bregma
level -1.4 to -2.5 mm) (Paxinos and Franklin, 2001). Counts were made by an
observer blinded to both genotype and injury condition.

Cognitive and motor behavioral measures
Morris water maze
Post-injury memory retention was assessed using a modified Morris water
maze (MWM) paradigm (Morris, 1984, Saatman et al., 2006), a well-established
and commonly used task known to recruit the hippocampus. For all swim trials,
mice were placed in a 1-m diameter water tank filled with water (19-21°C) made
opaque with non-toxic white paint (Rich Art Co., Northvale, NJ) to conceal a 6.3
cm diameter platform placed 0.5 cm below the water surface. Mice underwent
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two sets of five training trials (total 10 trials per day, 30 minute delay between
sets) for three days prior to CCI injury with the platform in place. During each
trial, mice were placed in the tank at different quadrant locations and, using
externally placed visual cues, had to locate the submerged platform within the
maze. Latency to the platform was recorded. If the mice did not locate the visible
platform within 60 sec, they were placed on the platform for 10 sec after the first
trial and 5 sec on subsequent trials. Five zones, including the submerged
platform and its surrounding locations, were designated for memory score
calculation (Saatman et al., 2006). Memory retention was tested 48 h post-injury
by removing the submerged platform (probe trial) and recording the time spent in
each zone of the maze using an aerial video camera and tracking software
(EZVideo version 5.51DV, Accuscan Instruments Inc., Columbus, OH). A
memory score was calculated as previously described (Saatman et al., 2006).
Following each swim trial, mice were returned to a heated cage for recovery.

Neuroscore
Motor behavior was evaluated using a modified 12-point neuroscore
assessment that is sensitive to both injury severity and treatment (Scherbel et al.,
1999, Saatman et al., 2006) . At 1 d or 2, 4, and 8 d following injury, mice were
subjected to scored behavioral tasks from which points were deducted if the mice
were unable to complete the task. During the grid walk assessment (2 points
total), mice walked on a wire cage top with bars spaced 1.5 cm apart elevated 20
cm above a table. One point each was deducted for a forelimb or hindlimb footfall

57

during 60 sec of free exploration. A cage top task assessed flexion responses of
the forelimbs (3 points) and hindlimbs (3 points) as mice were suspended by the
tail above a cage top. One point deductions were given for hindlimb curling and
for the absence of hindlimb extension and toe splaying. Similarly, one point
deductions were each given for forelimb crossing, hyperactivity, and lack of
forelimb grip strength when lowered to grasp the cage top. Finally, mice were
prodded on one side and guided laterally along a ribbed plastic mat (68.6 cm x
62.2 cm) for four trials with increasing speed as determined by the evaluator. The
ability of the mouse to maintain balance was observed (4 points total, -1
deduction for each trial that results in loss of balance).

Novel object recognition
Cognitive performance was also evaluated using a novel object
recognition (NOR) paradigm (Bertaina-Anglade et al., 2006, Tsenter et al., 2008).
Following an acclimation period in an empty Plexiglas cage (1 h; 1 mouse/cage),
mice underwent baseline (pre-injury) recognition testing in which mice were
individually introduced to two identical objects (object #1), placed in opposite
corners of the cage. The amount of time spent exploring each object was
recorded over 5 min. A mouse was considered to be exploring an object if its
nose was positioned toward the object of interest at a distance of less than 2 cm.
After a 4-h interval, one of the familiar objects was replaced with a novel object
(object #2) and the time of exploration of each object was recorded for 5 min.
Object recognition was assessed prior to injury to evaluate the effect of
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calpastatin overexpression on normal memory function. On the following day,
mice were subjected to CCI injury. At 7 d post-injury, mice were re-introduced to
the initial identical objects for 5 min and, after a 4-hour interval, one object was
replaced with a novel object (object #3). To evaluate the persistence of injury and
transgene effects, mice were introduced to the same familiar object (object #1)
and a novel object (object #4) at 14 d post-injury. Data is reported as a
recognition index which represents the percentage of interaction time spent
exploring the novel object.

Neurological severity score
The neurological severity score (NSS) composite motor function test was
developed for use with a closed head injury model (Tsenter et al., 2008). We
adapted this test for assessing motor deficits 1 h, 1 d, 2 d, 3 d, 5d, and 7d
following CCI injury, focusing on components of coordinated motor function and
balance. Mice were observed traversing Plexiglas beams of 3, 2, 1, and 0.5 cm
width and a 0.5 cm diameter wooden rod (elevated 47 cm), during which deficits
in their movement were recorded. All mice were acclimated for 30 sec to the
beams and rod 24 h prior to CCI injury. Upon post-injury testing, mice were
allowed up to 30 sec to cross the beams and rod, receiving a maximum of 14
points (3 points/beam and 2 points/rod). No points were lost when mice were
successfully able to cross the beam or rod with normal limb movement. Points
were deducted during beam testing for footfalls (-1 point), hanging upside-down
(-1 point), or unwillingness to traverse (-1 point). A mouse that fell from the beam
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received 0 points. During the rod testing, points were deduced for hanging
upside-down (-1 point) and inability to cross the rod (-1 point). Two points were
deducted for falling off the rod.

Statistical analysis
Data are expressed as mean + standard error of the mean (SEM).
Analysis was performed using Statistica (StatSoft, Tulsa, OK). Calpastatin
inhibitory activity was assessed using a two-way ANOVA (genotype x calpain).
Levels of 150 kDa and 145 kDa spectrin breakdown products in the cortex and
hippocampus were separately analyzed using a t-test (0.5 mm injury) or a nested
two-way ANOVA (1.0 mm injury, genotype x injury condition) where the triplicate
samples were treated as a nested variable. Fluoro-jade B-positive neurons,
cortical tissue damage and Morris water maze memory data were assessed
using a two-way ANOVA (genotype x injury condition). Morris water maze
learning data, neurological severity score, and novel object recognition tasks
were analyzed using a repeated measures one-way ANOVA. Neuroscore data
was analyzed as a repeated measures two-way ANOVA (genotype x injury
condition). A p value <0.05 was considered significant and Newman-Keuls posthoc testing was performed when appropriate.
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RESULTS

Calpastatin expression in transgenic mice
The regional and cellular localization of calpastatin expression was
examined in brain sections from naïve CaMKII-hCAST Tg and WT littermate
mice (n=3/genotype). Brains from WT mice were only weakly immunolabeled for
calpastatin in cells that appeared neuronal (Figure 2.1A, C). In contrast, robust
labeling of neurons in all cortical layers and hippocampal regions was evident in
CaMKII-hCAST Tg mouse brains (Figure 2.1B, D). Within the neocortical layers,
calpastatin expression was highest in layers II, III and V, appearing primarily
within the neuronal cytoplasm (Figure 2.1B). In the hippocampus, neuronal
labeling was evident in pyramidal cells of the CA1 and CA3 regions and within
the granule cell layer and hilar region of the dentate gyrus (Figure 2.1D).
Calpastatin labeling in cell bodies was also identified in the striatum, globus
pallidus, and thalamic areas; labeling of calpastatin was lowest in white matter
tracts. Immunoblot analysis using an antibody specific for hCAST confirmed
expression in both cortical and hippocampal homogenates of naïve CaMKIIhCAST transgenic mice, with no detectable levels in WT littermates
(n=4/genotype; Figure 2.1E).
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Figure 2.1.
Calpastatin expression in the cortex and hippocampus of naïve
wildtype and CaMKII-hCAST transgenic mice. Immunohistochemical labeling using
an antibody recognizing mouse and human calpastatin (hCAST) was analyzed in the
cortex (A, B) and hippocampus (C, D) of brain sections obtained from naïve wildtype
(WT) (A, C) and CaMKII-hCAST transgenic (Tg) (B, D) mice. Neocortical layers (II-V)
are indicated. Low calpastatin immunoreactivity was noted in wildtype tissue, indicative
of basal levels of calpastatin expression. With hCAST overexpression, increased
immunoreactivity was identified in CaMKII-hCAST Tg mice, appearing primarily
neuronal (B, inset) compared to WT mice (A, inset). Scale bars represent 100 m for
images A-D; 20 m for insets. E) Immunoblot analysis for human calpastatin in cortical
and hippocampal homogenates of WT and CaMKII-hCAST Tg mice confirms the
presence of human calpastatin exclusively in transgenic mice.
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In vitro calpastatin inhibitory activity
To verify the functionality of human calpastatin in CaMKII-hCAST Tg
mice, the ability of calpastatin to inhibit protease activity was assessed. Protease
activity in cortical and hippocampal homogenates from naïve WT mice was very
low, consistent with the majority of calpains being in an inactive state under
physiological conditions. Overexpression of calpastatin resulted in a small
reduction in endogenous protease activity in neocortical tissue that was not
statistically significant (n=4-5/genotype; Figure 2.2). In order to mimic the
increased calpain activation evident after traumatic injury, neocortical and
hippocampal homogenates were spiked with exogenous calpain resulting in a
nearly 4-fold increase in protease activity in WT mice (p<0.0005). Under this
calpain challenge, homogenates from calpastatin overexpressing mice exhibited
a highly significant inhibition of protease activity in compared to WT mice
(p<0.0005). Although the addition of calpain resulted in a modest elevation in
protease activity above endogenous levels in cortical homogenates from
CaMKII-hCAST Tg mice (p<0.01) (Figure 2.2A), calpastatin overexpression
completely prevented increased protease activity in hippocampal homogenates
(Figure 2.2B), consistent with a high expression level of calpastatin in the
hippocampus of the CaMKII-hCAST Tg mice (Higuchi et al., 2005).
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Figure 2.2.
Protease activity in cortical and hippocampal homogenates of naïve
wildtype and CaMKII-hCAST transgenic mice. Protease activity (fluorescence
units/mg of protein) was measured in cortical (A) and hippocampal (B) homogenates
obtained from naïve (uninjured) wildtype (WT) and CaMKII-hCAST transgenic (Tg)
mice. Without the addition of exogenous calpain, protease activity was low compared to
the response following exogenous calpain addition in WT mice to mimic elevated calpain
activation following traumatic brain injury. With a calpain challenge, calpastatin
overexpression significantly inhibited protease activity in both cortical and hippocampal
homogenates.
Data are represented as mean + SEM; n=4-5/genotype; two-way ANOVA (genotype x
calpain condition) with Newman-Keuls post-hoc tests; *p<0.01, **p<0.0005 compared to
respective homogenates without exogenous calpain; #p<0.0005 compared to WT +
exogenous calpain.
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Acute calpain-mediated spectrin proteolysis
Spectrin is cleaved from its intact 280 kDa form into 150 kDa and 145 kDa
breakdown products (BDPs) by calpains or into 150 kDa and 120kDa BDPs by
caspase-3 (Nath et al., 1996, Pineda et al., 2004). In the mouse CCI model,
calpain activity peaks around 6 h while accumulation of spectrin fragments is
maximal at 24 h (Kampfl et al., 1996, Hall et al., 2005, Deng et al., 2007). Levels
of spectrin breakdown are undetectable or very low in naïve or sham animals
(Saatman et al., 1996a, Hall et al., 2005, Aikman et al., 2006, Thompson et al.,
2006, Deng et al., 2007, McGinn et al., 2009). At 4 h following a moderate injury,
levels of the 145 kDa calpain-specific spectrin BDP in the cortex were
significantly reduced in homogenates obtained from CaMKII-hCAST Tg
compared to WT mice (p<0.05; n=3-4/genotype) (Figure 2.3A). The 145 kDa
calpain-specific BDP also appeared to be reduced in hippocampal homogenates
of CaMKII-hCAST Tg mice compared to WT mice; however, this did not reach
statistical significance (p=0.13). Severe injury resulted in an increase in calpainspecific (145 kDa) spectrin breakdown in the cortex of WT mice at both 6 h and
24 h post-injury (p<0.0005 and p<0.05, respectively; n=3-6/time point) (Figure
2.3B). In severely injured CaMKII-hCAST Tg mice, cortical spectrin cleavage to
the 145 kDa fragment was effectively inhibited at 6 h post-injury (p<0.0005
compared to WT) and remained at sham levels at 24 h post-injury. Brain-injured
WT mice also exhibited increased calpain-specific BDP levels in the
hippocampus at 6 h and 24 h following severe injury (p<0.0005; n=4-6/time point)
(Figure 2.3C). Human calpastatin overexpression in Tg mice prevented injury-
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induced elevation of the 145 kDa spectrin BDP in the hippocampus at both 6 and
24 h (p<0.05 and p<0.0005, respectively, compared to WT). Compared to sham
injury, severe CCI produced a significant elevation in the 150 kDa spectrin BDP
at both time points in the cortex and hippocampus (Figure 2.3B, C). However, for
either moderate or severe CCI, 150 kDa spectrin BDP levels were not
significantly different for WT and CaMKII-hCAST Tg mice. The 120 kDa spectrin
BDP resulting from cleavage by caspase-3 was not detected in cortical and
hippocampal samples from either WT or CaMKII-hCAST Tg mice after injury.
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Figure 2.3.
-Spectrin proteolysis following graded traumatic brain injury in
wildtype and CaMKII-hCAST transgenic mice. Spectrin breakdown in cortical and
hippocampal homogenates obtained from wildtype (WT) and CaMKII-hCAST
transgenic (Tg) mice was analyzed acutely after moderate and severe controlled cortical
impact injury (CCI). A) At 4 h following moderate injury (0.5 mm depth), calpainmediated spectrin proteolysis was evident in both the cortex and hippocampus.
Calpastatin overexpression reduced cortical spectrin cleavage into the 145 kDa
fragment, particularly in cortical homogenates. Spectrin cleavage was also measured in
B) cortical homogenates and C) hippocampal homogenates from WT and CaMKIIhCAST Tg mice at 6 and 24 h after 1.0 mm depth CCI injury. Significant elevations in
spectrin fragmentation were again noted in WT homogenates, which were blunted in
CaMKII-hCAST Tg mice.
Data are represented as the proteolytic fragment band normalized to intact spectrin
(measured as optical density units) and expressed as mean + SEM; n=36/genotype/time point; unpaired Student’s t-test (0.5 mm injury) or nested two-way
ANOVA (1.0 mm injury, genotype x injury condition) with Newman-Keuls post-hoc tests;
*p<0.05, **p<0.0005 compared to sham-injured controls; #p<0.05, ##p<0.0005
compared to respective WT. Representative blots are shown at right.
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Assessment of acute motor function
To examine whether the inhibition of calpain-mediated spectrin proteolysis
in CaMKII-hCAST overexpressing mice observed within the first 24 h after brain
injury resulted in early cortical neuroprotection and concomitant improvement in
behavioral function, cohorts of mice were subjected to moderate or severe CCI
brain injury and evaluated for motor function prior to euthanasia at 24 h. Motor
function was assessed using a composite neuroscore test, similar to the test we
previously used to demonstrate attenuation of posttraumatic motor dysfunction
with calpain inhibitor administration in rats (Saatman et al., 1996b). Both
moderate (n=9/genotype) and severe (n=8/genotype) CCI brain injury resulted in
motor impairment in WT and CaMKII-hCAST Tg mice compared to their
respective sham controls (n=3/genotype; p<0.05) (Figure 2.4). Calpastatin
overexpression significantly attenuated acute motor dysfunction after either
moderate or severe injury (p<0.005 compared to WT brain-injured mice).
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Figure 2.4.
Posttraumatic motor function assessment by neuroscore testing
following graded controlled cortical impact injury in wildtype and CaMKII-hCAST
transgenic mice. Both moderate (0.5 mm impact depth) and severe (1.0 mm impact
depth) controlled cortical impact (CCI) brain injury resulted in significant acute motor
deficits as revealed by neuroscore analysis 24 h following injury in wildtype (WT) mice.
Calpastatin overexpression in CaMKII-hCAST transgenic (Tg) mice significantly
improved motor function in moderate and severe brain-injured groups.
Neuroscores are expressed as mean + SEM; shams n=3/genotype, injured n=89/genotype/severity; two-way ANOVA (genotype x injury severity with Newman-Keuls
post-hoc tests; *p<0.05, **p<0.0005 compared to respective sham-injured controls;
#p<0.005 compared to WT injured mice.
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Assessment of acute cortical tissue damage
At the site of impact, widespread neuronal death with occasional
intraparenchymal hemorrhage was observed 24 h following either 0.5 mm or 1.0
mm CCI injury, although severe CCI resulted in more extensive cortical neuron
loss, with well-developed neocortical cavitation (Figure 2.5). Damaged but
surviving neurons with a shrunken, pyknotic phenotype generally surrounded the
contusion area while healthy, rounded cells populated areas distal to the impact
site (Figure 2.5C insets). Quantitative analyses revealed a significantly larger
volume of neocortical tissue damage after severe CCI compared to moderate
CCI (p<0.0005) (Figure 2.5F). However, hCAST overexpression did not reduce
neocortical tissue damage at 24 h following CCI (n=5-6/genotype/injury severity).
Severe CCI was typically associated with loss of continuity in the
subcortical white matter tract beneath the contused cortex and occasionally with
hippocampal distortion. The hippocampus sustained focal cellular damage,
evident in areas of cell loss within the dentate gyrus granular layer and hilus,
which was more extensive with increased injury severity. No qualitative
differences in hippocampal cell survival at either injury severity were evident in
Nissl-stained tissue sections from CaMKII-hCAST Tg mice compared to those
from WT mice. However, Nissl staining is relatively insensitive for detecting small
numbers of dying cells. Therefore, we labeled degenerating neurons with the
sensitive fluorochrome marker, Fluoro-jade B (Schmued et al., 1997). At 24 h
following moderate or severe CCI injury, Fluoro-jade B-positive (FJB+) cells were
localized primarily in the dentate gyrus area, with fewer in the CA3/CA3c and
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CA1 regions (Figure 2.6). The quantity of FJB+ neurons in all regions analyzed
increased with greater injury severity (injury effect, p<0.05). Calpastatin
overexpression resulted in significantly reduced numbers of FJB+ cells in the
dentate gyrus of mice subjected to moderate injury (p<0.005) (Figure 2.6C).
However, no significant genotypic differences in FJB+ cell numbers were
identified at a 1.0 mm depth injury (Figure 2.6F).
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Figure 2.5.
Histological damage in wildtype and CaMKII-hCAST transgenic
mice after graded controlled cortical impact brain injury. Compared to moderate
(0.5 mm) controlled cortical impact (CCI) brain injury (A, B), severe (1.0 mm) CCI (C, D)
resulted in a larger contusion and more extensive damage to the subcortical white
matter at 24 h after injury. Peri-contusional areas contained shrunken, pyknotic neurons
while sites more distal to the impact contained healthy neurons (C, insets). However, no
genotype differences were observed between wildtype (WT) (A, C) and CaMKIIhCAST transgenic (Tg) (B, D) mice. E) Coronal image from the contralateral hemisphere
of a WT mouse is shown for reference. Scale bar represents 500 m; 20 m for insets.
F) Quantification of cortical tissue damage in WT and CaMKII-hCAST Tg mice
following moderate and severe CCI brain injury. Although contusion volume increased
significantly with increasing depth of impact, no genotypic differences were revealed
between CaMKII-hCAST Tg and WT mice.
Tissue damage is calculated as a percent of the volume of the contralateral neocortex
and expressed as mean + SEM; n=5-6/genotype/injury severity; two-way ANOVA
(genotype x injury severity); *p<0.0005.
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Figure 2.6.
Hippocampal neurodegeneration following moderate and severe
controlled cortical impact in wildtype and CaMKII-hCAST transgenic mice. The
fluorochrome, Fluoro-jade B, was used to identify degenerating neurons within the
hippocampus acutely following controlled cortical impact (CCI) injury in wildtype (WT)
and CaMKII-hCAST transgenic (Tg) mice. Fluoro-jade B-positive (FJB+) neurons were
particularly notable in the hilus and granular layer of the dentate gyrus of the
hippocampus 24 h following moderate (0.5 mm) injury (A, B), which were more
numerous following severe (1.0 mm) (C, D) CCI in WT (A, D) and CaMKII-hCAST Tg
(B, E) mice. Quantification of FJB+ neurons in hippocampal regions of WT and
CaMKII-hCAST Tg mice with C) moderate and F) severe CCI revealed reduced FJB+
cells in the dentate gyrus with calpastatin overexpression compared to WT mice after
moderate injury, but not after severe injury. Scale bar represents 100 m.
The number of FJB+ neurons was averaged across three sections per brain and
expressed as mean + SEM; n=8-9/genotype/injury severity; two-way ANOVA (genotype
x injury severity); *p<0.005 compared to WT.

73

Assessment of posttraumatic cognitive and motor function over 1-2 weeks after
TBI
While attenuation of acute calpain-mediated spectrin proteolysis by
calpastatin overexpression was associated with modest hippocampal
neuroprotection and no notable neocortical protection at 24 h after injury, motor
function was significantly improved. Therefore, to provide a more thorough
evaluation of the time course of recovery of motor function in calpastatin
overexpressing transgenic mice and to determine whether elevated calpastatin
levels also conferred improvements in cognitive function, two sets of WT and
CaMKII-hCAST Tg mice were subjected to severe brain injury and evaluated
using tests of cognitive and motor function over a 1-2 week period after TBI.
The first group of mice received severe (1.0 mm) CCI and was evaluated
using tests traditionally used in our lab: a MWM visuospatial memory test and the
neuroscore test for motor function. During pre-injury training, average latency to
the platform decreased significantly over 3 d (p<0.0001, time effect) with an
equivalent pattern of visuospatial learning for WT (n=29) and CaMKII-hCAST
Tg (n= 25) mice (Figure 2.7A). These data suggest that calpastatin
overexpression did not substantially alter learning ability in naïve mice. Memory
retention was then evaluated at 48 h after CCI brain injury. Brain-injured mice
(n=15-17/genotype) displayed significant memory impairment compared to shaminjured mice (n=10-11/genotype) (p<0.0001, injury effect; Figure 2.7B). However,
calpastatin overexpression did not significantly enhance memory function in the
MWM. Motor function was assessed in this same cohort at 2, 4 and 8 d post-

74

injury using the composite neuroscore test. Compared to sham controls which
demonstrated consistently high neuroscores across all time points, mice
receiving severe CCI brain injury exhibited significant motor deficits at 2 and 4 d
post-injury (p<0.0005, injury effect; Figure 2.7C). Due to spontaneous recovery of
function over the first week, only a small, but non-significant motor deficit
remained at 8 d (p=0.06, injury effect). Although neuroscores of brain-injured
CaMKII-hCAST Tg mice were slightly higher than WT mice at 2 and 4 d after
injury, no significant genotype-dependent differences were detected by two-way
ANOVA (Figure 2.7C).
Subsequent to this behavioral evaluation, we characterized two additional
behavioral tests for use with mouse CCI: NOR and a modified NSS. As
compared to memory testing using our MWM paradigm, the NOR paradigm has
the advantage that it can be utilized at multiple intervals after injury in the same
group of mice to allow assessment of the duration of memory impairment. To
verify that overexpression of calpastatin did not result in a pre-existing alteration
in cognitive ability, mice were tested using the NOR prior to injury. Naïve
CaMKII-hCAST Tg and WT mice demonstrated an equivalent preference for the
novel object (Figure 2.8A). After severe CCI injury (n=10-11/genotype), WT mice
exhibited profound deficits in the ability to recognize the novel object at 7 d
(p<0.05 compared to pre-injury) which persisted to 14 d (p<0.01) (Figure 2.8A).
Calpastatin overexpression effectively prevented trauma-induced memory
impairment in the NOR task. The performance of CaMKII-hCAST Tg mice after
injury was equivalent to their pre-injury performance and significantly greater
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than WT littermates at both 7 d and 14 d post-injury (p<0.01) (Figure 2.8A). The
modified NSS revealed acute motor deficits that, in both genotypes, lessened
over time (p <0.0001, time effect; Figure 2.8B). However, CaMKII-hCAST Tg
mice showed significantly improved NSS across the 7 d post-injury period
(p<0.01, genotype effect; Figure 2.8B). Due to spontaneous recovery of motor
function, mice were not evaluated beyond 7 d.
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Figure 2.7.
Cognitive and motor behavioral analyses using the Morris water
maze and neuroscore tests following severe controlled cortical impact brain injury
in wildtype and CaMKII-hCAST transgenic mice. A) Prior to injury, wildtype (WT)
and CaMKII-hCAST transgenic (Tg) mice show an equivalent ability to learn the
location of the hidden platform on successive training days, expressed as latency time to
the platform within the Morris water maze. Thus, overexpression of the calpastatin
transgene did not negatively interfere with normal learning ability. B) Although controlled
cortical impact (CCI) brain injury resulted in significant memory impairment, no
significant genotype-dependent differences were detected at 48 h post-CCI. C) Brain
injury also produced significant impairment of motor function assessed by use of the
composite neuroscore at 2 d and 4 d after severe CCI. No significant genotypedependent differences were observed at any time point.
All data are expressed as mean + SEM; shams n=10-11/genotype, injured n=1517/genotype; repeated measures one-way ANOVA (A) or two-way ANOVA (genotype x
injury condition, B, C); *p<0.0001, **p<0.0005 compared to sham-injured controls.
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Figure 2.8.
Additional cognitive and motor function analyses using the novel
object recognition and modified neurological severity score paradigms with
wildtype and CaMKII-hCAST transgenic mice after severe brain injury.
A) Recognition ability of a novel object by wildtype (WT) mice declined at 7 and 14 d
after severe brain injury. In contrast, injured CaMKII-hCAST transgenic (Tg) mice
maintained their pre-injury ability to distinguish the novel object, resulting in significantly
higher scores compared to WT mice. Recognition index is defined as the percent
interaction time spent on the novel object. B) Across the 7 day post-injury period,
CaMKII-hCAST Tg mice showed significantly improved neurological severity scores
compared to WT mice.
All data are expressed as mean + SEM; n=10-11/genotype; repeated measures one-way
ANOVA with Newman-Keuls post-hoc tests; *p<0.05 compared to pre-injury, #p<0.01
compared to WT mice.
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Assessment of long-term cortical tissue damage
Although in our current model, the majority of cortical neuronal damage
occurs within the contusion site by 24 h after CCI brain injury in mice (Pleasant et
al., 2011), other reports have suggested that neuron loss in the contusion may
continue for as much as 7 d after injury (Fox et al., 1998, Hannay et al., 1999,
Saatman et al., 2006). Therefore, to evaluate whether calpastatin overexpression
may have protected against delayed neuronal loss in the cortex despite a lack of
acute protection, we measured contusion volume in hCAST and WT mice 8 d
following severe (1.2 mm) CCI injury. The volume of the ipsilateral neocortex
damaged in CaMKII-hCAST mice (15.7 ± 1.1%) was comparable to that in WT
mice (15.5 ± 0.9%; n=12-13/genotype). The volume of neocortical contusion was
similar to that observed at 24 h following severe CCI (Figure 2.5F), suggesting
little expansion of the contusion after 24 h in mice.
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DISCUSSION

Numerous studies in multiple models of TBI have demonstrated that
calpains are activated in the first minutes to hours after injury and that their
persistent activation is associated with neurodegenerative changes (Saatman et
al., 2010). Although calpastatin is co-localized with calpains in neurons, the
persistent activation of calpains after traumatic injury argues that endogenous
calpastatin levels are insufficient to prevent proteolytic activity of calpains in the
acute phase of injury. Although relatively little is known of the effects of TBI on
calpastatin, TBI appears to elicit only delayed increases in calpastatin protein
(Newcomb et al., 1999) and mRNA (Ringger et al., 2004) levels on the order of 1
day to 1 week after CCI brain injury. Therefore, enhancing calpastatin expression
early after TBI may attenuate posttraumatic calpain activation and subsequent
neurodegeneration. Here we provide the first evidence that, in a model of TBI,
overexpression of calpastatin reduces calpain-mediated spectrin proteolysis and
improves motor and cognitive behavioral performance. Behavioral efficacy was
observed without reductions in neocortical contusion size and with modest
hippocampal neuroprotection.
Overexpression of human calpastatin under the CaMKII promoter
resulted in enhanced calpastatin immunoreactivity and expression specifically
within the neocortex and hippocampus, areas vulnerable after CCI injury. The
functionality of calpastatin was verified by an in vitro fluorogenic assay,
demonstrating reduced proteolytic activity in response to a calpain challenge.
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These results are consistent with previous studies with this hCAST transgenic
mouse line, reporting robust expression in the neocortex and hippocampus and
an approximate 3-fold greater calpain inhibition compared to non-transgenic mice
(Higuchi et al., 2005). CaMKII-hCAST Tg mice exhibited no overt phenotype,
and uninjured calpastatin overexpressing mice performed similarly to their WT
counterparts in motor tasks as well as in a visuospatial, hippocampal-dependent
learning task and a novel object recognition memory task. These findings
suggest that calpastatin overexpression in this transgenic line does not produce
notable changes in baseline learning and memory functions, despite evidence
implicating calpains in hippocampal long-term potentiation (LTP). Application of
calpain inhibitors has been shown to reduce or block hippocampal LTP (del
Cerro et al., 1990, Denny et al., 1990, Suzuki et al., 1992, Farkas et al., 2004),
although some inhibitors tested were not selective. Conversely, rats with a
genetic deficiency in calpastatin exhibited enhanced LTP (Muller et al., 1995).
Recent reports, however, cite no effect on LTP in calpain-1 knockout mice
(Grammer et al., 2005) and normal hippocampal-dependent memory formation in
calpastatin knockout mice (Nakajima et al., 2008).
Calpain-mediated proteolysis of spectrin has been well documented in
experimental models of TBI, with peak breakdown during the first days after
injury (Kampfl et al., 1996, Saatman et al., 1996a, Newcomb et al., 1997, Pike et
al., 1998, Kupina et al., 2003, Hall et al., 2005, McGinn et al., 2009, Thompson et
al., 2010). Our results extend these findings, demonstrating that calpastatin
overexpression effectively blunts or prevents early accumulation of calpain-
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specific breakdown products in the cortex and hippocampus. The efficacy of
exogenously administered calpain inhibitors in reducing calpain-mediated
spectrin proteolysis has been inconsistent in models of TBI. Treatment with
calpain inhibitor II or MDL28170 decreased spectrin breakdown (Posmantur et
al., 1997, Thompson et al., 2010). However, two other calpain inhibitors,
SJA6017 (Kupina et al., 2001) and AK295 (Saatman et al., 2000), did not reduce
cortical or hippocampal spectrin breakdown despite positive effects on behavioral
outcomes. Differences in the calpain inhibitor used, the dose, duration, frequency
and route of administration, and the injury model and species employed make it
difficult to draw generalized conclusions about the effectiveness of calpain
inhibitor treatment after TBI. The improved reduction in calpain-mediated spectrin
proteolysis achieved in the CaMKII-hCAST Tg mice in comparison to previous
studies utilizing calpain inhibitor administration may be related to the specificity of
calpastatin for calpains, its overexpression specifically within neurons in the
vulnerable neocortex and hippocampus, the level of calpain inhibitor present in
the brain, or the early and continued elevation of calpastatin achieved through
genetic overexpression.
Despite acute protection against spectrin degradation in the cortex after
both moderate and severe CCI injury, CaMKII-hCAST Tg mice showed no
genotypic differences in neuronal death in the contused cortex. These data
suggest that inhibition of spectrin proteolysis by calpains is not sufficient to
prevent cortical neuron death after contusion TBI. This result is in accordance
with previous TBI studies, in which short- or long-term administration of
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MDL28170 or AK295 produced no reduction in hemispheric or cortical lesion size
48 h following injury (Saatman et al., 2000, Thompson et al., 2010). Although
contusion TBI is associated with substantial excitotoxic injury and may involve
degrees of hypoxia and ischemia (Palmer et al., 1993, Kochanek et al., 1995,
Clark et al., 1997), calpain inhibition has been more successful in reducing
localized neuronal death in models of hippocampal excitotoxicity (Higuchi et al.,
2005, Takano et al., 2005, Bevers et al., 2009, Bevers et al., 2010), contusive
spinal cord injury (Yu and Geddes, 2007, Yu et al., 2008) and cerebral ischemia
(Bartus et al., 1994a, Bartus et al., 1994b, Markgraf et al., 1998, Koumura et al.,
2008) than in models of contusion TBI. This differential efficacy may reflect
differences in the injury pathology or the extent of calcium dysregulation.
Interestingly, calpains may be required for the repair of plasma membranes
(Howard et al., 1999, Mellgren et al., 2009). Thus, at sites of membrane damage
within contused areas (Whalen et al., 2008), calpain inhibition may prevent
membrane resealing necessary for neuron survival. To achieve neuroprotection
in contusion TBI, calpain inhibitors may need to be utilized in combination with
other neuroprotective agents.
Only one study, to our knowledge, has evaluated hippocampal cell death
after calpain inhibitor treatment and TBI (Saatman et al., 2000). Continuous
infusion of the calpain inhibitor AK295 did not reduce apoptotic cell death at 48 h
after lateral fluid percussion brain injury in rats. In contrast, calpastatin
overexpression resulted in partial protection of hippocampal neurons, as
evidenced not only by prevention of calpain-mediated spectrin proteolysis, but

83

also by decreased granule neuron degeneration after moderate CCI. Although
Fluoro-jade staining has been co-localized with other cell death markers,
including those specific for apoptosis, in other injury paradigms (Chidlow et al.,
2009, Naseer et al., 2009, Serrano et al., 2011), the mechanism of cell death
accompanying Fluoro-jade positivity in TBI has not been established. A reduction
in dentate gyrus granule cell death after moderate but not severe CCI may
suggest a greater involvement of secondary injury cascades unrelated to
calpains in severe TBI or the need for higher levels of calpastatin overexpression
to protect against severe injury. The CaMKII-hCAST Tg mice utilized here have
a 3-fold increase in calpastatin activity compared to WT mice. An alternative line
of calpastatin overexpressing mice has been developed with a 7-fold greater
CAST expression level compared to WT mice (Rao et al., 2008) and we have
investigated a transgenic mouse line with an approximate 80-fold increase in
calpastatin above endogenous levels owing to its expression under the
ubiquitous prion protein promoter (Chapter 3).
Importantly, calpastatin overexpression was associated with improved
functional outcome in several behavioral measures in brain-injured mice. These
results support previous studies observing motor and cognitive behavioral
improvements with posttraumatic administration of exogenous calpain inhibitors
(Saatman et al., 1996b, Kupina et al., 2001), arguing for calpain inhibition as a
potential treatment for TBI. In CaMKII-hCAST Tg mice, simple motor function
(neuroscore) was improved early (24 h) after moderate or severe injury, but a
significant benefit was not observed in repeated testing over the first week after
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severe injury, perhaps due in part to the high degree of spontaneous motor
recovery after CCI. Coordinated motor function assessed through beam walking
(NSS test) was consistently improved in calpastatin overexpressing mice over
the first week post-injury. In our hands, the modified NSS test yielded larger
trauma-induced deficits as a percentage of sham scores than did the neuroscore,
which may have enhanced sensitivity for detecting effects of calpain inhibition. In
our cognitive tests, the NOR test revealed robust protection against
posttraumatic memory dysfunction in CaMKII-hCAST Tg mice, but the MWM
memory paradigm showed only a slight improvement in memory retention. It is
possible that memory tasks such as the NOR may utilize brain regions or circuits
that were better preserved through calpastatin overexpression than those
mediating visuospatial MWM memory function.
Interestingly, our results demonstrate behavioral improvements after injury
without accompanied cortical neuroprotection, a disconnection also reported in
past studies evaluating calpain inhibitor treatment (Saatman et al., 1996b,
Saatman et al., 2000, Kupina et al., 2001). Likewise, it is unclear whether
behavioral effects are directly related to acute spectrin preservation. While
spectrin is important in receptor localization at the membrane, sparing of other
proteins such as receptors, channels, signaling proteins, or synaptic proteins
may also contribute to the observed behavioral improvements. To this end, we
have expanded our investigations into calpain-mediated substrate proteolysis to
include the collapsin response mediator protein-2 (CRMP-2) and voltage gated
sodium channel following severe CCI injury (Chapter 3). Notably, calpain inhibitor
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treatments have attenuated axonal pathology and improved axonal function in
TBI (Buki et al., 2003, Ai et al., 2007) and other models of nerve injury (Araujo
Couto et al., 2004, Hassen et al., 2008), implicating calpains as a mediator of
axonal degeneration. Future studies could also address structural or functional
axonal protection mediated by calpastatin overexpression.
Utilizing a transgenic mouse model of neuronal-specific calpastatin
overexpression, we have confirmed specific and robust inhibition of calpain by
calpastatin through in vitro assay and attenuations in spectrin proteolysis after
CCI injury. However, CaMKII-driven calpastatin expression failed to provide
overt cortical and hippocampal neuroprotection, despite improvements in
behavioral function both acutely and at later times post-injury. The limited
expression of calpastatin within a specific population of forebrain neurons may be
inadequate to effectively hinder the rapid, persistent calpain activation after injury
and significantly reduce posttraumatic cell death. Therefore, in Chapters 3 and 4,
we evaluate a novel transgenic mouse with calpastatin expression driven by the
prion protein (Prp) promoter, which is expressed ubiquitously throughout the
CNS. We hypothesize that this Prp-hCAST transgenic mouse will exhibit a
greater and more widespread calpastatin expression pattern, providing
substantial inhibition of calpain after injury and improved histological and
behavioral outcomes.

Copyright © Kathleen Marie Schoch 2013
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CHAPTER 3

Preface

Chapter 3 is reprinted, with alterations, from Journal of Neurochemistry,
K.M. Schoch, C.R. von Reyn, J. Bian, G.C. Telling, D.F. Meaney, and K.E.
Saatman, “Brain injury-induced proteolysis is reduced in a novel calpastatinoverexpressing transgenic mouse”, in press. Copyright 2013, with permission
from Jon Wiley and Sons. Alterations to the previously published manuscript
were made to the “Introduction” to reduce redundancies with Chapter 1. Figure
legends were expanded from the original manuscript to provide greater detail.
Minor additions to other sections were included for coherency.
Experimental data were generated, analyzed and prepared for publication
by K.M. Schoch and K.E. Saatman, with the exception of the following:
Methodology and data (Figure 3.1A) regarding creation of Prp-hCAST founder
mice were generously provided by J. Bian and G.C. Telling. Injured brain tissue
for analysis of sodium channel proteolysis was generated by K.M. Schoch;
however, equipment, reagents, and antibodies to detect sodium channel
proteolysis were provided by C.R. von Reyn and D.F. Meaney. Sodium channel
immunoblot quantification and imaging (Figure 3.6) were performed by C.R von
Reyn, with subsequent analysis as included in the manuscript by K.M. Schoch.
The manuscript was written by K.M. Schoch with consultation and editing by K.E.
Saatman and other coauthors.
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CHAPTER 3

Brain injury-induced proteolysis is reduced in a novel calpastatin
overexpressing transgenic mouse

INTRODUCTION

Calpains are multi-faceted regulators of normal physiological functions
such as cytoskeletal remodeling for cell growth and motility, cell cycle and
differentiation processes, apoptosis, and long-term potentiation (Goll et al., 2003,
Saatman et al., 2010, Sorimachi et al., 2011), mediated by discrete alterations in
intracellular calcium. Under pathological conditions and overwhelming calcium
levels, altered intracellular calcium homeostasis leads to calpain activation,
resulting in the cleavage of cellular substrates including cytoskeletal elements,
membrane receptors, cytosolic proteins, and cell death mediators (Saatman et
al., 2010). Calpain-mediated proteolysis typically is considered unregulated as its
cleavage patterns are not site-specific and no known substrate preference exists
in vivo (Goll et al., 2003). Many calpain substrates have been identified through
in vitro experiments testing for cleavage products. The proteolytic cascade
triggered by calpains in the context of TBI is much more difficult to predict and
interpret.
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As the most well characterized calpain substrate following TBI, the
cytoskeletal component -spectrin is a valuable surrogate marker of calpain
activation and its early proteolysis may indicate the severity of cellular damage
and subsequent neuronal death (Saatman et al., 1996a). Through the use of
calpain inhibitors and identification of calpain-specific breakdown products
(BDPs), the number of calpain substrates verified in models of TBI is expanding.
Collapsin response mediator protein-2 (CRMP-2) proteolysis was detected in
response to excitotoxic insult and attenuated with in vitro calpain inhibitor
application. Identical calpain-mediated CRMP-2 cleavage patterns were identified
in brain homogenates after experimental TBI (Zhang et al., 2007). Similarly,
voltage-gated sodium channel cleavage, triggered by exogenous calpain
activation or using an in vitro model of TBI, was reversed with viral-mediated
calpastatin overexpression or treatment with the calpain inhibitor MDL28170 (von
Reyn et al., 2009). Limited cleavage characteristic of calpains may modulate ion
flux and receptor function, contributing to exacerbated calcium dysfunction,
further calpain activation, and neuronal damage associated with brain injury.
Efforts to mitigate posttraumatic calpain activation and subsequent
calpain-mediated proteolysis have met with mixed success. Reductions in
calpain-mediated spectrin or neurofilament breakdown with use of calpain
inhibitor II, MDL-28170, and SNJ-1945 following CCI injury (Posmantur et al.,
1997, Thompson et al., 2010, Bains et al., 2012) were not reproduced with
administration of AK295 or SJA-6017 (Saatman et al., 2000, Kupina et al., 2001).
Neuronal-specific human calpastatin (hCAST) overexpression in a transgenic
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mouse reduced acute spectrin proteolysis and select behavioral deficits following
severe contusion TBI but did not affect cortical tissue damage (Chapter 2,
Schoch et al., 2012). Calpastatin overexpression in this model was driven by the
CaMKII promoter, limiting expression to forebrain neurons (Higuchi et al.,
2005). Given the widespread activation of calpains after injury, we sought a
mouse model with greater cellular distribution of calpastatin to ensure inhibition
of calpains in all vulnerable regions. To this end, we entered into a collaboration
with Glenn Telling, Ph.D. in the department of Microbiology, Immunology and
Pathology at Colorado State University. Dr. Telling had developed a novel
transgenic mouse with hCAST under constitutive control of the ubiquitous prion
protein promoter (Prp) enabling our desired widespread calpastatin expression.
We hypothesized that greater calpastatin expression in additional neuronal
regions may produce enhanced calpain inhibition, linking reduced substrate
proteolysis with acute neuroprotection. Our previous results using the CaMKIIhCAST mice underscore the potential for calpastatin to mitigate calpains’
damaging effects after injury; however, the lack of overt cortical and hippocampal
neuroprotection despite behavioral improvements is perplexing. Characterization
of an alternative hCAST overexpressing mouse model was undertaken to provide
additional investigations into the role of calpains and how regional and
expression level changes in calpastatin may alter outcome after TBI or other
neurodegenerative conditions.
Here we demonstrate that Prp-hCAST transgenic (Tg) mice have cortical
and hippocampal calpastatin levels approximately 80-fold greater than wildtype

90

(WT) mice and use this new transgenic tool to verify the effectiveness of
calpastatin in reducing calpain-mediated damage after TBI. To this end, we
subjected WT and calpastatin overexpressing Tg mice to severe contusion CCI
injury and evaluated acute posttraumatic proteolysis of three proteins critical for
neuronal structure and function: -spectrin, CRMP-2, and voltage-gated sodium
channel 1.2 (Nav1.2). In addition, we assessed acute regional hippocampal
neurodegeneration in brain-injured WT and Prp-hCAST transgenic mice.
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METHODS

Human calpastatin overexpressing transgenic mice
Human calpastatin (hCAST) cDNA (Genbank accession number D16217)
in the pTicCS plasmid was obtained from Dr. Masatoshi Maki (Higuchi et al.,
2005). The hCAST sequence was cloned into the unique XhoI site of the
MoPrP.Xho expression vector (Borchelt et al., 1996), containing ~12 kb of the
mouse prion protein (Prp) gene including the promoter, the smaller of the two 5’
introns, and the 3’ untranslated sequences. The transgene expression cassette
was released from the Prp-hCAST plasmid with NotI, and the resulting purified
fragment was microinjected into the pronuclei of fertilized FVB/N oocytes.
Transgenic founder animals were identified by PCR screening of tail genomic
DNA using primers phgPrP5’ (5’GAACTGAACCATTTCAACCGAG3’) and
phgPrP3’ (5’AGAGCTACAGGTGGATAACC3’). The MoPrP.Xho vector has
previously been used to produce transgenic mice expressing coding sequences
under the control of mouse Prp gene transcriptional elements (Li et al., 2007,
Angers et al., 2009); thus, widespread hCAST expression in the CNS of
transgenic mice was expected. Calpastatin expression in the CNS of founder
mice was assessed by immunoblotting and compared with previously generated
transgenic mice in which the hCAST was expressed under the CaMKII
promoter (Higuchi et al., 2005). The generation and initial immunoblot
characterization of founder mice were performed in the Telling laboratory.
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In the Saatman lab, mice were maintained as heterozygotes by breeding
FVB/N females (Harlan Laboratories, Indianapolis, IN) with Prp-hCAST
transgenic males, exhibiting normal litter sizes and survival rates with no overt
phenotype. Mice were housed in controlled conditions under a 14:10 light:dark
photoperiod and provided with chow diet and water ad libitum. For experimental
procedures, young adult transgenic and WT littermates were used. For
qualitative measures, both males and females were analyzed. Although no
notable sex-specific expression patterns were observed, efforts were made to
utilize a consistent gender (male or female) within each quantitative experiment
when possible in order to minimize any potential variation. All husbandry care
and surgical procedures were approved by the University of Kentucky
Institutional Animal Care and Use Committee and were consistent with federal
guidelines (National Research Council (U.S.). Committee for the Update of the
Guide for the Care and Use of Laboratory Animals. et al., 2011) with all possible
effort made to minimize pain and discomfort of the animal.

Controlled cortical impact injury
Contusion brain injury was modeled using a CCI device (TBI-0310
Impactor, Precision Systems and Instrumentation, Fairfax Station, VA) as
previously described (Schoch et al., 2012). In brief, mice were placed in a
stereotaxic head frame, receiving inhalant isoflurane anesthesia. A midline scalp
incision exposed the skull and a 5 mm craniotomy was drilled on the left
hemisphere, lateral to the central suture between bregma and lambda. A
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rounded, 3.0 mm diameter steel impactor, controlled by a pneumatically driven
cylinder, was programmed to contact the exposed dura at a 1.0 mm depth, 3.5
m/s velocity, and 500 ms dwell time. These parameters result in a severe injury,
defined by progressive cortical and hippocampal cell losses over the first 24 h
after insult (Pleasant et al., 2011). Following the impact, a small cranioplast made
of dental acrylic was placed over the craniotomy site and secured to the skull.
The incision was sutured and the animal was placed on a 37°C heating pad until
ambulating. Sham-injured mice received all surgical procedures except the
impact injury.

Tissue preparation
Tissue designated for calpastatin inhibitory assays or immunoblots was
obtained following carbon dioxide asphyxiation and immediate decapitation.
Contralateral and ipsilateral cortical and hippocampal tissues were separately
dissected and rapidly frozen in cold (-80C) methanol. Samples were stored at 80C until use.
For immunochemistry and Fluoro-jade C experiments, mice were perfused
transcardially with 0.9% heparinized sterile saline and 10% neutral buffered
formalin under anesthesia (65 mg/kg sodium pentobarbital, intraperitoneally).
Heads were placed in formalin for 24 h after which the brain was removed for
additional overnight fixation. Following cryoprotection in 30% sucrose solution,
the brain was frozen in cold isopentanes (-25C to -35C). Brain tissue was cut
on a sliding microtome (Dolbey-Jamison, Pottstown, PA) in the coronal plane at a
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thickness of 40 m. Unused sections were stored in a cryoprotectant solution
(30% ethylene glycol, 30% glycerol) at -20C.

Calpastatin inhibitory assay in naïve mice
Frozen cortical tissue was sonicated in a calcium-free buffer solution (20
mM Tris, 1 mM EDTA, 100 mM KCl, 0.1% 2-mercaptoethanol) without protease
inhibitors and centrifuged at 21,500 g for 20 min at 4C. Supernatants were
assayed for calpastatin inhibitory activity in the presence of porcine kidney mcalpain (14.06 g/ml, Calbiochem, Gibbstown, NJ) and a fluorescentlyconjugated BODIPY-FL casein calpain substrate (EnzChek® Protease Assay Kit,
Invitrogen, Carlsbad, CA). In the presence of proteases, the casein substrate is
cleaved to emit a fluorescent signal, which is read on a spectrafluorometer
(Synergy HT Multi-Mode Microplate Reader, Biotek Instruments, Winooski, VT)
at 485 nm excitation and 528 nm emission wavelengths. Fluorescence values
were normalized to the amount of protein in the sample as determined by BCA
assay (Pierce BCA protein assay kit, Thermo Scientific, Rockford, IL) and
reported as units/mg of total protein. An average fluorescent reading was
obtained from cortical samples run in duplicate.

Calpastatin immunohistochemistry in naïve mice
Tissue sections were rinsed in Tris-buffered saline (TBS) and treated with
3% hydrogen peroxide solution in methanol and water for 30 min to quench
endogenous peroxidases associated with blood-brain barrier breakdown and
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normal vasculature. Following additional TBS washes, the tissue was blocked in
5% normal horse serum in TBS/0.1% Triton X-100 for 30 min. Tissue was
incubated overnight in 4C with primary antibody recognizing calpastatin of both
mouse and human origin (Table 3.1). Biotinylated donkey anti-rabbit IgG
secondary antibody (1:5000, Jackson ImmunoResearch Laboratories, Inc., West
Grove, PA) was applied for 1 h at room temperature, subsequently amplified by
avidin and biotin complex (1:50, Vectastain Elite ABC kit, Vector Laboratories,
Inc., Burlingame, CA), and developed in diaminobenzidine (DAB). Negative
control tissue was treated identically but without addition of primary antibody.
Tissue was viewed under a light microscope (Eclipse 50i, Nikon Corporation,
Japan).
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Primary antibody

Species

Concentration

Source

-spectrin

Mouse

1:5000

Millipore Co.

-actin

Mouse

1:1000

Sigma-Aldrich

-tubulin

Rabbit

1:1000

Abcam

Calpain-1

Rabbit

1:1000

Calbiochem

Calpain-2

Rabbit

1:1000

Abcam

Calpastatin

Rabbit

1:500

Santa Cruz Biotechnology

Caspase-3

Rabbit

1:500

Abcam

CRMP-2

Mouse

1:1000

IBL-America

ERK1/2

Rabbit

1:2000

Cell Signaling Technology

GAPDH

Mouse

1:10000

Millipore Co.

MAP-2

Mouse

1:1000

Sigma-Aldrich

Nav1.2 I-II loop

Rabbit

1:1000

Alomone Labs

p35/25

Rabbit

1:600

Cell Signaling Technology

Pan NaCh

Mouse

1:1000

Sigma-Aldrich

Phospho-ERK1+2

Rabbit

1:1000

Invitrogen

Table 3.1.
Primary antibodies used in immunohistochemistry and immunoblot
experiments. Primary antibody dilutions used for experiments within Chapter 3 were
recommended by supplier specifications and previously optimized. Host species and
commercial source are listed for reference.
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Immunoblot of proteins from naïve and injured mice
Tissue was homogenized by sonication in a lysis buffer (20 mM Tris, 150
mM NaCl, 5 mM EGTA, 10 mM EDTA, 10 mM HEPES, 1% Triton-X, 10%
glycerol) containing protease inhibitors (Complete MiniTM Protease Inhibitor
Cocktail tablet, Roche Applied Science, Indianapolis, IN). Samples were
centrifuged at 19,000 g for 20 min at 4C and the soluble fraction collected for
protein concentration determination. For analysis, equal amounts of protein were
run on polyacrylamide gels (3-8% Tris-Acetate, 4-20% Tris-HCl, or 10% Tris-HCl
Criterion Precast Gels, Bio-Rad Laboratories, Hercules, CA), transferred to
polyvinylidene difluoride or nitrocellulose membrane, and blocked in a 5% dry
milk/TBS/0.05% Tween 20 solution for 1 h. Membranes were incubated in
primary antibody (Table 3.1) diluted in 5% dry milk/TBS/0.05% Tween 20
overnight at 4C. Secondary antibodies conjugated to either horseradish
peroxidase (goat anti-mouse IgG 1:3000; Bio-Rad Laboratories) or infrared dye
(goat anti-mouse IgG, goat anti-rabbit IgG 1:5,000-10,000, Rockland
Immunochemicals, Gilbertsville, PA) were similarly prepared in 5% dry
milk/TBS/Tween 20 solution and applied for a 1 h incubation at room
temperature. Membranes probed for -spectrin were visualized on an Odyssey
LI-COR imaging station (LI-COR Biosciences, Lincoln, NE) and quantified by
Odyssey imaging software. All other membranes were visualized by enhanced
chemiluminescence on a Kodak imager (Kodak 1D Image Analysis, Eastman
Kodak Company, Rochester, NY) and quantified by ImageJ software (National
Institutes of Health, Bethesda, MD). Membranes were subsequently probed for -
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actin, -tubulin, or glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (Table
3.1) to verify equal protein loading across lanes.

Fluoro-jade C staining and analysis of injured tissue
The fluorochrome Fluoro-jade C (FJC) was used to detect neuronal
degeneration using methodology previously described (Chapter 2, Schoch et al.,
2012). Fluoro-jade B (Chapter 2) and FJC are derivatives of the same fluorescent
compound and can generally be used interchangeably to identify degenerating
neurons; however, FJC exhibits slightly greater resolution and contrast labeling
(Schmued et al., 2005). In brief, three 40 m tissue sections were selected at 400
m intervals between approximate bregma level -1.4 to -2.5 mm corresponding
to the injury epicenter (Paxinos and Franklin, 2001). Tissue sections were initially
exposed to DAB to quench endogenous peroxidases, thereby eliminating
nonspecific fluorescence associated with hemorrhage, and were subsequently
mounted on gelatin-coated slides. Following overnight drying, tissues were
rehydrated in 1% NaOH and alcohol gradient, treated with 0.06% potassium
permanganate, and stained with 0.01% Fluoro-jade C (Millipore Co., Billerica,
MA) in 0.1% acetic acid. Tissue sections were dried on a slide warmer before
immersion in xylenes and covered with Cytoseal XYL (Richard-Allen Scientific,
Kalamazoo, MI).
Image analysis was performed by an observer blinded to genotype using a
microscope equipped with epifluorescence (AX80, Olympus America Inc.,
Melville, NY). Fluoro-jade C-positive cells (FJC+) were counted separately within
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the dentate gyrus, CA3/CA3c, and CA1 regions of the hippocampus and
averaged across the three selected tissue sections. Although degenerating
neurons were also evident in the cortex of injured tissue, these FJC+ cells were
not quantified.

Statistical analysis
All data are presented as mean + standard error of the mean (SEM) and
analyzed using Statistica software (StatSoft, Tulsa, OK). Calpastatin inhibitory
activity was evaluated by one-way ANOVA. -spectrin BDPs, 150 kDa and 145
kDa, were analyzed by nested (triplicate samples) two-way ANOVA (genotype x
injury condition). Quantification of CRMP-2 BDPs was evaluated with a two-way
ANOVA (genotype x injury condition). Full-length sodium channel and its
proteolytic fragments were compared by nested (duplicate samples) one-way
ANOVA. Numbers of Fluoro-jade C-positive cells within each hippocampal region
were analyzed by unpaired t-test. A value of p<0.05 was considered significant
and Newman-Keuls post-hoc testing performed when appropriate.
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RESULTS

Calpastatin expression in wildtype and Prp-hCAST transgenic mice
Three Prp-hCAST transgenic founders were mated with FVB/N mice to
produce lines hemizygous for the transgene array, referred to as 7472+/-, 7473+/-,
and 7474+/-. Using an antibody that detects both mouse and human calpastatin,
expression levels of calpastatin in whole brains of 7474+/- mice were estimated to
be ~1.8-fold higher than levels in the brains of previously characterized
calpastatin overexpressing transgenic mice (CaMKII promoter) which express
hCAST exclusively in forebrain regions (Higuchi et al., 2005) (Figure 3.1A).
Calpastatin was not detectable in the CNS of mice derived from the two
remaining transgenic founders.
Regional calpastatin expression levels were assessed in cortical and
hippocampal homogenates from Prp-hCAST transgenic and WT littermates
(n=4/genotype). Immunoblots performed with equal protein loading (5 g) and
developed to visualize the strong calpastatin signal in hCAST transgenic mice
produced no discernible calpastatin signal in WT homogenates (Figure 3.1B). To
compare endogenous levels of calpastatin in WT mice to the much higher levels
in Prp-hCAST transgenic mice, differential amounts of protein from WT and PrphCAST cortical homogenates (n=4/genotype) were loaded for immunoblot
analysis. With a 40-fold increase in protein loading of WT homogenates
compared to transgenic homogenates, the signal in Prp-hCAST mice was
approximately double the signal from WT samples, indicating a nearly 80-fold
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human calpastatin expression above endogenous, mouse calpastatin levels
(Figure 3.1C). Blots also revealed a slight difference in the molecular weight of
mouse calpastatin (mCAST) and hCAST, allowing differentiation of the two
proteins. In addition to cortical and hippocampal brain regions, various central
and peripheral tissues were also examined for calpastatin expression
(n=4/genotype, 5 g protein). Reactivity for hCAST was noted in the cerebellum
and spinal cord of Prp-hCAST homogenates (Figure 3.1D). Consistent with
previous literature identifying high levels of calpastatin within the cerebellum
compared to other brain regions (Sato et al., 2011), endogenous mCAST was
more readily detectable in cerebellar homogenates from WT mice. In peripheral
tissue such as the gastrocnemius and heart muscle, calpastatin reactivity was
observed exclusively in samples from Prp-hCAST mice (Figure 3.1D), again
indicative of a many-fold overexpression of calpastatin in the transgenic mice
compared to WT. Calpastatin was not evident in the liver, lung, kidney, and
spleen (data not shown).
Immunohistochemical labeling (n=3/genotype) using an antibody that
recognizes both mouse and human calpastatin demonstrated a low level of
reactivity in gray matter regions of WT mouse brain (Figure 3.2A), with faint
neuronal labeling in the cortex (Figure 3.2C) and neuropil staining within the
hippocampus (Figure 3.2E). Brain sections from Prp-hCAST transgenic mice
exhibited a robust increase in calpastatin immunoreactivity compared to WT mice
in cell bodies, neuropil, and white matter tracts (Figure 3.2B). All cortical layers,
especially layers III and V, showed specific labeling within the neuronal
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cytoplasm (Figure 3.2D, inset). Reactivity within neuronal cell bodies was also
clearly evident in CA1, CA3, and dentate gyrus hilar regions of the hippocampus
(Figure 3.2F).
Immunoblot and immunohistochemistry analyses included both male and
female mice and no notable differences between genders were observed.
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Figure 3.1.
Calpastatin expression in tissue homogenates obtained from naïve
wildtype and Prp-hCAST transgenic mice. A) Calpastatin expression in whole brain
homogenates of three founder hemizygous Prp-hCAST transgenic (Tg) mice (7472+/-,
7474+/-, and 7473+/-) compared the calpastatin Tg model used in Chapter 2 (CaMKIITg). The presence of the human calpastatin (hCAST) transgene was identified in mouse
7474+/-, with robust expression mediated by the prion protein promoter. Regional
calpastatin expression in cortical and hippocampal tissue of Tg and wildtype (WT) mice
with B) equal amounts (5 g) of protein loaded or C) a 40-fold difference in protein load
to enhance detection of mouse calpastatin (mCAST). D) Calpastatin expression was
also identified in cerebellar and spinal cord tissue and peripheral tissues, including
gastrocnemius and heart tissue from Tg and WT mice (5 g protein/region).
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Figure 3.2.
Calpastatin localization in naïve wildtype and Prp-hCAST transgenic
mice. Immunohistochemical labeling using an antibody recognizing mouse and human
calpastatin in A) wildtype (WT) and B) Prp-hCAST transgenic (Tg) mice demonstrates a
robust increase in calpastatin in transgenic mice. Magnified areas of cortical layers II-V
(C, D) and the hippocampus (E, F) are shown below each respective genotype,
illustrating the neuronal localization of human calpastatin in Prp-hCAST mice. Scale bars
represent 1 mm for images A-B, 100 m for images C-F and 20 m for insets.
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In vitro calpastatin inhibitory activity
The functionality of the hCAST construct within Prp-hCAST transgenic
mice was assessed using an in vitro fluorogenic assay. Under baseline
physiological conditions, calpain activity is low, consistent with its normally
inactive conformation in the neuron. With the addition of exogenous calpain to
mimic the elevated protease activity seen with pathological insults such as TBI,
contralateral (or uninjured) cortical homogenates from WT mice (n=5, male)
exhibited high protease activity measured in fluorescence units per total amount
of protein (Figure 3.3A). In contrast, cortical homogenates from Prp-hCAST
transgenic mice (n=6, male) exhibited an approximately 7-fold decrease in
protease activity compared to WT littermates (p<0.001), indicative of effective
inhibition by the overexpressed calpastatin protein.

Expression of calpains and calpain substrates in naïve mice
Inhibition of calpain proteases by constitutive calpastatin overexpression
may produce compensatory changes in protease or calpain substrate
expression. To test whether Prp-hCAST transgenic mice exhibited alterations in
protease expression, levels of calpain-1, calpain-2, and caspase-3 proteins were
assessed in homogenates from Prp-hCAST and WT mice (n=4/genotype).
Protease expression did not differ between WT and Prp-hCAST mice in either
the cortex or hippocampus (Figure 3.3B). Similarly, selected calpain substrates
including p35, -tubulin, MAP-2, ERK, and phospho-ERK were unaltered by
calpastatin overexpression in naïve Prp-hCAST mice (Figure 3.3B).
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Figure 3.3.
Characterization of the inhibitory activity of calpastatin and basal
levels of putative calpain substrates in wildtype and Prp-hCAST transgenic mice.
A) Calpastatin inhibitory activity in contralateral (uninjured) cortical homogenates
following the addition of exogenous calpain to mimic a state of elevated calpain activity.
Homogenates from Prp-hCAST transgenic (Tg) mice show significantly reduced
protease activity compared to homogenates obtained from wildtype (WT) mice. Data are
represented as mean + SEM; n=5-6/genotype; one-way ANOVA; ##p<0.001. B)
Expression of select proteases and calpain substrates in cortical and hippocampal
homogenates obtained from naïve WT and Prp-hCAST Tg mice. Overexpression of
calpastatin in Tg mice did not induce compensatory expression of calpains or caspase-3
proteases or affect the baseline proteolysis of several common calpain substrates.
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Posttraumatic calpain-mediated proteolysis of -spectrin
To understand the action of calpastatin during in vivo activation of
calpains, male WT and Prp-hCAST transgenic mice were subjected to severe
CCI brain injury. Calpains are activated acutely after experimental brain injury in
the mouse, resulting in early proteolysis of -spectrin and subsequent increase in
spectrin BDPs. To correspond to the suggested peak activation of -calpain after
CCI injury (Kampfl et al., 1996) and maximal breakdown of spectrin after brain
injury (Deng et al., 2007), calpain-mediated spectrin proteolysis was analyzed at
both 6 and 24 h following severe CCI. Calpains cleave intact -spectrin (280
kDa) into 150 and 145 kDa BDPs; the 145 kDa product is specific to calpain
proteolysis while the 150 kDa fragment can result from calpain and caspase
activity (Pike et al., 1998). As expected, severe CCI injury resulted in calpainmediated spectrin proteolysis evident by an increase in cortical 145 kDa BDP
levels in WT mice at 6 h (n=5) and 24 h (n=7) following injury (p<0.001 compared
to sham controls). In contrast, in brain-injured Prp-hCAST mice, levels of the
calpain-specific proteolytic fragment (145 kDa) were maintained at sham control
levels at both 6 h (n=6) and 24 h (n=6) (Figure 3.4A). The attenuation of calpainspecific spectrin proteolysis in Prp-hCAST mice relative to WT mice was
statistically significant at 6 h and 24 h after injury (p<0.001).
Spectrin proteolysis in WT mice was also evident within the hippocampus
following CCI, with increases in the 145 kDa fragment at 6 h and 24 h (p<0.001
compared to sham). Similar to the effect observed in the cortex, hCAST
overexpression suppressed the proteolysis of spectrin to the 145 kDa fragment to
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near sham levels (Figure 3.4B). Although elevated breakdown was noted at 6 h
(p<0.001) and 24 h post-injury (p<0.05) compared to sham, 145 kDa spectrin
BDP levels were significantly reduced in injured Prp-hCAST mice compared to
injured WT mice in the hippocampus at 24 h post-injury (p<0.001) (Figure 3.4B).
Severe brain injury resulted in increased levels of the 150 kDa fragment in
both cortical and hippocampal homogenates above those in sham (p<0.001; n=45/genotype); however, calpastatin overexpression did not significantly alter this
BDP (Figure 3.4). Caspase-mediated spectrin fragments (120 kDa) were notably
absent in all time points and regions analyzed.
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Figure 3.4.
-Spectrin proteolysis following severe controlled cortical impact
injury in wildtype and Prp-hCAST transgenic mice. Calpain-mediated spectrin
breakdown (150 kDa and 145 kDa) in A) cortical and B) hippocampal homogenates at 6
and 24 h after controlled cortical impact (CCI) injury. Severe CCI resulted in an injuryinduced increase in spectrin proteolysis to the 150 kDa product in both wildtype (WT)
and Prp-hCAST transgenic (Tg) homogenates compared to sham controls. The increase
in cortical and hippocampal 145 kDa fragment was effectively blunted by calpastatin
overexpression in Prp-hCAST Tg mice at 6 and 24 h post-CCI in the cortex and 24 h in
the hippocampus.
Breakdown product (BDP) optical densities are represented as mean + SEM; sham n=45/genotype, injured n=5-7/genotype; nested (triplicate samples) two-way ANOVA
(genotype x injury condition) with Newman-Keuls post-hoc tests; *p<0.05, **p<0.001 vs.
sham and ##p<0.001 vs. respective WT. Representative blots with -tubulin loading
control are shown to the right.
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Posttraumatic calpain-mediated proteolysis of collapsin response mediator
protein-2
Due to its potential role in trauma-induced neurodegeneration (Taghian et
al., 2012), posttraumatic axon sprouting (Wilson et al., 2012) and NMDA
trafficking (Brittain et al., 2011), CRMP-2 was investigated in WT and calpastatin
overexpressing transgenic mice following TBI. From its full-length form, CRMP-2
is cleaved by calpains to a fragment of approximately 55 kDa in response to
apoptotic stimuli, excitotoxic challenge, and TBI (Zhang et al., 2007). Immunoblot
analysis of cortical and hippocampal homogenates from WT mice (n=35/condition, female) demonstrated the progressive accumulation from 6 h to 24 h
following CCI brain injury of a 55 kDa CRMP-2 fragment (Figure 3.5), consistent
with calpain-mediated proteolysis. Calpastatin overexpression (n=3-4/condition,
female) prevented the accumulation of this BDP for up to 24 h in the cortex,
resulting in a significant decrease in levels of CRMP-2 fragments in brain-injured
Prp-hCAST mice relative to brain-injured WT mice (p<0.05 and p<0.0005 at 6 h
and 24 h, respectively; Figure 3.5A). Within the hippocampus, CRMP-2
breakdown in Prp-hCAST mice was reduced at 6 h, and completely inhibited at
24 h post-injury (p<0.005, Figure 3.5B). These results both confirm the calpainspecific cleavage of CRMP-2 and further support the protective effect of
calpastatin overexpression following in vivo calpain activation.
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Figure 3.5.
Collapsin response mediator protein-2 (CRMP-2) breakdown
following severe controlled cortical impact injury in wildtype and Prp-hCAST
transgenic mice. Quantification of a 55 kDa CRMP-2 fragment in A) cortical and B)
hippocampal homogenates of wildtype (WT) and Prp-hCAST transgenic (Tg) mice at 6
and 24 h after controlled cortical impact (CCI) injury. A progressive accumulation of a 55
kDa CRMP-2 fragment was identified from 6 h to 24 h post-CCI in WT mice, consistent
with calpain-mediated proteolysis. Calpastatin overexpression attenuated appearance of
the CRMP-2 breakdown product for up to 24 h after injury in the cortex with statistically
significant reductions in fragment levels in Prp-hCAST Tg mice compared to WT mice.
Similarly, CRMP-2 proteolysis within the hippocampus of Prp-hCAST Tg mice was
lessened at 6 h and effectively inhibited at 24 h post-CCI.
Breakdown product (BDP) optical densities are represented as mean + SEM; n=35/genotype/condition; two-way ANOVA (genotype x injury condition) with Newman-Keuls
post-hoc tests; **p<0.005 vs. sham and #p<0.05, ##p<0.005 vs. respective WT.
Representative blots with actin loading control are shown to the right. Full-length CRMP2 bands (bracketed) appear overexposed in representative immunoblot images in order
to identify the CRMP-2 BDP.
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Posttraumatic calpain-mediated proteolysis of voltage-gated sodium channel
To investigate Nav1.2  subunit proteolysis in vivo, a separate cohort of
female WT and Prp-hCAST transgenic mice was subjected to severe CCI injury.
Based on spectrin and CRMP-2 proteolysis data in which the most robust effect
was identified in cortical homogenates, our analysis of sodium channel cleavage
was restricted to the cortex. Immunoblots probed with a pan sodium channel
antibody (Table 3.1) identified the full-length Nav1.2  subunit protein (260 kDa)
as well as a fragment at approximately 100 kDa (Figure 3.6A). Brain injury
resulted in a progressive loss in full-length protein which was statistically
significant at 24 h post-injury in WT (p<0.001) and Prp-hCAST (p<0.05) cortical
homogenates. WT mice (n=4-5) exhibited a pronounced (p<0.01 compared to
sham controls), but transient, increase in the 100 kDa BDP that was suppressed
in Prp-hCAST mice (n=4). Use of an antibody that detects an epitope within the
intracellular loop between domains I and II of the Nav1.2  subunit yielded
fragments of 170, 111, 100, and 85 kDa (Figure 3.6B). Brain injury resulted in a
statistically significant increase in the 85 kDa fragment in WT homogenates
(p<0.01), which was greatly attenuated in Prp-hCAST mice at both 6 and 24 h
post-CCI (p<0.05 and p<0.01 compared to WT, respectively).
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Figure 3.6.
Cleavage of the voltage-gated sodium channel (Nav1.2)  subunit in
cortical homogenates of wildtype and Prp-hCAST transgenic mice following
severe controlled cortical impact injury. A) A pan sodium channel (NaCh) antibody
detected full-length and an injury-induced 100 kDa molecular weight fragment at 6 and
24 h post-CCI. Intact NaCh protein was progressively lost with severe brain injury in
cortical homogenates from both wildtype (WT) and Prp-hCAST transgenic (Tg) mice. A
robust but transient increase in the 100 kDa fragment appeared with injury in WT mice,
but was blocked in Prp-hCAST Tg mice. B) Detection of 170, 111, 100, and 85 kDa
fragment accumulation with an antibody that recognizes an epitope within the I-II loop of
the Nav1.2  subunit revealed a significant posttraumatic increase in the 85 kDa
fragment in WT homogenates at 6 and 24 h post-CCI. Calpastatin overexpression in
Prp-hCAST Tg mice attenuated the injury-induced appearance of this channel fragment.
Breakdown product (BDP) and intact optical densities are represented as mean + SEM;
n=4-5/genotype/condition; nested (duplicate samples) one-way ANOVA with NewmanKeuls post-hoc tests; *p<0.05, **p<0.01 vs. sham and #p<0.05, ##p<0.01 vs. respective
WT. Representative blots with GAPDH loading control are shown to the right. Black
outlines delineate samples run on the same blot (i.e. sham and 6 h samples) from
samples run on a separate blot (i.e. 24 h samples). Optical density analysis was
performed on injured (ipsilateral, I) cortical samples. Contralateral (C) cortical samples
are shown in adjacent lanes for reference only.
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Acute hippocampal neurodegeneration in brain-injured mice
Reductions in calpain-mediated proteolysis of selected substrates with
calpastatin overexpression may result in enhanced neuronal survival after CCI
brain injury. To address this possibility, tissue sections obtained 24 h following
severe CCI from male and female WT (n=9) and Prp-hCAST transgenic (n=10)
mice were stained for Fluoro-jade C, identifying neuronal degeneration. Positive
cellular staining was evident within the cortex and hippocampus of both WT and
Prp-hCAST transgenic mice. Qualitative comparison of cortical Fluoro-jade C
staining did not reveal an overt difference in acute neurodegeneration between
genotypes. In the hippocampus, Fluoro-jade C-positive (FJC+) cells were found
predominantly in the dentate gyrus and CA3/CA3c, with far fewer within the CA1
region. In all hippocampal regions analyzed, no statistically significant differences
in numbers of degenerating neurons were identified between WT and PrphCAST transgenic mice (Figure 3.7).
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Figure 3.7.
Hippocampal neurodegeneration assessed using Fluoro-jade C
staining of tissue obtained from wildtype and Prp-hCAST transgenic mice
following severe controlled cortical impact injury. Numbers of Fluoro-jade C-positive
(FJC+) cells were analyzed in the dentate gyrus (DG), CA3/CA3c, and CA1 regions of
the hippocampus in wildtype (WT) and Prp-hCAST transgenic (Tg) tissue to identify
neuronal degeneration. No quantitative differences in acute hippocampal
neurodegeneration were identified between genotypes at 24 h post-CCI.
FJC+ cell counts were averaged across three sections and represented as mean +
SEM; n=9-10/genotype; unpaired t-test.
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DISCUSSION

Calpains are important mediators of neuronal damage and death under
conditions of neurodegenerative disease and traumatic insults. Due to the risk
calpain activation poses toward neuronal cell viability, we have investigated an
avenue of calpain inhibition using overexpression of calpastatin in a new
transgenic mouse line. Our results demonstrate that Prp-hCAST mice robustly
express calpastatin throughout the brain, yielding potent inhibition of exogenous
calpain. Following in vivo activation of calpains by experimental TBI, calpastatin
overexpression reduced calpain-mediated proteolysis of the substrates spectrin, CRMP-2, and voltage-gated sodium channel. These findings confirm
calpains as a pathological target and validate calpastatin as an agent for
modulating calpain activity following TBI.
Prp-hCAST transgenic mice were found to express calpastatin at levels on
the order of 80-fold higher than endogenous levels in WT mice in the cortex and
hippocampus, with near complete inhibition of in vitro protease activity. Other
transgenic models of constitutive calpastatin overexpression have also
demonstrated significant elevations in calpastatin levels or inhibitory function. In
the mouse line investigated in Chapter 2, neuronal expression of calpastatin via
the CaMKII promoter produced a 3-fold greater calpastatin inhibitory activity,
although hCAST and mCAST protein levels were not quantitatively compared
(Higuchi et al., 2005). Use of the Prp promoter to initiate gene expression may
yield a more widespread distribution throughout the brain, particularly
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concentrated in axons and terminals (Barmada et al., 2004). In addition to its
central distribution, calpastatin expression was also noted in peripheral tissues,
making this mouse an attractive tool for many models of both central and
peripheral nerve injury and other pathologies involving non-neuronal tissues. An
alternative calpastatin transgenic mouse, developed using the Thy1.1 promoter,
achieved an approximately 15-fold greater calpastatin expression over WT
resulting in effective calpain-2 inhibition but also in changes in basal levels of
calpain-1 and calpain-2 and certain calpain substrates (Rao et al., 2008). Altered
basal levels of proteases or calpain substrates was not evident in the Prp- or
CaMKII-driven models, suggesting constitutive overexpression of calpastatin
did not produce compensatory upregulation of proteases or widespread changes
in substrate regulation. Both transgenic models (using CaMKII and Thy1.1
promoters) reduced pathological activation of calpain and proteolysis of multiple
calpain substrates after excitotoxic stimulus. Prp-driven hCAST overexpression
was similarly successful in abating posttraumatic calpain-mediated proteolysis of
structurally and functionally relevant proteins.
-spectrin is an essential protein component of the neuronal
cytoarchitecture that functions in both structural support and membrane protein
anchoring. Its cleavage may contribute to neuronal pathology due to alterations
in membrane stability or membrane-associated protein function. Severe TBI led
to increased -spectrin proteolysis into its characteristic 150 and 145 kDa
fragments in WT mice, consistent with previous literature documenting potent
and early spectrin cleavage in neurons of affected brain regions following
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experimental contusion injury (Saatman et al., 1996a, Pike et al., 1998).
Calpastatin overexpression in Prp-hCAST transgenic mice prevented
appearance of the calpain-specific 145 kDa BDP in the cortex and hippocampus
up to 24 h after severe CCI injury. Targeting calpain activity via administration of
pharmacological calpain inhibitors has produced inconsistent results in the ability
to decrease spectrin breakdown following TBI (Posmantur et al., 1997, Saatman
et al., 2000, Kupina et al., 2001, Thompson et al., 2010), which may be a
reflection of the differences in treatment parameters or limitations associated with
the drugs themselves. Notably, some calpain inhibitors are not solely selective
for calpains, have poor blood-brain barrier permeability, and are metabolically
unstable (Carragher, 2006). Newer inhibitors designed to mimic calpastatin show
promise in preventing calpain-specific spectrin breakdown in response to
elevated intracellular calcium (McCollum et al., 2006) or ischemic insult (Anagli et
al., 2009).
Calpastatin overexpression in our transgenic model was unable to inhibit
spectrin proteolysis into the 150 kDa fragment. Although a 150 kDa fragment can
be generated through caspase activity, which is not inhibited by calpastatin, it is
unlikely that caspase-3 contributed significantly to the accumulation of a 150 kDa
BDP given the absence of the signature 120 kDa fragment (Pike et al., 1998).
Rather, the 150 kDa product may represent the initial cleavage product of
spectrin, later cleaved to a 145 kDa fragment (Zhang et al., 2009). Why calpain
inhibition would be effective in inhibiting the second, but not the initial cleavage of
-spectrin is not clear. The 145 kDa BDP has been suggested to be a more
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sensitive marker for calpain activation (Zhang et al., 2009) and a biomarker for
injury severity in experimental TBI (Pike et al., 2001, Ringger et al., 2004) and
human TBI patients (Mondello et al., 2010). Thus, inhibition of spectrin
breakdown in Prp-hCAST mice may be an indication of reduced injury severity.
The collapsin response mediator proteins are a family of intracellular
proteins expressed within the CNS during development and periods of axonal
growth (Quinn et al., 1999). CRMP-2, in particular, is important in protein
trafficking (Rahajeng et al., 2010), microtubule assembly (Fukata et al., 2002),
and neurite outgrowth (Quinn et al., 2003). Calpain digestion of CRMP-2 results
in generation of a 55 kDa BDP which is inhibited with SJA6017 application in
cortical lysates digested with calpain-2 (Zhang et al., 2007). Here we
demonstrate that CCI injury results in the appearance and subsequent
accumulation of a 55 kDa CRMP-2 fragment as previously described (Zhang et
al., 2007), which is attenuated by calpastatin overexpression. CRMP-2 cleavage
by calpains following TBI may disrupt the protein’s interactions with axonal
transport proteins (Touma et al., 2007) and act to down-regulate surface
expression of NMDA receptors (Bretin et al., 2006) and voltage-gated calcium
channels (Brittain et al., 2009). Thus, CRMP-2 processing may not only affect
axonal function, but also modulate receptors and channels, potentiating the
characteristic ionic imbalance of TBI and neurodegenerative conditions. Inhibition
of CRMP-2 cleavage in the presence of the calcium channel-binding domain
prevents hippocampal cell death following TBI (Brittain et al., 2011), supporting a
link between CRMP-2 cleavage and neuronal death.
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Multiple voltage-gated sodium channel isoforms are present within the
CNS, participating in action potential generation and propagation. The Nav1.2
protein is localized to axons and terminals of neurons (Westenbroek et al., 1989)
and, with injury, is cleaved by calpains (Iwata et al., 2004, von Reyn et al., 2009).
Due to the sodium channel’s pivotal role in action potential generation and ion
flux, injury-induced Nav1.2 damage or dysfunction may result in increased
sodium influx and prolonged membrane depolarization, further exacerbating
calcium dysregulation and calpain activation (Yuen et al., 2009). Severe CCI
resulted in -subunit breakdown evidenced by the appearance of fragments of
similar size to in vitro findings. Calpastatin overexpression inhibited the
accumulation of two distinct channel fragments (85 kDa, 100 kDa) up to 24 h
post-CCI, providing strong support that these products are calpain specific. We
are the first to demonstrate attenuated sodium channel proteolysis into select
fragments with calpain inhibition by calpastatin in vivo, confirming results with
application of the calpain inhibitor MDL28170 after in vitro stretch injury (von
Reyn et al., 2009, von Reyn et al., 2012). Slight differences in the molecular
weights of fragments between in vivo and neuronal stretch injury were evident,
likely reflecting differences in injury pathology or gel migration patterns.
In cases where multiple breakdown products were evident, calpastatin
overexpression in Prp-hCAST transgenic mice inhibited the appearance of some
but not all cleavage products. In particular, Nav1.2 proteolysis into various
fragments was coincident with loss of full length protein expression suggesting
that calpastatin overexpression is most effective in inhibiting the progressive
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breakdown of the channel into smaller sized fragments. Alternatively, cleavages
may indicate the activity of alternative proteolytic pathways that function
independent of calpain activation and are therefore unaffected by calpastatin
overexpression. It is unknown whether partial breakdown of spectrin, CRMP-2, or
sodium channel imparts irreversible damage to the protein and cell or whether
the fragments may exhibit independent functions in mediating cell death. Our
results demonstrate an absence of acute hippocampal neuroprotection after
severe CCI brain injury, consistent with findings in Chapter 2 using CaMKIIdriven calpastatin overexpression (Schoch et al., 2012). Nevertheless, reduced
calpain-mediated proteolysis may delay neuronal damage, allowing the cell to
repair itself or expanding the therapeutic window for additional survival
interventions. While the accumulation of calpain-mediated fragments assessed in
this study was definitively reduced in Prp-hCAST mice, subacute cell survival and
functional improvements will need to be investigated.
Calpastatin overexpression within Prp-hCAST mice ensures inhibition of
multiple calpain isoforms thereby allowing for broad inhibition of calpains’
proteolytic activity following TBI. However, we are unable to draw conclusions
about the differential roles of calpain-1 versus calpain-2 in mediating
posttraumatic damage. This study introduces a novel calpastatin overexpressing
transgenic mouse, and demonstrates reduced posttraumatic proteolysis of key
cellular substrates, spectrin, CRMP-2, and sodium channel. Boosting
endogenous calpastatin through genetic manipulation promotes inhibitory
mechanisms at the initiation of damage and maintains this inhibition long past the
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primary insult, a strategy that may be critical to prevent acute, overwhelming
calpain activity.
Characterization of the novel Prp-hCAST transgenic mouse has confirmed
greater calpastatin expression within the cortex and hippocampus compared to
the alternative CaMKII-hCAST transgenic mouse (Chapter 2). Boosting
endogenous calpastatin levels afforded acute attenuation in calpain-mediated
cleavage of several vital neuronal proteins, motivating subsequent histological
and behavioral studies to examine the therapeutic potential of calpain inhibition in
the Prp-hCAST line. Although acute hippocampal neurodegeneration was
unaffected by calpastatin overexpression in the current study, longer-term
outcome was not assessed. Therefore, in Chapter 4, we evaluate the efficacy of
calpastatin in mitigating cortical and hippocampal cell death at 10 d following
severe CCI. While cell death is an important factor in determining the success of
calpain inhibition, we also performed motor and cognitive testing to identify the
functional benefit of calpastatin overexpression.

Copyright © Kathleen Marie Schoch 2013
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CHAPTER 4

Preface

Experiments within this chapter were developed by K.M. Schoch and K.E.
Saatman. All behavioral testing was performed by J.M. Brelsfoard to ensure
observation blinded with respect to genotype and injury condition. All other
experimental procedures, including surgeries and immunohistochemistry, and
data analyses were performed by K.M. Schoch.
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CHAPTER 4

Ubiquitous calpastatin overexpression attenuates posttraumatic motor and
cognitive behavioral deficits despite lack of overt neuroprotection

INTRODUCTION

Traumatic brain injuries (TBIs) affect approximately 1.7 million U.S.
individuals each year (Faul et al., 2010), resulting in 3.2-5.3 million brain injury
survivors with long-term disabilities (Coronado et al., 2011). Persistent symptoms
of TBI include motor impairments, memory loss, anxiety, and depression,
depending on the type and severity of injury sustained. Primary injury events that
physically shear axons and compromise neuronal membranes not only cause cell
death but also trigger secondary, neurodegenerative events that continue to
mediate functional abnormalities. This cascade characterized by ion
dysregulation, protease activity, reactive oxygen species, and inflammation
dominates in the acute phase of injury (Ray et al., 2002, Farkas and Povlishock,
2007) and contributes to the chronic damage of TBI (Masel and DeWitt, 2010).
Increased understanding of the pathological mechanisms of injury has
identified several potential therapeutic targets for the treatment of TBI. Calpains
are well-characterized calcium-activated proteases that function physiologically in
cell cycle regulation, cell motility, and programmed cell death (Goll et al., 2003).
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Under conditions of neurodegeneration and trauma, calcium dysregulation as a
result of elevated intracellular calcium or altered calcium handling mechanisms
results in calpain activation and proteolysis of various structural proteins,
membrane receptors, and cytosolic elements (Goll et al., 2003, Ray and Banik,
2003). Following TBI, calpains are activated early with documented cleavage of
the cytoskeletal protein, -spectrin, in areas associated with later neuronal death
(Saatman et al., 2010). Despite its co-localization with calpains, the endogenous
levels or activity of calpastatin appears to be inadequate to prevent the increased
and prolonged activity of calpains after injury.
In order to limit the pathological effect of calpains after TBI, strategies for
calpain inhibition have been studied. Treatment with pharmacological calpain
inhibitors appeared to improve behavioral outcome after experimental TBI
(Saatman et al., 1996b, Kupina et al., 2001) but did not consistently result in the
attenuation of spectrin proteolysis or reduction in tissue damage (Posmantur et
al., 1997, Saatman et al., 2000, Kupina et al., 2001, Thompson et al., 2010,
Bains et al., 2012). However, issues related to drug delivery and specificity
complicate interpretation of the posttraumatic action of calpains. To circumvent
these complications, we pursued a more specific approach for calpain inhibition
using genetic modulation of calpastatin expression. In our initial studies, neuronspecific overexpression of calpastatin (CaMKII promoter) demonstrated
behavioral improvements similar to effects seen with pharmacological inhibitor
treatment but with more robust protection against spectrin breakdown. Although
reduced hippocampal cell death was evident in calpastatin overexpressing
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transgenic mice exposed to excitotoxic injury (Higuchi et al., 2005), these overt
neuroprotective effects could not be reproduced in a model of severe contusion
brain injury (Chapter 2, Schoch et al., 2012). Interestingly, calpastatin
overexpression afforded neuronal protection within the dentate gyrus with
moderate injury, which was lost with severe injury. Neuroprotection may be
enhanced after severe injury with greater calpastatin expression. In Chapter 3,
we characterized a transgenic mouse line with human calpastatin (hCAST)
expression levels well above previous models owing to the ubiquitous prion
protein (Prp) promoter. Prp-hCAST mice subjected to severe contusion injury
reproduced attenuations in -spectrin proteolysis and showed significantly
reduced breakdown of additional calpain substrates, voltage-gated sodium
channel and collapsin-response mediator protein-2 (CRMP-2) (Chapter 3,
Schoch et al., 2013). Calpastatin overexpression was unable to reduce
hippocampal neurodegeneration at 24 h post-CCI injury; however, cumulative
cell survival was not assessed.
Based on the enhanced protection of calpain-mediated proteolysis,
increased calpastatin expression obtained in Prp-hCAST mice may exhibit
behavioral recovery after injury as identified in the previous transgenic mice.
While this latter mouse line exhibited modest neuronal protection in the
hippocampus alone, Prp-hCAST mice may show greater or more widespread
neuroprotection not evident with calpastatin overexpression limited to neuronal
subpopulations under the CaMKII promoter. To extend our investigations on the
functional and neuroprotective benefit of calpain inhibition through calpastatin
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overexpression, we assessed motor and cognitive behavioral function in PrphCAST and wildtype mice after severe traumatic brain injury. Additionally, cortical
contusion size and surviving hippocampal neurons were measured to determine
the effect of calpastatin overexpression on cell survival.
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METHODS

Human calpastatin overexpressing transgenic mice
Transgenic mice with human calpastatin (hCAST) under control of the
ubiquitous prion protein (Prp) promoter were originally created on an FVB/N
background strain and previously characterized for experimental brain injury
(Schoch et al., 2013). However, previous reports have identified behavioral and
visual deficits in FVB/N mice (Taketo et al., 1991, Fox et al., 1999, Mineur and
Crusio, 2002), making this strain inadequate for assessing functional outcomes
after TBI. To provide consistent comparisons to published data from our lab and
others, Prp-hCAST transgenic mice (FVB/N) were backcrossed onto a C57Bl/6
background strain for a minimum of 10 generations. Mice were housed in a
controlled environment consisting of a 14:10 light:dark photoperiod and chow diet
and water ad libitum. For experimental procedures, male 3- to 4-month-old PrphCAST transgenic and wildtype littermates were used. Husbandry and surgical
procedures were approved and performed in accordance with University of
Kentucky Institutional Animal Care and Use Committee and federal guidelines
(National Research Council (U.S.). Committee for the Update of the Guide for the
Care and Use of Laboratory Animals. et al., 2011).

Controlled cortical impact brain injury
Contusion brain injury was produced using the well-established controlled
cortical impact (CCI) device (TBI-0310 Impactor, Precision Systems and
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Instrumentation, Fairfax Station, VA). This model of experimental brain injury is
designed to transiently deliver a rapid, focal impact to the exposed brain and has
previously been described in detail (Pleasant et al., 2011, Schoch et al., 2012). In
brief, mice were placed under continuous 3.0% isoflurane anesthesia and
immobilized in a stereotaxic frame. A midline incision was made along the scalp
and the skin resected. A circular, 5 mm-diameter craniotomy was created over
the left hemisphere, lateral to the sagittal suture and positioned within bregma
and lambdoidal sutures. Injured transgenic and wildtype mice were subjected to
a severe (0.9 mm depth) impact using a 3 mm rounded metal impactor tip at a
velocity of 3.5 m/s and 500 ms dwell time. Following injury, a small cranioplast of
dental acrylic was secured over the injured area and the incision was closed.
Sham mice received all surgical procedures except CCI injury. Mice recovered
from anesthesia on a heating pad (37C) until ambulatory.

Behavioral assessments
Morris water maze
Post-injury learning was assessed using a modified Morris water maze
(MWM) paradigm (Morris, 1984). On days 6 through 9 post-injury, mice were
placed in a water-filled tank at four different locations and, for each 70-sec swim
trial, were required to locate a submerged, concealed platform using externally
placed visual cues. Latency time (sec) to reach the platform was recorded. If the
mice did not locate the platform within the 70 sec, they were placed on the
platform by the observer for 5 sec. Following final (day 9) post-injury testing, the
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platform was made visible for two successive swim trials to ensure mice
understood the goal of the task to find the platform. Following each swim trial,
mice were placed in a heated cage for the recovery of body temperature.

Novel object recognition
Cognitive function was also evaluated using a novel object recognition
(NOR) paradigm (Bertaina-Anglade et al., 2006, Tsenter et al., 2008) used
previously to identify deficits in brain-injured mice (Schoch et al., 2012). Mice
were acclimated to an individual empty Plexiglas cage for 1 h followed by
baseline (pre-injury) recognition testing. During baseline testing, each mouse
was introduced to two identical objects (object #1), placed in opposite corners of
the cage. The amount of time spent exploring each object was recorded over 5
min to ensure identical preference prior to injury. Object exploration was
identified when the mouse nose was positioned toward the object of interest at
less than a 2 cm distance. On the following day, mice were subjected to sham or
CCI injury. At 10 d post-injury, mice were re-introduced to the initial identical
objects (object #1) for 5 min and, after a 4 h delay, one object was replaced with
a novel object (object #2). The time of exploration of each object was recorded
and reported as a recognition index, which represents the percentage of total
interaction time spent exploring the novel object.

Neurological severity score
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A modified 14-point neurological severity score (NSS) assessing
coordinated motor function and balance was used to identify motor deficits at 1 h,
24 h, 48 h, 3 d, 5 d, and 7 d following CCI injury (Tsenter et al., 2008, Schoch et
al., 2012). At each time point, mice traversed elevated beams of decreasing
width (3, 2, 1, and 0.5 cm) and a 0.5 cm diameter rod, receiving a maximum of
14 points (3 points/beam and 2 points/rod). Mice were allotted 30 sec for each
beam crossing, at which time points were deducted for footfalls (-1 point),
hanging upside-down (-1 point), and/or unwillingness to traverse (-1 point) or
falling off the beam (-3 points). Points during the 30-sec rod testing were lost for
hanging upside-down (-1 point), inability to cross the rod (-1 point), or falling off
the rod completely (-2 points).

Brain tissue preparation for histological analyses
Anesthetized mice (65 mg/kg sodium pentobarbital, intraperitoneally) were
transcardially perfused with 0.9% heparinized saline followed by 10% neutral
buffered formalin. Following fixation, mice were decapitated and heads post-fixed
in situ overnight. Brain tissue was removed from the skull, fixed for an additional
24 h, and dehydrated in 30% sucrose. Brains were frozen in cold (-30°C)
isopentanes and cut in coronal sections (40 m) on a sliding microtome (DolbeyJamison, Pottstown, PA). Free-floating tissue sections were stored in
cryoprotectant solution at -20C until use.

Neocortical contusion volume
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Free-floating tissue sections taken at 400 m intervals from bregma 0 to 3.5 mm (Paxinos and Franklin, 2001) were mounted on gelatin-coated slides and
dried overnight. Slides were rehydrated through a gradient of alcohols, stained
for Nissl substance with 0.5% cresyl violet and coverslipped. Coronal sections
were imaged using a light microscope (BH2, Olympus America Inc., Center
Valley, PA) equipped with a CCD camera. Cortical tissue was analyzed on a live
image, alternating between 2X and 10X magnification, to separately outline the
ipsilateral and contralateral hemisphere boundaries containing surviving neurons
using Bioquant Life Science software version 8.40.20 (Bioquant Image Analysis
Corporation, Nashville, TN). Cell exclusions were determined by both the
absence of Nissl staining and morphological appearance. Image analysis was
performed by an investigator blinded to genotype. The volume of cortical tissue
damage was calculated as the difference between contralateral and ipsilateral
cortical areas for each section integrated over the inter-section distance and was
expressed as a percentage of contralateral cortical volume to control for variation
in brain size due to tissue processing.

NeuN immunohistochemistry
For hippocampal cell count estimations, neuronal cell bodies were
immunostained for NeuN, a neuronal nuclear marker. Cryoprotected coronal
tissue sections taken at 400 m intervals from bregma -1.0 to -3.5 mm (Paxinos
and Franklin, 2001) were rinsed in Tris-buffered saline (TBS) and pretreated in a
solution of methanol and distilled water and 3% (v/v) of 30% H2O2 to quench
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endogenous peroxidases. Sections were then blocked with 5% normal horse
serum (NHS) in TBS/0.1% Triton X-100 solution and incubated overnight in
primary antibody (anti-NeuN 1:1,000; Millipore Co., Billerica, MA) at 4C. The
following day, tissue was incubated in biotinylated secondary antibody (donkey
anti-mouse IgG, 1:2,000; Jackson ImmunoResearch Laboratories, Inc., West
Grove, PA) for 1 h at room temperature. All antibody solutions were diluted in 5%
NHS/TBS/0.1% Triton X-100. Biotinylated signal from the secondary antibody
was amplified using an avidin-biotin complex solution (1:50, Vectastain Elite ABC
kit, Vector Laboratories, Inc., Burlingame, CA) and developed with
diaminobenzidine (Vector Laboratories, Inc.). Negative controls were treated
identically but without overnight incubation in primary antibody. Sections were
mounted onto gelatin-coated slides and dried overnight. Slides were dehydrated
through a gradient of ethanol solutions and coverslipped.

Two-dimensional cell counting procedure
Hippocampal subregions were delineated by cellular landmarks (Paxinos
and Franklin, 2001) and imaged on light microscope (BX53, Olympus America
Inc.) equipped with a CCD camera. Cell count (NeuN+) analysis was performed
separately within the CA1 and CA3 pyramidal layers, dentate gyrus granular cell
layer, and dentate hilus by an observer blind to both genotype and injury
condition.
CA1, CA3, and granular cell subregions were analyzed in every 10th
section (400 m interval) from bregma -1.0 to -3.5 mm and outlined at 2X
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magnification using Bioquant design-based stereology software (Bioquant Image
Analysis Corporation). Bregma levels for the CA1 pyramidal cell layer were
restricted (approximately -1.3 to -2.0 mm) to avoid poorly defined caudal regions.
A counting frame was identified by random overlay of a 100 x 100 m sample
grid size. A counting frame size of 20 x 20 m was used for CA1 and CA3
pyramidal subregions and 15 x 15 m for the dentate gyrus granular cell layer, at
randomly chosen grid intersection points. Individual NeuN+ cells were counted
under a 60X 1.4 NA oil-immersion objective and used to estimate the total
number of neurons (N) within each subregion by the formula N= 1/ssf  1/asf 
1/hsf  Q where ssf is the section sampling frequency, asf the area sampling
frequency, hsf the height sampling frequency and Q the summed total of NeuN+
cells counted.
Due to the diffuse spatial arrangement and small number of cells within
the dentate hilus, individual analysis of this structure does not require designbased stereology. For this reason, total counts of NeuN+ cells within the dentate
hilus were performed based on densitometric threshold values using Image-Pro
Plus 6.0 analysis software (Media Cybernetics, Inc., Rockville, MD). The hilus
was manually outlined in each section according to conventional landmarks
(Paxinos and Franklin, 2001) and both size and intensity thresholds were
defined. The total number of cells identified in the injured (ipsilateral) hilus was
recorded from sections at 400 m intervals between bregma -1.3 and -3.5 mm.

Statistical analysis
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Data are expressed as mean + standard error of the mean (SEM) and
analyzed using Statistica software (StatSoft, Tulsa, OK). Morris water maze
learning data and neurological severity scores were evaluated using a repeated
measures two-way ANOVA (genotype x injury condition). Novel object
recognition index and hippocampal cell counts were assessed using a two-way
ANOVA (genotype x injury condition) while cortical tissue damage was evaluated
using a t-test. A p value <0.05 was considered significant and Newman-Keuls
post-hoc testing was performed when appropriate.
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RESULTS

Temporal progression of post-injury motor recovery
We have previously demonstrated that neuronal-specific calpastatin
overexpression resulted in improved motor function over the first week following
severe contusion injury in mice using the modified neurological severity score
(NSS) task (Chapter 2, Schoch et al., 2012). As compared to the motor
assessment using neuroscore analysis in this study, which failed to show longterm genotypic differences in gross motor behavior, the NSS offered a more
sensitive measurement to evaluate motor performance in mice. Therefore, the
NSS task was selected for assessing injury-induced motor dysfunction in the
current Prp-hCAST transgenic model, which shows a greater level of calpastatin
overexpression (Chapter 3, Schoch et al., 2013) than neuron-specific hCAST
mice. Coordinated movement was evaluated while mice traversed a beam or rod
at 1 h, 24 h, 48 h, 3 d, 5 d, and 7 d post-injury to identify the temporal
progression of posttraumatic motor recovery. Sham-injured mice (n=12/genotype;
p<0.001, injury effect) exhibited normal motor behavior, consistently receiving
near maximum scores. Slightly lower scores at 1 h likely reflect a transient effect
of anesthesia in sham mice. Severe CCI resulted in a marked, early reduction in
motor function in both WT and Prp-hCAST transgenic mice (n=19-20/genotype)
characterized by repeated hanging of the limbs or the inability to cross the
beam/rod (Figure 4.1). Initial deficits lessened as mice spontaneously recovered
coordination over the 7 d post-CCI period (p<0.0001, time effect). However,
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brain-injured Prp-hCAST transgenic mice exhibited significantly better motor
function over the first week compared to injured wildtype mice (p<0.005,
genotype effect; Figure 4.1).
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Figure 4.1.
Coordinated motor function of wildtype and Prp-hCAST transgenic
mice following severe controlled cortical impact injury. Motor function was
assessed using the neurological severity score (NSS) in wildtype (WT) and Prp-hCAST
transgenic (Tg) mice subjected to sham or severe controlled cortical impact injury
(injured). A) Scores were obtained, in part, by point deductions for foot falls (indicated by
arrow) from the beam, characteristic of hemiparesis or uncoordinated movement in
injured mice. B) Brain injury resulted in an early reduction in motor function followed by
spontaneous recovery over the first week post-injury. Compared to brain-injured WT
mice, injured Prp-hCAST Tg mice showed significantly improved NSS over 7 d following
CCI (p<0.005, genotype effect).
Motor scores are expressed as mean + SEM; shams n=12/genotype, injured n=1920/genotype; repeated measures two-way ANOVA (genotype x injury condition) with
Newman-Keuls post-hoc tests.
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Subacute spatial learning behavior after severe brain injury
To assess whether long-term motor behavior improvements with
ubiquitous calpastatin overexpression in Prp-hCAST mice were associated with
greater cognitive recovery, post-injury spatial learning ability was evaluated by
Morris water maze paradigm. On days 6, 7, 8, and 9 post-injury, WT and PrphCAST transgenic mice were tested for their ability to locate a hidden platform
within the maze (Figure 4.2). Across all groups, latency to the platform decreased
over time (p<0.0005, time effect), consistent with learning behavior; however, this
effect did not depend significantly on either injury or genotype. A significant
interaction was identified between injury and genotype (p<0.05). Post-hoc testing
revealed an injury effect in WT mice (n=19; p<0.0005, WT injured compared to
WT sham), indicative of impaired post-injury learning ability as expected following
CCI injury. In contrast, calpastatin overexpression prevented injury-induced
learning deficits in Prp-hCAST transgenic mice (n=20; p=0.39, hCAST injured
compared to hCAST sham). Sham-injured Prp-hCAST transgenic mice
unexpectedly showed increased latency over time compared to their uninjured
WT counterparts (n=20/genotype; p=0.02), indicative of a slight impairment in
learning ability, resulting in no statistical difference in latency between braininjured WT and Prp-hCAST transgenic mice across the four-day testing (p=0.23).
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Figure 4.2.
Learning performance in a Morris water maze following severe
controlled cortical impact injury in wildtype and Prp-hCAST transgenic mice. Postinjury learning performance was evaluated in wildtype (WT) and Prp-hCAST (Tg) mice
beginning on day 6 following severe controlled cortical impact (CCI) injury. Decreased
latency to locate the hidden platform was observed for all groups across days 6, 7, 8,
and 9 post-CCI. When compared to sham-injured WT mice (), injured WT mice ()
showed significantly impaired post-injury learning ability (p<0.0005) whereas calpastatin
overexpression prevented post-injury learning deficits in Tg mice () (p=0.39 when
compared to sham-injured Tg mice ()). However, Tg sham mice exhibited decreased
latencies over time compared to WT sham mice (p=0.02). Post-injury latency to the
hidden platform was not significantly different between brain-injured WT and Tg mice.
Latency time is expressed as mean + SEM; shams n=12/genotype; injured n=1920/genotype; repeated measures two-way ANOVA (genotype x injury condition) with
Newman-Keuls post-hoc tests.
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Assessment of novel object recognition ability
In addition to spatial learning, cognitive function was also evaluated using
a novel object recognition task which has previously been shown to detect both a
robust injury-induced deficit as well as modulation by calpastatin overexpression
in CaMKII-hCAST mice (Chapter 2, Schoch et al., 2012). Pre-injury testing of all
mice established equal preference for two identical objects, which was also
confirmed after injury (data not shown). At 10 d following sham or severe CCI
injury, WT and Prp-hCAST transgenic mice were evaluated for recognition ability
when one familiar object was replaced with a novel object. Uninjured mice
(n=12/genotype) exhibited a preference for exploring the novel object, resulting in
an approximately 73% recognition index (Figure 4.3). Brain-injured WT mice
(n=19) displayed significant impairment in recognition ability compared to sham
controls (p<0.0005) at 10 d post-injury. WT mice failed to distinguish the new
object from a previously explored object, spending equal amounts of time on both
objects receiving an approximately 52% recognition index. In contrast, braininjured Prp-hCAST transgenic mice (n=20) spent a proportionally greater time
exploring the novel object, resulting in improved recognition scores (62%
recognition index) compared to brain-injured WT mice (p<0.0005), although not
equivalent to sham levels (p<0.0005) (Figure 4.3). Based on these results, longterm posttraumatic recognition memory is partially spared with calpastatin
overexpression.
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Figure 4.3.
Novel object recognition assessment of wildtype and Prp-hCAST
transgenic mice following controlled cortical impact injury. Ten days following
injury, recognition of a novel object by wildtype (WT) and Prp-hCAST transgenic (Tg)
mice was tested. Brain-injured WT mice showed significant impairment in novel object
recognition compared to sham-injured mice. However, injured Tg mice exhibited
improved scores compared to WT mice, demonstrating retention of memory ability after
severe CCI injury, although not equivalent to sham levels at 10 d post-injury.
Recognition index is calculated as the percent of total interaction time spent on the novel
object and expressed as mean + SEM; shams n=12/genotype, injured n=1920/genotype; two-way ANOVA (genotype x injury condition) with Newman-Keuls posthoc tests; *p<0.0005 compared to respective sham, #p<0.0005 compared to WT injured.
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Long-term evaluation of neocortical tissue and hippocampal cell damage
In Chapter 3, we demonstrated sparing of select calpain substrates,
spectrin, CRMP-2, and voltage-gated sodium channel, in Prp-hCAST mice
following severe brain injury that may, in turn, impart neuroprotection of damaged
cells. Furthermore, improved behavioral outcome in Prp-hCAST transgenic mice
may result from the prevention or delay of neuronal death. To evaluate this
premise, subsets of tissue from WT and Prp-hCAST transgenic mice tested for
behavioral function were analyzed for neuroprotection in both the neocortex and
hippocampus, regions that mediate motor and cognitive functions and exhibit
progressive neuronal damage after injury (Pleasant et al., 2011).
In the neocortex, CCI injury produced cellular pathology characteristic of a
severe contusion in WT (Figure 4.4A) and Prp-hCAST transgenic (Figure 4.4B)
mice. Extensive cortical cavitation was noted throughout the area of mechanical
impact, indicative of a loss of tissue within days after impact compared to the
contralateral hemisphere (Figure 4.4C). Staining of Nissl substance revealed
distorted neuronal architecture and dense gliosis in areas bordering the
contusion site. These regions were directly adjacent to areas of healthy, rounded
neuronal morphology located distal to the injury epicenter. At a 0.9 mm impact
depth, CCI injury consistently resulted in complete loss of underlying subcortical
white matter, often associated with mild distortion of the hippocampal formation.
Quantitative analysis of contusion volume revealed equivalent neocortical tissue
damage in WT and Prp-hCAST transgenic mice (n=12/genotype) 10 d after
severe CCI (Figure 4.4D).
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Analysis of Nissl-stained tissue also identified select populations of
hippocampal cells vulnerable to severe CCI within the dentate gyrus granular
layer, dentate hilus, CA3 and CA1 regions. To more clearly identify and
accurately quantify neurons within hippocampal subregions, tissue was stained
with NeuN to label neuronal nuclei. Compared to uninjured, sham controls
(Figure 4.5A, B), severe CCI injury resulted in substantial loss of NeuN staining
within the hilus and CA3 regions as well as thinning of the dentate gyrus granular
cell layers (Figure 4.5 C, D), irrespective of genotype. Stereological estimation of
total neuron numbers revealed a significant injury-induced loss of neurons at 10
d post-CCI (n=7/genotype) within defined regions of the CA1 (p<0.05; Figure
4.5E), CA3 (p<0.05; Figure 4.5F), and dentate gyrus granular layer (p<0.001;
Figure 4.5G) compared to sham controls (n=3/genotype). Automated cell counts
performed within the hilus also demonstrated loss of neurons after severe injury
(p<0.05 for WT injured, p<0.001 for Prp-hCAST transgenic injured; Figure 4.5H).
In all areas analyzed, neuronal counts of Prp-hCAST transgenic mice were not
statistically different from injured WT mice. Therefore, calpastatin overexpression
did not attenuate the injury-induced neuronal loss within the hippocampus 10 d
after severe CCI.
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Figure 4.4.
Cortical tissue damage of wildtype and Prp-hCAST transgenic mice
after severe controlled cortical impact injury. Severe controlled cortical impact (CCI)
injury resulted in extensive cortical damage and loss of the subcortical white matter in
both (A) wildtype (WT) and (B) Prp-hCAST transgenic (Tg) tissue, although no
differences were observed between genotypes. C) The contralateral hemisphere of a Tg
mouse is shown for reference, demonstrating uninjured histological characteristics.
Scale bar represents 500 m. D) Quantification of the cortical contusion volume at 10 d
following severe CCI revealed no significant genotypic differences between WT and PrphCAST Tg mice.
Volumetric tissue damage is calculated as a percent of contralateral cortex and
expressed as mean + SEM; n=12/genotype; t-test.
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Figure 4.5.
Hippocampal neuron loss following severe controlled cortical
impact injury in wildtype and Prp-hCAST transgenic mice. NeuN (neuronal nuclei)
staining in the hippocampus of wildtype (WT) and Prp-hCAST transgenic (Tg) mice
clearly identifies neuronal cells within the CA1 and CA3 pyramidal layers, dentate gyrus
granular cell region, and hilus. No overt losses in neuronal labeling were revealed in
sham A) WT or B) Prp-hCAST Tg mice. With contusion brain injury, neuron loss was
evident within all hippocampal subregions, most notably in the CA3 pyramidal layer and
hilus. No differences in NeuN staining were evident between injured C) WT and D) PrphCAST Tg mice. Scale bar represents 250 m. Using stereological methodology, NeuN+
cells were quantified within the E) CA1, F) CA3, and G) dentate gyrus granular cell layer
(DG GL) to estimate the total number of neurons, or N, within a region. In contrast,
neurons within the dentate gyrus hilar region (H) were determined by computerautomated counting with size and densitometric threshold limits to generate the total (or
sum) number of NeuN+ cells. CCI injury resulted in a significant loss of NeuN+ cells at
10 d post-injury in all regions analyzed, which was not affected by calpastatin
overexpression in Tg mice.
Cell counts are expressed as mean + SEM; shams n=3/genotype; injured n=7/genotype;
two-way ANOVA (genotype x injury condition) with Newman-Keuls post-hoc tests;
*p<0.05, **p<0.001 compared to respective sham.
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DISCUSSION

The long-term cellular consequences of traumatic injury are mediated by a
myriad of secondary events, including a rise in intracellular calcium levels,
calcium dysregulation, and activation of the calpain proteases. Subsequent
calpain-mediated proteolysis of numerous cellular substrates is a notable
contributor to the secondary pathogenesis of TBI. In Chapter 3, we characterized
a novel calpastatin overexpressing transgenic mouse (Prp-hCAST) for the
purpose of evaluating calpain inhibition after traumatic injury. Compared to
alternative genetic models, Prp-hCAST mice exhibited robust calpastatin
expression throughout the brain tissue with attenuation of -spectrin, CRMP-2,
and voltage gated sodium channel breakdown following brain injury (Schoch et
al., 2013). We have continued our investigations on the therapeutic potential of
calpastatin by presently evaluating posttraumatic neuroprotection and behavioral
outcome in Prp-hCAST mice over the first week after injury. We conclude that,
while neuron survival was unaffected, calpastatin overexpression attenuated both
motor and cognitive behavioral deficits after severe CCI injury. Due to the
prevalent and often sustained physical and cognitive disturbances of human TBI
patients, our findings have clear implications toward establishing calpain
inhibition as an effective therapeutic strategy following brain injury.
Common motor deficits including gait and balance abnormalities
experienced by human TBI patients are often reproduced in animal models of
experimental injury and quantified by various scored tasks to evaluate reflexes,
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movement, coordination, and/or strength. In order to assess motor function
following trauma, we employed a modified neurological severity score (NSS)
originally developed for neurological assessments of rats subjected to closed
head injury (Tsenter et al., 2008). When adapted for mice following CCI, injured
mice exhibited an initial, marked deficit that lessened over the 7-d post-injury
period, comparable to our previous results (Chapter 2, Schoch et al., 2012).
While both WT and Prp-hCAST transgenic mice exhibited spontaneous motor
improvement over the post-injury time course, Prp-hCAST mice showed
significantly better recovery from injury-induced motor deficits. These results
support our recent findings with an alternative transgenic model of calpastatin
overexpression (CaMKII promoter) identifying improvements in motor function
acutely following TBI (Chapter 2, Schoch et al., 2012). Similarly, our findings are
consistent with numerous calpain inhibitor studies assessing motor function
following traumatic injury. Continuous 48 h administration of the calpain inhibitor
AK295 improved function one week after lateral fluid percussion brain injury
(Saatman et al., 1996b) while acute improvements in grip score were reported
following single, immediate post-injury administration of SJA6017 (Kupina et al.,
2001). Similarly, treatment with calpain inhibitors CEP4143 or MDL28170
improved hindlimb locomotor performance days to weeks after spinal cord injury
(Schumacher et al., 2000, Hung et al., 2005, Yu and Geddes, 2007, Yu et al.,
2008). Based on these findings with pharmacological inhibitors, calpain activation
appears to contribute to motor dysfunction following injury, and may necessitate
early post-injury calpain inhibition for therapeutic intervention and successful
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mitigation of injury-induced deficits. Constitutive overexpression of calpastatin
was similarly effective in improving motor behavior after severe contusion brain
injury.
Cognitive deficits including memory difficulties are particularly common in
the clinical manifestation of TBI. Experimentally, cognitive deficits have been
routinely studied using the Morris water maze, employing different paradigms to
assess encoding, consolidation, and retrieval aspects of learning and memory.
CCI-injured rodents show both learning and memory impairments compared to
sham-injured animals for days to weeks following injury (Smith et al., 1995,
Schoch et al., 2012, Zhao et al., 2012). As anticipated, injured WT mice showed
a decline over time in latency to the platform, yet plateaued above sham levels,
suggestive of learning impairment a week after injury. However, injured PrphCAST demonstrated preserved spatial learning behavior evidenced by learning
latencies comparable to transgenic sham mice. Although no other study has
evaluated the effect of calpastatin on post-injury learning, investigations on
memory function show that while treatment with AK295 significantly improved
memory retention in a MWM task one week following brain injury (Saatman et al.,
1996b), no improvement in a similar task was identified in calpastatin transgenic
mice tested 48 h post-injury (Schoch et al., 2012). In addition to variations in
study methodologies, cognitive parameters measured by the maze task (e.g.,
post-injury learning or memory retention) may be differentially influenced by
calpain inhibition.
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Notably, Prp-hCAST sham mice exhibited slower latency times compared
to WT sham mice, suggestive of a preexisting cognitive impairment with
transgenic calpastatin overexpression. Calpain inhibitors have been shown to
interfere with long-term potentiation (LTP), implicating calpains in mediating
substrate proteolysis and structural reorganization necessary for learning and
memory formation (Oliver et al., 1989, del Cerro et al., 1990, Denny et al., 1990,
Suzuki et al., 1992, Farkas et al., 2004). Despite this evidence, naïve mice
overexpressing calpastatin (CaMKII promoter) showed equivalent latencies to
the platform compared to WT littermates during pre-injury water maze training
(Schoch et al., 2012), suggesting normal learning ability in transgenic mice
despite an intracellular environment primed for calpain inhibition. In accordance
with this finding, calpain-1 knockout mice showed no LTP dysfunction (Grammer
et al., 2005) despite results seen with pharmacological calpain inhibitor
treatment. However, recent evidence suggests calpain-2 may play a predominant
role in mediating plasticity changes as silencing calpain-2 or conditional
disruption of the calpain small subunit demonstrated impaired LTP and cognitive
behavior function in naïve mice (Amini et al., 2013, Zadran et al., 2013). Genetic
deficiency in calpastatin resulted in enhanced LTP in rats (Muller et al., 1995),
while calpastatin deletion in mice did not interfere with normal hippocampaldependent memory formation (Nakajima et al., 2008). Prp-driven expression
results in higher levels of calpastatin compared to CaMKII-driven expression
(Schoch et al., 2013), levels that may reveal LTP and learning impairments in
Prp-hCAST mice. Uninjured Prp-hCAST mice achieve equivalent latencies to WT
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mice upon multiple, successive testing days indicating a possible delay in
learning ability as opposed to an overt deficiency. Calpastatin overexpression
was effective in preventing injury-induced learning deficits yet inducible models of
calpastatin manipulation should be investigated to ensure normal memory
formation.
Alternative cognitive tests that do not rely on spatial cues and navigation
strategy, such as the novel object recognition (NOR) paradigm, are also useful in
evaluating cortical and hippocampal function (Clark et al., 2000, Balderas et al.,
2008). In the present study, brain-injured mice exhibited significant impairment in
the ability to recognize a novel object at 10 d post-injury, consistent with previous
reports following experimental TBI (Prins et al., 2010, Wakade et al., 2010,
Schoch et al., 2012, Zhao et al., 2012). Calpastatin overexpression attenuated
object recognition deficits in brain-injured mice, but had no effect on recognition
ability in sham controls. These results are similar to our results in Chapter 2
reporting the maintenance of recognition ability in calpastatin overexpressing
mice at 7 and 14 d post-CCI injury (Schoch et al., 2012). However, brain-injured
CaMKII-hCAST mice maintained recognition ability similar to sham levels
weeks post-injury while injured Prp-hCAST mice in the current study still
exhibited a mild deficit at 10 d. This latter finding may again suggest a
disadvantage to excessive calpastatin expression after injury.
The parietal or motor cortex, presumably responsible for integrating and
executing many motor behavioral responses in mice, exhibits notable cell loss
hours to days following CCI brain injury (Pleasant et al., 2011). Not surprisingly,
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we report development of a large cortical contusion and significant hippocampal
cell losses by 10 d post-CCI injury. However, cortical contusion volume
measurements and regional hippocampal cell counts were statistically equivalent
between genotypes following injury, despite behavioral improvements in PrphCAST mice. Cortical neuroprotection has not been reported after brain injury
with use of pharmacological calpain inhibitors (Saatman et al., 2000, Thompson
et al., 2010) or previous genetic calpastatin modification (Schoch et al., 2012).
Within the hippocampus, calpain inhibitor administration did not protect against
apoptosis after lateral FPI (Saatman et al., 2000); however, calpastatin
overexpression showed acute, modest reductions in neurodegeneration after
moderate, but not severe CCI (Schoch et al., 2012). Greater calpastatin
overexpression in Prp-hCAST mice failed to produce cortical neuroprotection or
enhance hippocampal cell survival days after severe CCI injury, suggesting that
calpain inhibition alone may be ineffective at measurably altering cumulative
neuronal death in the injured cortex and hippocampus after severe brain injury.
Despite the mixed results seen in TBI, calpain inhibition has shown
improved pathological outcomes in models of ischemia and spinal cord and
axonal injury. Reductions in cortical infarct produced by focal ischemia have
been consistently identified with either single or continuous administration of
pharmacological calpain inhibitors (Bartus et al., 1994a, Bartus et al., 1994b,
Markgraf et al., 1998, Tsubokawa et al., 2006, Koumura et al., 2008). Similarly,
selective CA1 cell death accompanying global ischemia was lessened with
continuous calpain inhibitor administration (Lee et al., 1991, Rami et al., 2000,
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Frederick et al., 2008). Disparate neuroprotective outcomes between ischemia
and TBI may result from inherent differences in injury mechanisms related to
glutamate release, calcium levels and entry modes, or vascular contributions.
Following spinal cord and axonal injury, pharmacological calpain inhibition
reduced apoptosis (Arataki et al., 2005, Sribnick et al., 2007, Colak et al., 2009),
lesion size (Yu and Geddes, 2007, Yu et al., 2008), and other histological
indicators of axonal damage (Buki et al., 2003, Ai et al., 2007, Ma et al., 2012a),
suggesting calpain activation and substrate proteolysis more directly affect
axonal structure and transport function. Therefore, calpastatin overexpression
may be ameliorating subtle axonal damage without overt neuronal protection in
trauma.
Calpain inhibition via pharmacological intervention has been successful at
reducing posttraumatic calpain-mediated proteolysis or behavioral deficits,
outcomes that were collectively achieved with genetic calpastatin overexpression
in our studies (Schoch et al., 2012, Schoch et al., 2013); however, these results
generally do not equate to neuroprotection within the primary injury sites.
Although we speculate that the reduced breakdown of critical substrates delays
cell demise, partially proteolyzed substrates may be unable to function normally
within the cell. In addition, calpain activation is one of several neurodegenerative
cascades responsible for injury-induced cell dysfunction. Other secondary
mechanisms including blood-brain barrier breakdown, mitochondrial dysfunction,
reactive oxygen species, and inflammation may also predominate after severe
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contusive trauma (Ray et al., 2002), necessitating an intervention strategy
involving calpain inhibition in combination with additional therapies.
Not only are calpains one of many contributors to cell damage, but they
also may be activated in regions undetected by traditional analyses. Standard
cortical contusion volume measurements delineate the area of damaged tissue
receiving the most direct impact from the injury. Due to the direct shearing of cell
membranes, immediate calcium dysregulation, and ensuing excitotoxic injury,
these cells undergo excitotoxic necrotic cell death (Kochanek et al., 1995), a
process a recent study determined to be unaffected by calpain inhibition (D'Orsi
et al., 2012). Delayed calpain activation and neuronal protection with calpain
inhibition occurred only under conditions of excitotoxic apoptosis characterized
by bax-dependency, mitochondrial depolarization, and delayed calcium
dysregulation (D'Orsi et al., 2012). In addition, standard contusion volume and
cell count measurements are gross assessments of cell viability, unable to
discern subtle changes in axonal structure or function that may be mediating
functional improvements or preservation after injury. Behavioral outcomes noted
with calpain inhibition may indicate spared axonal connections or synaptic
structures in regions or circuitry not easily distinguished after CCI injury.
Although calpastatin inhibits both m- and -calpain, the relative
participation of different calpain isoforms in the pathogenesis of trauma and
neurodegeneration is largely unknown. Constitutive calpastatin overexpression
also prevents manipulation of the temporal activity of calpains following trauma.
Due to their role in cytoskeletal reorganization, calpains are reported to be
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involved in membrane repair after cell scrape damage (Mellgren et al., 2007)
and, therefore, may need to remain active for a period of time to promote
membrane resealing after brain injury. Thus, both the isoform- and time-specific
activation of calpains may be important factors in determining the optimal
therapeutic strategy for calpain inhibition after injury, achieving both
neuroprotection and functional improvements. Despite limitations associated with
a transgenic mouse model, calpastatin overexpression afforded motor and
cognitive recovery after trauma, highlighting calpain as an important therapeutic
target and the use of calpastatin as a potential intervention for the amelioration of
behavioral morbidity associated with contusion brain injury.

Copyright © Kathleen Marie Schoch 2013
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CHAPTER 5

Discussion and Conclusions

REVIEW OF MAJOR FINDINGS
Calcium-activated calpain proteolysis appears to be a key mediator in the
pathogenesis of TBI and neurodegenerative disease. Although the use of
exogenously administered calpain inhibitors has achieved positive outcomes in
excitotoxicity, ischemia, and spinal cord injury, studies that seek to
pharmacologically manipulate calpain activity after TBI have produced
inconsistent results owing, in part, to differences in the relative selectivity of
inhibitors for calpains and their variable pharmacokinetic properties. Calpastatin,
the endogenous inhibitor of calpains, is not known to inhibit any other protease,
making it ideal for the exclusive targeting of calpains. Therefore, we
hypothesized that specific calpain inhibition through calpastatin overexpression
would effectively reduce calpain activity, spare protein substrates, and afford
neuronal and behavioral protection in mice subjected to contusion brain injury.
We confirmed robust calpastatin immunoreactivity in the cortex and hippocampus
of two calpastatin overexpressing transgenic mouse lines, identifying higher
expression levels with the prion protein promoter (Prp-hCAST) compared to
neuronal-specific CaMKII promoter (CaMKII-hCAST). The hCAST construct in
each line was equally effective in suppressing protease activity under exogenous
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calpain challenge, which was validated by the attenuation of calpain-specific
spectrin breakdown in calpastatin overexpressing mice within the first 24 h after
CCI injury. In this respect, we confirmed our hypothesis that specific inhibition of
calpain through transgenic calpastatin overexpression provided better protection
of substrates compared to post-injury pharmacological calpain inhibitor
treatment. We extended our studies on acute calpain-mediated substrate
proteolysis to the proteins CRMP-2 and voltage-gated sodium channel, showing
reduced breakdown of both substrates in injured Prp-hCAST mice. Although we
originally proposed that specific inhibition of calpain by calpastatin would provide
promote neuron survival, no overt cortical or hippocampal histological
neuroprotection was evident in Prp-hCAST mice after severe injury. However,
consistent with our hypothesis, posttraumatic motor and cognitive behavioral
deficits were significantly lessened in both CaMKII- and Prp-hCAST transgenic
mice, providing key support for the therapeutic benefit of calpastatin and calpain
inhibition in trauma.

IMPLICATIONS FOR CELLULAR DAMAGE FOLLOWING TRAUMATIC BRAIN
INJURY
Cellular damage associated with the initial impact and the secondary
phase of neurodegeneration is a major facet of TBI (Ray et al., 2002). Due to the
shearing of cell membranes, inappropriate channel opening, and excessive
release of excitatory neurotransmitters, calcium becomes dysregulated leading to
numerous consequences including the activation of calpains (Kampfl et al.,
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1997). Calpains cleave a variety of substrates contributing to cellular damage
and death (Saatman et al., 2010) despite the endogenous presence of
calpastatin, capable of inhibiting four molecules of calpain (Goll et al., 2003).
While spectrin breakdown is the most well-characterized calpain substrate after
injury, calpain-mediated cleavage of proteins involved in other structural or
functional aspects of the neuron could collectively influence neuronal damage.
The voltage-gated sodium channel regulates ion flux and membrane
depolarization and CRMP-2 has been cited for its involvement in axonal
outgrowth as well as membrane protein trafficking. The calpain-specific cleavage
of these proteins serves as a marker for calpain activation, but may also indicate
the important or preferential cellular mechanisms affected with injury. Although
limited knowledge on the relative timeline, substrate contribution, or threshold of
calpain-mediated proteolysis necessary to commit a cell to death is available,
early calpain activation is evident within injured neurons after trauma (Saatman
et al., 1996a, Ringger et al., 2004), suggesting a role for calpains in the process
of cell death. In the CCI model of contusion brain injury in rodents, areas of acute
neuronal damage progress to a cortical cavity and regional hippocampal cell loss
within days post-injury (Hall et al., 2005, Saatman et al., 2006, Pleasant et al.,
2011). However, calpain inhibition by pharmacological intervention has been
unable to reduce cell death, possibly due to limitations posed by the drugs’
solubility, penetration, and kinetics.
To specifically implicate calpains in mediating cell dysregulation and
death, we investigated the effect of increased calpastatin expression to limit
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pathological calpain activation and subsequent neuronal death. Calpastatin
overexpression in transgenic mice effectively reduced acute posttraumatic
substrate proteolysis, supporting numerous studies using pharmacological
calpain inhibitors in the CCI trauma model (Posmantur et al., 1997, Thompson et
al., 2010, Bains et al., 2012). Although reduction in spectrin or MAP-2 cleavage
was not evident with calpain inhibitor treatment in models of FPI (Saatman et al.,
2000) or weight-drop injury (Kupina et al., 2001, Haranishi et al., 2005), the
inhibitor used, dosage, delivery paradigm, or treatment duration may have
impacted the effectiveness of calpain inhibition. Use of calpastatin
overexpressing transgenic mice in these injury models may provide substrate
protection but, to date, has not been investigated. While the use of calpastatin
confirms specific calpain inhibition after TBI, calpastatin overexpression did not
afford histological cortical or hippocampal neuroprotection after TBI, suggesting
that reductions in calpain-mediated substrate proteolysis are not enough to
reduce posttraumatic neurodegeneration. Although we argue that calpastatin
insufficiency allows for the prolonged activation of calpains after TBI, increasing
the expression level of calpastatin overexpression did not enhance histological
outcome. Thus, another factor not tested with our methods may act to perpetuate
calcium dysregulation and/or pathological calpain activation following CCI injury
in areas most vulnerable to the initial and immediate impact.
One calpastatin molecule can feasibly inhibit four calpains, yet an
overabundance of calpastatin in CaMKII- and Prp-hCAST transgenic mice failed
to protect against cell death after TBI. The regulation of calpains and calpastatin
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by calcium concentration, subcellular localization, and oxidation or
phosphorylation status collectively influence the activation or inhibition of
calpains in vitro and under physiological conditions (Salamino et al., 1997, Goll et
al., 2003, Maddock et al., 2005); however, relatively little is known about the
biochemical nature or relative localization of calpains and calpastatin after TBI
that, in addition to sustained free calcium levels, can result in prolonged calpain
activation. For instance, calpains’ catalytic residues are susceptible to oxidation,
which resulted in decreased in vitro activity of -calpain (Maddock et al., 2005).
Conversely, oxidative conditions and phosphorylation of calpastatin by protein
kinases were shown to decrease the ability of calpastatin to inhibit calpains
(Salamino et al., 1997, Averna et al., 2001, Maddock et al., 2005). While
oxidative stress and alterations in kinase expression have been identified in TBI
(Yang et al., 1993, Padmaperuma et al., 1996, Lewen et al., 2000, Raghupathi et
al., 2003, Atkins et al., 2007), no studies to our knowledge have investigated
redox state or phosphorylation status of calpains and calpastatin after brain
injury. Based on these possibilities, more information on the biochemical
properties of calpain and calpastatin under pathological insults is necessary to
completely understand calpain-calpastatin regulation after TBI.
The subcellular localization of calpains and calpastatin has been
considered a mechanism to regulate calpain activation under low, physiological
intracellular free calcium concentrations. Accordingly, studies have identified
hydrophobic or basic amino acid residues within calpain domains III and V
(Tompa et al., 2001, Gil-Parrado et al., 2003b) that may allow for redistribution to
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the membrane to facilitate proteolytic activation (Kuboki et al., 1987, Goll et al.,
2003) or in association with specific subcellular organelles (Mellgren and Lu,
1994, Hood et al., 2003, Garcia et al., 2005). The different calpastatin isoforms
that result from distinct promoters or alternative splicing may also affect the
localization of each isoform in relation to calpains. The L domain of calpastatin, in
particular, contains sequences that function in membrane binding (Mellgren et
al., 1989) while additional N-terminal regions are phosphorylation sites that can
induce aggregation (Averna et al., 2001) or increased membrane association
(Adachi et al., 1991). Although changes in protease-inhibitor localization seem
plausible in vitro or under physiological conditions to regulate calpain activity,
these mechanisms have not been confirmed in neurons following pathological
insult. Under conditions such as TBI, changes in the localization, aggregation or
compartmentalization of calpains and calpastatin may preclude appropriate or
potent calpain inhibition, resulting in continued cellular damage.
Despite possible biochemical alterations or subcellular location differences
between calpains and calpastatin, calpastatin overexpression in our studies was
able to specifically inhibit calpains based on in vitro assay and proteolysis data.
However, calpains are one of many known contributors to cell damage after TBI.
Calcium dysregulation notably triggers additional neurodegenerative
mechanisms including mitochondrial dysfunction, oxidative stress, and lipid
peroxidation and associated membrane disruption (Ray et al., 2002), creating a
complex and multifactorial situation such that inhibition of calpains alone may not
fully protect the neuron after injury. In addition, non-calcium-mediated injury
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cascades such as blood-brain barrier breakdown, caspase activation, vascular
leakage, and inflammation can promote neuronal damage and death (Lenzlinger
et al., 2001, Ray et al., 2002, Shlosberg et al., 2010). Recent preclinical
strategies that target other acute mediators of neurodegeneration including
plasmalemma permeability (Mbye et al., 2012), mitochondrial dysfunction
(Sullivan et al., 2000, Mbye et al., 2009, Readnower et al., 2011), oxidative stress
(Zhang et al., 2012, Singh et al., 2013), and inflammation (Yi et al., 2008,
Sauerbeck et al., 2011, Atkins et al., 2013) have been effective in reducing cell
death or lesion size after CCI injury. Therefore, a combination of therapies
targeting calpains and other secondary mechanisms may yield a superior
neuroprotective outcome with both histological and functional improvements.
Finally, the relative contribution of apoptotic or necrotic cell death
pathways can vary depending on the severity, duration, or mechanism of injury
and aspects of both processes can occur simultaneously within the same brain
region or single neuron after TBI (Raghupathi, 2004, Stoica and Faden, 2010).
This heterogeneity of cell death phenotypes and participation of different
intracellular executioners complicates attempts to target specific mediators, like
calpains, to reduce overall posttraumatic cell death. Based on a recent in vitro
study, calpain activation was not detected in neurons undergoing NMDA-induced
excitotoxic necrosis characterized by immediate, irreversible calcium
dysregulation and sustained depolarization of the mitochondrial membrane
potential (D'Orsi et al., 2012). Calpain inhibition was more effective in achieving
neuroprotection under conditions of excitotoxic apoptosis in which neurons
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experienced delayed mitochondrial depolarization and subsequent calcium
dysregulation prior to calpain activation (D'Orsi et al., 2012). Perhaps the level of
calcium dysregulation and degree of cellular injury experienced by neurons within
the primary contusion site is too rapid and irreversible to respond to intervention
by calpain inhibition alone and instead, adjacent dysfunctional neurons with
delayed calcium alterations are more receptive to specific blockade of calpains
after TBI. Standard cortical contusion volume and cell death measurements that
quantify the absence of dead neurons or presence of surviving neurons cannot
distinguish cell death mechanisms and, therefore, may not be the best tool for
assessing cell death modulation by calpain inhibition. More sensitive markers of
apoptotic or necrotic pathways or the state of calcium dysregulation after brain
injury may help to delineate neurons or brain regions in which calpains are
activated in order to better target calpastatin overexpression.

IMPLICATIONS FOR BEHAVIORAL FUNCTION FOLLOWING TRAUMATIC
BRAIN INJURY
Pathological calpain activation mediates cellular substrate damage,
contributing to cell death and behavioral impairments. Although calpastatin
overexpression was unable to spare neurons after TBI, multiple motor and
cognitive assessments revealed reduced behavioral deficits in transgenic mice
following contusion brain injury. These data indicate that the pathological
activation of calpains appears to alter processes or regions involved in
posttraumatic behavioral deficits, which can be prevented through inhibition by

164

calpastatin. Our results are consistent with studies using pharmacological calpain
inhibitors demonstrating reductions in motor and cognitive deficits in diffuse
models of TBI (Saatman et al., 2000, Kupina et al., 2001). Furthermore, our
results demonstrate that functional benefits do not require overt cortical or
hippocampal neuroprotection, a surprising disconnection that has been
reproduced in both rats and mice with calpain inhibition by pharmacological
inhibitors and calpastatin overexpression. Instead, improved functional outcomes
may represent spared axonal or synaptic structure and function in areas adjacent
to the contused region.
Evidence from studies on axonal injury supports a role for calpains in
mediating damage to axonal structure and function that can be diminished with
pharmacological or viral-mediated calpain inhibition. Pretreatment with MDL28170 decreased immunohistochemical indications of structural damage (Buki et
al., 2003) and preserved axolemmal integrity (Czeiter et al., 2009) following
impact acceleration injury. Calpain inhibition also reduced ischemia-induced
cleavage of cytoskeleton proteins within the axon initial segment, thereby
preserving ion channel clustering (Schafer et al., 2009), which may contribute to
the maintenance of action potential propagation and neuronal polarity. Although
treatment with the calpain inhibitor MDL-28170 did not affect stretch-induced
axonal transport disruption after in vivo optic nerve stretch injury (Ma et al.,
2012a), axonal transport function was partially protected with viral-mediated
calpastatin overexpression (Ma et al., 2012b), suggesting that long-term or more
specific calpain inhibition is required for improved functional outcome. Calpain
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inhibition reduced cytoskeleton breakdown but was ineffective at preventing
electrophysiological dysfunction after optic nerve anoxia (Jiang and Stys, 2000)
or electromyography after sciatic nerve transection (Ma et al., 2013), perhaps
highlighting additional injury mechanisms that occur simultaneous to calpain
activation. Subtle changes in axonal structure or function that may be mediating
functional preservation or improvement after brain injury may not be easily
assessed by the injury model or histological measurements used in our studies.
Calpain inhibition may be more effective in diffuse or mild TBI in which axonal
pathology greatly contributes to the overall tissue damage and functional deficits;
therefore, models such as midline FPI or impact acceleration injury models could
be used to test the hypothesis that calpastatin overexpression ameliorates
calpain-induced axonal damage and dysfunction. Additional assessments
including electrophysiology, axonal and synaptic labeling, or other measure of
axonal integrity may help elucidate the mechanisms by which calpain inhibition
affords behavioral efficacy without neuronal protection.

LIMITATIONS AND ALTERNATIVE INTERPRETATIONS
Calpastatin overexpression via genetic manipulation effectively enhanced
endogenous inhibitory mechanisms, achieving robust calpain inhibition. However,
the absence of neuroprotection despite behavioral efficacy is puzzling. In addition
to our speculations above, several caveats and limitations associated with using
transgenic mouse models must also be considered. Along with these
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considerations, alternative interpretations regarding calpain function and
sublethal cellular injury are discussed.
Constitutive calpastatin overexpression may result in unintentional and
abnormal compensatory responses associated with developmental calpain
inhibition that could interfere with posttraumatic outcomes and interpretations.
Although no compensatory changes in caspase-3 expression or caspasemediated spectrin breakdown were observed in Prp-hCAST transgenic mice, we
did not investigate upregulation of other caspase family members or alternative
proteolytic enzymes such as cathepsins that are increased or activated after TBI
(Knoblach et al., 2002, Larner et al., 2004, Ringger et al., 2004, Larner et al.,
2005, Luo et al., 2010). Although evidence suggests that calpains function in LTP
and memory formation (del Cerro et al., 1990, Denny et al., 1990, Suzuki et al.,
1992, Muller et al., 1995, Farkas et al., 2004, Amini et al., 2013, Zadran et al.,
2013), CaMKII-driven calpastatin overexpression did not affect normal cognitive
function in naïve or uninjured transgenic mice using a hippocampal-dependent
task (Schoch et al., 2012). However, we did note a slight learning impairment in
uninjured Prp-hCAST mice compared to WT controls, suggesting a delay in
cognitive function or plasticity with increased and more widespread calpastatin
overexpression. Without additional cognitive testing or electrophysiological data
to confirm possible LTP abnormalities in these transgenic mice, cognitive data
obtained from calpastatin overexpressing mice must be interpreted with caution.
Conditional models of calpastatin overexpression that may lessen or eliminate
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problems associated with developmental and constitutive genetic manipulation
should be investigated.
A major advantage to transgenic calpastatin overexpression is its specific
and sustained inhibition of calpains, affording inhibition of both - and m-calpains
during the entirety of traumatic insult. However, these characteristics notably limit
interpretation of the temporal and isoform-specific role of calpains. Genetic
calpain knockout and knockdown strategies have suggested distinct pathological
roles for each calpain isoform in mediating ischemic and posttraumatic cell death
(Bevers et al., 2009, Bevers et al., 2010, Yamada et al., 2012, Yu et al., 2012).
Based on these studies, - and m-calpains may function independently or exert
different functions, which can only be delineated by selective isoform targeting.
Atypical calpain isoforms, including calpains 5, 7, and 10, also have ubiquitous
tissue distributions but lack EF-hand domains predicted for calcium-binding
(Sorimachi et al., 2011) and, thus, may contribute to proteolytic damage after
injury in a manner dissimilar to - and m-calpains; however, their precise
regulation by calpastatin and role in trauma have not been previously
investigated. In addition, calpastatin overexpression could compromise calpains’
physiological or reparative functions following injury. For example, in vitro studies
have cited a function for calpains in proteolyzing substrates responsible for
membrane repair after injury (Howard et al., 1999, Mellgren et al., 2009);
therefore, sustained calpastatin overexpression during TBI may actually prolong
membrane permeability after injury, resulting in greater cell death in the contused
region. Calpains also participate in the recovery of dendritic structure following
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sublethal NMDA-induced excitotoxicity (Faddis et al., 1997) perhaps resulting in
sustained injury if calpains are inhibited. Temporal changes in calpain inhibition
could verify such a function in TBI, perhaps necessitating early calpain activation
to seal neuronal membranes and remodel dendrites but subsequent calpain
inhibition to prevent functional impairments.
Finally, CCI injury reliably replicates focal, contusion injuries with aspects
of excitotoxicity, ischemia, hypoxia, and traumatic axonal injury (Lighthall et al.,
1990, Palmer et al., 1993, Kochanek et al., 1995, Clark et al., 1997). Yet, given
the functional benefits of calpastatin overexpression in transgenic mice, axonal
stretch or shearing injury may be more susceptible to calpain activation and thus
modulation by calpastatin, but these pathologies are difficult to assess with direct
contusion and tearing of axons in a CCI injury model. Investigations using
alternative injury models such as FPI or axonal stretch can help to verify calpainmediated pathology and may reveal a mechanism for spared behavioral function
with calpastatin overexpression.
Therapeutic strategies for traumatic insults, including contusion brain
injury, often seek to reduce cell death and behavioral dysfunction following injury.
Our studies clearly demonstrate improved posttraumatic behavioral performance
with calpastatin overexpression but without histological neuroprotection within the
primary contusion site. Although we have historically sought a neuroprotective
outcome with calpain inhibition, perhaps our focus should be shifted to
surrounding areas or other cell types to identify the source of improved
behavioral function after injury. Transient or sublethal neuronal dysfunction has
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been identified using electrophysiological techniques (Bain et al., 2001, Reeves
et al., 2005). Calpain activation may contribute to the initial functional deficits and
calpastatin overexpression, therefore, may improve recovery or prevent
permanent cellular damage. In accordance with this supposition, spared
proteolysis of the voltage-gated sodium channel may promote the recovery of
action potential generation and, in turn, lead to improved recovery of normal
behavioral function.
Outcomes to assess calpain activation and its consequences have
concentrated on neuronal populations; however, injury-induced alterations to
subpopulations of neurons and glial cells could influence our interpretations on
overall neuronal death and potential histological neuroprotection with calpain
inhibition. Staining with Fluoro-jade, Nissl, or NeuN fails to distinguish between
neuronal subpopulations (i.e. excitatory or inhibitory neurons) that could be
differentially affected by injury or calpastatin overexpression. In addition, glial cell
activation in response to neuronal death may be modulated by calpastatin
overexpression, thereby meditating an improved behavioral outcome.

FUTURE DIRECTIONS
The mechanism by which calpastatin overexpression is able to spare
posttraumatic behavioral function without overt neuroprotection in our model is
still unknown. Neither the specificity of calpastatin toward calpains nor the
abundance of calpastatin appears to be a key determinant in enhancing
histological outcome, since data obtained from two separate transgenic models
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are consistent with administration of several less selective pharmacological
calpain inhibitors. Future studies should more closely identify electrophysiological
properties or axonal and synaptic markers that could pinpoint calpain activation
in mediating behavioral dysfunction. Methods like these may necessitate
alternative injury models that more specifically involve axonal injury or that
produce diffuse axonal pathology. Differences in these models compared to CCI
may also involve different biochemical and cell death mechanisms to further
indicate a role for calpains in mediating damage in some, but not all, types of
pathologies.
In order to avoid limitations in compensatory protein responses or possible
developmental abnormalities associated with constitutive calpastatin
overexpression, alternative manipulation strategies should be investigated as
well. Conditional calpain isoform knockouts may reveal isoform-specific roles
after TBI while a conditional, dual calpain knockout strategy can confirm
calpastatin inhibition of both isoforms achieved with calpastatin overexpression
transgenic mice. Strategies that can manipulate the temporal expression of
calpastatin, such as viral-mediated calpastatin delivery or calpastatin mimetic
administration, can be used to compare to results obtained with manipulation of
one or both calpain isoforms. Not only will these future directions promote
enhanced understanding of calpains and calpastatin after injury, but also may
lead to modified therapies to achieve both neuroprotection and behavioral
improvement after injury.
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CALPASTATIN OVEREXPRESSION AS A THERAPEUTIC APPROACH
While studies of pharmacological inhibitors that lack absolute specificity
for calpains complicate interpretation of pathological outcomes after TBI,
calpastatin overexpression in transgenic mice has produced little doubt that
calpains mediate cellular damage after traumatic insult. Furthermore, the ability
of calpastatin to specifically inhibit calpains resulted in reduced posttraumatic
protein breakdown and behavioral deficits, confirming the therapeutic benefit for
calpain inhibition after TBI. Behavioral protection seen with calpastatin
overexpression was not coincident with neuroprotection, implying that calpains
are mediating damage that affects surviving but dysfunctional neurons, synaptic
connections, or axonal function; yet, more information is necessary to confirm
these mechanisms. Overall, our results confirm the role of calpain in mediating
neuronal dysfunction after trauma, supporting the need for specific inhibitors of
calpain in the treatment of TBI. However, calpain inhibition alone is insufficient to
fully protect neurons from death, suggesting that combinatorial treatments may
be more beneficial to provide neuroprotection and reduce behavioral deficits after
TBI. Noting these considerations, calpastatin overexpression is a viable
therapeutic approach toward the treatment of TBI and other neurodegenerative
diseases.

Copyright © Kathleen Marie Schoch 2013
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